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Abstract 
Endothelin-1 (ET-1), the potent vasoconstrictor peptide, is synthesised from the 212 
amino acid precursor preproendothelin-1 (ppET-1). ET-1 is strongly implicated in 
cardiac and renal pathologies. However, ET receptor antagonists demonstrated only 
limited efficacy in clinical trials of chronic heart failure (HF) and hypertension. ET-1 
has a short circulating half-life and its plasma measurements have been inaccurate. Thus, 
alternative ppET-1 derived peptides may be more stable and could serve as better 
biomarkers of ET-1 synthesis. Moreover, alternative ppET-1 derived peptides may 
contribute to the biological effects resulting from EDN1 gene expression and may be 
interacting with the vasoconstrictor responses of ET-1 or other mediators. The aims of 
these investigations were to characterise ppET-1 derived peptide products and to 
evaluate their potential as biomarkers of ET-1 synthesis. 
A combination of specific immunoassays and HPLC were used to characterise ppET-1 
processing in human endothelial (EA.hy 926) and epithelial (A549) cells in culture. NT-
proET-1 (ppET-1[18 – 50]), endothelin-like domain peptide (ELDP, ppET-1[93 – 166]) and 
CT-proET-1 (ppET-1[169 – 212]) were identified in conditioned media samples as the main 
ppET-1 derived peptide products. The identities of ELDP and CT-proET-1 were 
confirmed by LC-MS/MS mass spectrometry.  
The three ppET-1 peptides were chemically synthesised and their in vivo clearance was 
investigated in male Wistar rats. Arterial plasma levels after intravenous administration 
of proET-1 peptides showed rapid clearance (<5 min) of NT-proET-1, while CT-proET-
1 had the slowest clearance rate. Studies of proET-1 peptide stability in blood samples 
also showed NT-proET-1 had lower stability. Specific double-recognition site sandwich 
ELISAs optimised for plasma measurements were used to evaluate plasma 
concentrations of ELDP and CT-proET-1 in patients with chronic HF and chronic 
kidney disease (CKD). 
In conclusion, the results described in this thesis provide further evidence linking ET-1 
to cardiac and renal disease processes. But the small differences between healthy 
individuals and patients with cardiovascular or renal disease indicate only a limited 
potential for proET-1 peptides as diagnostic biomarkers of EDN1-linked pathologies.  
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1  INTRODUCTION  
1.1  Identification of endothelin-1 
Endothelium-dependent contracting factor (EDCF) was first described in 1985 (Hickey 
et al., 1985). This peptidic EDCF was isolated, purified, sequenced and cloned by 
Yanagisawa and colleagues in 1988 from the conditioned medium of porcine aortic 
endothelial cells, and named as endothelin-1 (ET-1) (Yanagisawa et al., 1988). The 
human preproendothelin-1 (ppET-1) messenger RNA (mRNA) was cloned and 
complete nucleotide sequence was determined by Inoue et al., 1989. The human ET-1 
gene (EDN1) encodes a 212 amino acid precursor, ppET-1 (Bloch et al., 1989).  
Endothelin (ET) occurs as three isoforms ET-1, ET-2 and ET-3 that are generated from 
three distinct human genes encoding ppET-1, ppET-2, and ppET-3, respectively (Inoue 
et al., 1989). All ET peptides are 21 amino acids long, differ only in their N-terminal 
sequence, contain four cysteine residues forming two intra-chain disulphide bridges at 
Cys1 – Cys15 and Cys3 – Cys11 (Yanagisawa et al., 1988; Inoue et al., 1989) and share a 
common hydrophobic C-terminal with Trp21, which is essential for biological activity 
(Bouallegue et al., 2007) (Table 1.1). 
ET-1 is the principal cardiovascular isoform and the most potent vasoconstrictor peptide 
described yet (Yanagisawa et al., 1988). ET-1 contributes to the maintenance of vascular 
tone in healthy humans (Haynes & Webb, 1994). Nevertheless, ET-1 is also implicated 
in the pathophysiology of cardiovascular diseases including atherosclerosis (Lerman et 
al., 1991) where it has enhanced expression (Winkles et al., 1993) and contributes to 
increased constriction in atherosclerotic human coronary arteries (Kinlay et al., 2001). 
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Table 1.1: Comparison of the amino acid sequences of three human ET isoforms: ET-1, ET-2 and ET-3.  Homologous residues to ET-1 are 
represented as hyphens (-). Cysteine residues at positions 1 – 15 and 3 – 11 form disulphide bridges and are conserved in all peptides. The C-
terminal hydrophobic region is also highly conserved across the three ET peptides. 
 
 
ET peptide 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
ET-1 C S C S S L M D K E C V Y F C H L D I I W 
ET-2 - - - - - W L - - - - - - - - - - - - - - 
ET-3 - T - F T Y K - - - - - - Y - - - - - - - 
Chapter 1  Introduction 
4 
 
1.2  Processing of proendothelin-1  
Human ET-1 is derived from a 212 amino acid precursor ppET-1 (Bloch et al., 1989). 
The initial step in processing of the ET-1 precursor involves removal of the amino (N)-
terminal signal sequence of ppET-1 by a signal peptidase. This occurs in the 
endoplasmic reticulum (ER) on entry of the nascent protein into the secretory pathway 
(Steiner, 1982). This generates proendothelin-1 (proET-1), which is condensed and 
packed in the trans-Golgi network and then transported to the cell surface by the 
constitutive secretory pathway. Intracellular proteolytic processing of proET-1 occurs in 
secretory vesicles in endothelial cells (ECs) (Harrison et al., 1995). ProET-1 undergoes 
further proteolytic processing by pro-hormone/pro-protein convertases (PCs) at 
carboxyl (C)-terminal of pairs of basic residues (Rockwell & Thornier, 2004). This 
proteolytic processing generates the inactive intermediate big ET-1 (38 amino acid 
residues) following Lys51-Arg52 and Lys91-Arg92 (Kido et al., 1997). In ECs big ET-1 is 
generated from proET-1 via furin (Denault et al., 1995; Blais et al., 2002). The final step 
of ET-1 biosynthesis involves a novel endopeptidase, which is called endothelin-
converting enzyme (ECE) (Yanagisawa et al., 1988).  
ECE cleaves big ET-1 to the biologically active ET-1 and a C-terminal fragment (CTF) 
of big ET-1 (big ET-1[22 – 38]) by selective hydrolysis of the peptide bond at Trp
21 – Val22 
residues (Figure 1.1) (Emori et al., 1989; Ikegawa et al., 1990). These studies were also 
performed using pulmonary aortic endothelial cells (PAEC)/bovine aortic endothelial 
cells (BAEC) (Harrison et al., 1995) and this was subsequently confirmed in human 
umbilical vein endothelial cells (HUVEC) (Corder et al., 1995b).  
ProET-1 contains six potential cleavage sites by PCs that are beyond the sequence of big 
ET-1. Based on the human sequence, these potential cleavage sites are at C-terminal of 
Lys-Arg (KR) at 92/93; or Lys-Lys (KK) at 118/119, 144/145, and 154/155; or Arg-Lys 
(RK) at 165/166; or Arg-Arg (RR) at 168/169 (Figure 1.1). However, only two of these 
processing sites (Lys-Arg or Arg-Arg) occur frequently. Cleavage at these residues 
could generate potential proET-1 peptide fragments. This results in the co-secretion of 
the biologically active peptide ET-1 with other peptide fragments, which are generally 
considered to be biologically inert (Struck et al., 2005). However, these peptide 
fragments can act as markers for the release of the active vasoconstrictor ET-1 (Struck 
et al., 2005; Papassotiriou et al., 2006). 
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ppET-1
KRKR
1 17
53 90
proET-1
ECE-1
pre-peptide cleaved by signal peptidase
Trp21–Val22
53 73
Big ET-1
CTF of 
big ET-1
ET-1
74 90
Big ET-1
Cleavage of Trp21 – Val22 bond
via endothelin converting
enzyme (ECE) generates ET-1
and C-terminal fragment (CTF)
of big ET-1.
Double basic amino acid
residues [typically Lys-Arg
(KR) and Arg-Arg (RR)] are
cleaved by pro-hormone
convertases (e.g. furin).
Conserved double basic
residues as potential cleavage
sites in the ppET-1 human
sequence.
168/169118/119
KK│C
144/145 154/155 165/166
KK│G KK│C RK│IRR│SS
 
 
Figure 1.1: Biosynthesis of human preproendothelin-1. The signal sequence (position 
1 – 17) of ppET-1 is cleaved by a signal peptidase. ProET-1 is then proteolytically 
processed by PCs at double basic residues (typically Lys-Arg or Arg-Arg). These sites 
are marked with arrows and indicate cleavage possibly via furin-like convertase. This 
generates the inactive intermediate big ET-1, which is cleaved at a Trp21–Val22 bond 
(Trp73 – Val74amino acid residue numbers based on human ppET-1) by the proposed 
endopeptidase ECE. This generates the vasoactive peptide ET-1 and a C-terminal 
fragment (CTF) of big ET-1. Potential cleavage sites at conserved double basic residues 
are marked with dotted arrows. Cleavage at these sites could generate potential proET-
1 peptide fragments. 
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Two distinct pathways are involved in ET-1 release at the cell surface. Firstly, ET-1 is 
released by the constitutive pathway from vesicles originating from the trans-Golgi 
network as described. Secondly, ET-1 is also released from endothelial cell-specific 
storage granules, called Weibel-Palade bodies by a regulated pathway (Russell & 
Davenport, 1999). This occurs through the regulated pathway in response to an external 
physiological or pathophysiological stimulus including thrombin, hypoxia, and shear 
stress (Lowenstein et al., 2005). Weibel-Palade bodies also store von Willebrand factor 
(vWF), which plays a key role in thrombus formation by facilitating platelet adhesion 
(Turritto et al., 1985). 
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1.3  The role of pro-hormone/pro-protein convertases (PCs)  
There are seven members of PCs identified in humans and other mammals.  Furin is the 
best characterised member with Kex2/kexin being its homologous counterpart in yeast 
Saccharomyces cerevisiae (Fuller & Thorner, 1989). Other mammalian relatives are 
PC1/PC3, PC2, PACE4, PC4, PC5/PC6 and PC7/PC8/LPC/SPC7 (Rockwell & Thorner, 
2004). PCs are calcium-dependent serine proteases. All PCs contain an N-terminal 
signal sequence for directing entry into the secretory pathway, a pro-domain which has 
a role in protein folding and it is essential for activity, a subtilisin-related catalytic 
domain and a variable domain, which in furin and PACE4 includes a cysteine-rich 
domain (Henrich et al., 2003). Furin, PACE 4 and PC5/PC6 enzymes are more 
ubiquitously distributed while PC2, PC1/PC3 and PC4 enzymes are localised to 
endocrine/neuroendocrine cells and testicular spermatids (PC4). 
Full-length furin, the PC6 isoform, PC7 and kexin also contain an additional C-terminal 
transmembrane domain and a short cytoplasmic sequence (Henrich et al., 2003). Furin 
and kexin family of proteases recognise dibasic amino acid motifs typically Lys-Arg and 
Arg-Arg and less frequently Lys-Lys, Arg-Lys or Arg-X-X-Arg (Rockwell & Thornier, 
2004; Bergeron et al., 2000). A cleavage site followed by an Arg represented with a P1 
at the first residue on the N-terminal side of the cleaved peptide bond. In addition, furin 
is also specific for Arg at the -4 position relative to the scissile bond (P4-Arg) (Kido et 
al., 1997; Rockwell & Thornier, 2004). Both furin and kexin require an Arg at P1 and P4 
for cleavage. 
 
Furin and PC7 cleave proET-1 to big ET-1 in ECs (Blais et al., 2002). Similar to furin, 
PC7 requires Arg at P1 and P4 but, in addition, a P2 basic residue is also essential (Blais 
et al., 2002). The processing of proET-1 is not fully characterised in vivo and requires 
further investigation.  
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1.4  Endothelin Converting Enzyme (ECE) 
ET-1 biosynthesis is dependent on the hydrolysis of the intermediate big ET-1 by an 
endopeptidase designated as endothelin converting enzyme (ECE) (Yanagisawa et al., 
1988). ECE was initially proposed by Yanagisawa et al., 1988, with the first clear 
evidence being provided by studies showing the inhibitory effect of phosphoramidon on 
cultured porcine aortic endothelial cells (Ikegawa et al., 1990). ET-1 synthesis was 
markedly suppressed by the metalloprotease inhibitor phosphoramidon due to inhibition 
of ECE resulting in the accumulation of the inactive intermediate big ET-1 in cell culture 
conditioned medium (Sawamura et al., 1991; Ikegawa et al., 1991; Corder et al., 1995b; 
Isaka et al., 2003). This led to the understanding that ECE is a phosphoramidon-sensitive 
neutral metalloproteinase.  
The conformation of human big ET-1 is important for its hydrolysis by ECE (Corder, 
1996). This was confirmed by decreased specificity/interaction of ECE to hydrolyse the 
modified big ET-1 [incorporated with N-hydroxysuccinimide esters of 3-(p-
hydroxyphenyl)propionic acid (HPP) or S-acetylthioglycolic acid (ATG) groups, or 
removal of disulphide bridges] (Corder, 1996). 
Two ECE genes have been cloned and they are referred to as ECE-1 (Shimada et al., 
1995; Xu et al., 1994) and ECE-2 (Emoto & Yanagisawa, 1995). ECE-2 is expressed in 
the trans-Golgi network and shares 59% identity with the amino acid sequence of ECE-
1 (Emoto & Yanagisawa, 1995). ECE-3 was later described and purified from bovine 
iris microsomes and is specific for big ET-3 (Hasegawa et al., 1998). All ECE isoforms 
cleave big ET-1 with the same efficiency (D’Orléans-Juste et al., 2003). The cleavage 
of big ET-2 occurs at the Trp21 – Val22 bond, as in big ET-1, whereas big ET-3 is cleaved 
at the Trp21 – Ile22 bond to produce ET-3. ECE-2 is more selective for big ET-1 than for 
big ET-2 and big ET-3. Immunohistochemical studies shown highest ECE-1 expression 
in cardiovascular endothelium (Whyteside & Turner, 2013).  ECE-1 is the most 
abundant isoform and it is widely expressed in many cells and human tissues (Rossi et 
al., 1995; Valdenaire et al., 1995; Schweizer et al., 1997). 
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1.4.1  Structural features of ECE-1  
ECE-1 is a type II integral membrane-bound neutral metalloproteinase. ECE-1 has 
structural similarity to neutral endopeptidase 24.11 or neprilysin (NEP-24.11) (Malfroy 
et al., 1988) and Kell blood group protein (Lee et al., 1991) and both ECE-1 and NEP-
24.11 are localised on the plasma membrane of human ECs (Waxman et al., 1994; 
Corder et al., 1995b) (Table 1.2, page 11). 
ECE-1 consists of (1) a short N-terminal cytoplasmic domain, (2) a single 
transmembrane helix, and (3) a large extracellular domain that includes the active 
catalytic site (comprising the C-terminal end) and a HEXXH (His591, Glu592, X, X, 
His595) zinc-binding motif (Sansom et al., 1995; Whyteside & Turner, 2013). This 
suggested that ECE-1 has similar topology and cellular location and possibly exist as an 
ectoenzyme converting big ET-l to ET-1 at the extracellular face of the plasma 
membrane (Turner & Tanzawa, 1997). Mutational studies of ECE have established a 
conserved NAYY (Asn566, Ala567, Tyr568, Tyr569) motif to be important for substrate 
binding and unique to ECE (Sansom et al., 1998). 
In contrast to NEP-24.11, ECE-1 is highly glycosylated (ten N-linked glycosylation 
sites) and has ten highly conserved Cys residues. Under reducing conditions ECE-1 was 
estimated to exist with a molecular weight (MWt) of 120 – 130 kD (SDS-PAGE) (Xu et 
al., 1994; Turner & Murphy, 1996). Human ECE-1 was estimated to be ~250 kD (gel 
filtration chromatography) (Corder et al., 1995b). This suggested that ECE-1 has two 
disulphide-linked subunits (Takahashi et al., 1995; Shimada et al., 1996). 
Four human ECE-1 isoforms (ECE-1a – d) are expressed in ECs. These are derived from 
the same gene through alternative splicing of mRNA. They differ from each other in 
their N-terminal cytoplasmic tails (Valdenaire et al., 1995). These tails play a role in 
enzyme targeting and turnover with di-leucine and tyrosine-based motifs affecting 
localisation (Valdenaire et al., 1995). While ECE-1a (758 amino acid residues) and 
ECE-1c (754 amino acid residues) are found on the plasma membrane as ectoenzymes 
(Schweizer et al., 1997), ECE-1b (770 amino acid residues) is located intracellularly 
(Takahashi et al., 1995). Later, Muller et al., 2003 demonstrated in transfected AtT-20 
neuroendocrine cells that both ECE-1b and ECE-1d are located intracellularly in the 
endosomal system. ECE-1b mRNA is widely expressed in a variety of tissues, but ECE-
1a is more abundantly expressed than ECE-1b in ECs (Shimada et al., 1995) and human 
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tissue (Mockridge et al., 1998) but not in primary cultures of smooth muscle cells (SMC) 
(Valdenaire et al., 1999). In contrast, Schweizer et al., 1997 showed ECE-1c mRNA as 
the main isoform expressed in most human tissues while confirming ECE-1a as the 
predominant isoform in ECs. Subsequent studies showed ECE-1c and ECE-1d 
expression in vascular smooth muscle cells (VSMC) (Barker et al., 2001) while all 
isoforms were expressed in ECs. In general, ECE-1 is localised to the luminal surface 
on ECs rather than VSMC (Russell et al., 1998). Even though there is difference in their 
tissue distribution ECE-1a – c isoforms cleave big ET-1 with comparable efficiencies 
(Schweizer et al., 1997).  
 
Both ECE-1 and ECE-2 catalyse the conversion of big ET-1 to ET-1 with a neutral (pH 
6.8) and acidic (pH 5.6) pH optimum, respectively (Emato & Yanagisawa, 1995).  ECE-
2 is localised in secretion vesicles and ECs but not expressed on plasma membrane 
(Emato & Yanagisawa, 1995).  
 
The association between specific ECE-1 isoforms to ET-1 synthesis and factors 
regulating cell-specific expression of ECE-1 isoforms have been unclear (Corder et al., 
1998). In BAEC, Corder & Barker, 1999 found no relation between the level of ET-1 
synthesis or ppET-1 expression with the level of ECE-1 expression (ECE-1a, ECE-1c, 
or all the ECE-1 isoforms).   
  
ECE-1 activity is increased in isolated endothelium-denuded human atherosclerotic 
coronary arteries (Maguire & Davenport, 1998) as well as in rat balloon-injured arteries. 
In rat balloon-injured arteries, in contrast to EC localisation in uninjured vessels, 
immunohistochemical staining located ECE-1 in neointimal SMC in injured arteries 
(Minamino et al., 1997; Dashwood et al., 1999). Furthermore, ECE-1 was detected in 
the intimal and medial VSMC and localised in macrophages and fibrous cap of 
atherosclerotic lesions (Ihling et al., 2001). Upregulation of the ECE-1/ET-1 system was 
also shown to be associated with chronic inflammation and to be present in the early 
stages of atherosclerotic plaque development (Ihling et al., 2001). Together these data 
suggest a possible role of ECE-1 in the vascular remodelling process. Increased ECE-1 
activity may also contribute to increased big ET-1 conversion to ET-1 (Böhm et al., 
2002) that is evident with increased ET-1 levels observed in atherosclerosis (Zeiher et 
al., 1995).  
Chapter 1  Introduction 
11 
 
 Table 1.2: Distinguishing features of ECE-1 and NEP-24.11. 
 ECE-1 NEP-24.11 
Structure 
● ECE-1 (120 – 130 kD) forms 
covalent disulphide-linked 
dimers (as shown by site-
directed mutagenesis of Cys412 
in rat ECE-1 (Cys428 in human). 
● NEP-24.11 (90 – 100 kD) 
forms a non-covalent monomeric 
structure (Shimada et al., 1996). 
Substrate 
specificity 
● ECE-1 cleaves Trp21 – Val22 
bond of big ET-1 but also 
cleaves bradykinin (Hoang & 
Turner, 1997) substance P, and 
hydrolyses insulin B chain at 
multiple sites with similar 
efficiency to that of big ET-1 
(Johnson et al., 1999).  
● NEP-24.11 has broader 
substrate specificity. Cleaves 
peptide bonds on the N-terminal 
of hydrophobic amino acids 
(Turner & Tanzawa, 1997). 
Atrial natriuretic peptide (ANP) 
and oxytocin are also substrates 
of NEP-24.11. 
Sensitivity to 
inhibitors 
● Phosphoramidon inhibits both ECE-1 and NEP-24.11 but has a 
greater potency (lower Ki) for NEP-24.11.  
● Thiorphan is a potent inhibitor of NEP-24.11 but not ECE-1 
(Turner & Murphy, 1996). 
Metabolism 
of ET 
peptides 
● At lower concentrations (1 µM), NEP-24.11 rapidly degrades ET 
peptides.  
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1.4.2  Analysing the physiological role of ECE-1 in ET-1  
  biosynthesis 
1.4.2.1  Inhibitor studies with protease inhibitors  
In anaesthetised rats, the conversion of exogenously administered big ET-1 to ET-1 was 
observed with increased blood pressure (BP) and airway contractile responses 
(Fukuroda et al., 1990). Phosphoramidon inhibited the BP response of systemically 
administered big ET-1 but not to ET-1 (Fukuroda et al., 1990; Matsumura et al., 1990; 
Corder & Vane, 1995). In contrast, incubation of tissues from guinea pig gallbladder 
with protease inhibitors such as thiorphan inhibitor NEP-24.11 (3 x 10-4 M); or 
metalloprotease inhibitor 1,10-phenanthroline (10-4 M); an angiotensin converting 
enzyme (ACE)  inhibitor captopril (10-4 M); an inhibitor of aspartic proteases pepstatin 
A (10-5 M); an irreversible inhibitor of serine proteases PMSF (10-3 M); a serine protease 
inhibitor E-64; a trypsin-like serine protease inhibitor leupeptin (10-4 M); a 
chymotrypsin-like serine protease inhibitor chymostatin (10-4 M); aprotinin (10-6 M); 
and an inhibitor of aminopeptidases bestatin (10-5 M) before the addition of big ET-1 
were all insufficient to prevent the conversion to ET-1 (Battistini et al., 1995). 
   
Likewise neither captopril nor kelatorphan was able to block the pressor activity of big 
ET-1 in the anaesthetised rats (McMahon et al., 1991). However, thiorpan dose-
dependently inhibited the pressor response to big ET-1, but this inhibition was less 
potent than phosphoramidon (McMahon et al., 1991). These metalloprotease inhibitors 
(phosphoramidon, kelatorphan, and thiorphan) have equal potency for NEP-24.11 and 
since kelatorphan and thiorphan were unable to inhibit ECE activity, it confirmed that 
ECE and NEP-24.11 are distinct members of the metalloprotease family.  These results 
collectively showed evidence that ECE-1 is a phosphoramidon-sensitive 
metalloprotease. 
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1.4.2.2  Inhibitor studies in endothelial cells 
Incubation of big ET-1 with cultured ECs in the presence of phosphoramidon inhibited 
ET-1 production (Ikegewa et al., 1990; Corder et al., 1995b). Similarly, in cultured 
vascular ECs and VSMC phosphoramidon inhibited the conversion of exogenous big 
ET-1 to ET-1 (Ikegewa et al., 1991). Higher concentrations of phosphoramidon were 
required to inhibit endogenous sysnthesis of ET-1 in comparison to those required to 
inhibit exogenous big ET-1 (Corder et al., 1995b). Consistent with intracellular 
synthesis of ET-1 in the secretory vesicles, this was indicative of intracellular hydrolysis 
of the endogenous peptide, which is relatively inaccessible to phosphoramidon (Corder, 
2001).  
Phosphoramidon and thiorphan are zinc metallopeptidase inhibitors. While NEP-24.11 
is inhibited by both (at nM concentrations), ECE-1 is only sensitive to phosphoramidon 
(at µM concentrations). Phosphoramidon inhibits other metallopeptidases such as 
bacterial metalloendopeptidase thermolysin, which has similar substrate specificity as 
NEP-24.11. 
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1.4.2.3  Functional studies  
Although, ECE-1 has been proposed to be the physiological ECE that hydrolyses the 
Trp21 – Val22 bond in big ET-1 to generate vasoactive ET-1 (Yanagisawa et al., 1988; 
Turner & Murphy, 1996) it is still not known whether or not ECE-1 is the only enzyme 
involved in this process. Yanagisawa et al., 1998 reported developmental defects in 
cardiac- and neural crest-derived tissues in a targeted null mutation of ECE-1 gene in 
mouse (ECE-1-/-) that was virtually identical to the defects seen in ET-1 and ETA-
deficient embryos (Yanagisawa et al., 1998). In order to further investigate the role of 
ECE-2 in cardiovascular development Yanagisawa et al., 2000 generated a null mutation 
in ECE-2 by homologous recombination. ECE-2-/- knockout (KO) mice were healthy 
into adulthood and fertile in both sexes (Yanagisawa et al., 2000). However, when they 
were bred into an ECE-1 null background, defects in cardiac outflow structures became 
more severe than those in ECE-1-/- single KO embryos.  More interestingly, tissue levels 
of ET-1/ET-2 measured in whole-embryo extracts from ECE-1-/- and ECE-2-/- mutant 
embryos were similar to those from ECE-1 (48% reduction in ET-1 levels when 
compared to controls) without increases in big ET-1 levels (Yanagisawa et al., 2000). 
This indicated that protease(s) distinct from ECE-1 and ECE-2 can activate mature ET-
1/ET-2 in vivo (Yanagisawa et al., 2000).  
Furthermore, Barker et al., 2001 characterised ECE-1 isoforms in bovine pulmonary 
artery smooth muscle cells (BPSMC), and used an antisense oligodeoxynucleotide 
(ODN) for ECE-1c (the predominant isoform in BPSMC) to test the effect of ECE-1 
depletion on ET-1 synthesis. Treatment with ECE-1c antisense ODN specifically 
reduced ECE-1c mRNA levels and ECE-1 protein, but had a negligible effect on ET-1 
synthesis (Barker et al., 2001). This suggested that the physiological role of ECE-1 in 
ET-1 biosynthesis is not clear and still needs to be further elucidated. 
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1.5  Alternative processing pathways of ET-1 synthesis 
As well as metalloproteinases (Okada et al., 1990), serine and aspartic proteases 
(Ikegawa et al., 1990) can also cleave big ET-1 to produce ET-1. These include matrix 
metalloproteases (MMPs) and human chymase, which produce the vasoactive peptide 
ET-1[1 – 32] and ET-1[1 – 31], respectively.  
 
 
1.5.1  Matrix metalloproteinase-2 
Matrix metalloproteinase-2 (MMP-2, gelatinase A) is a zinc-dependent proteinase 
secreted from vascular endothelial and SMC (Li et al., 1999). MMP-2 cleaves human 
big ET-1 at Gly32 – Leu33 bond (Fernandez-Patron et al., 1999). TIMP-2 is an 
endogenous inhibitor of MMPs with preferred effects on MMP-2 (Woessner, 1998) 
inhibited MMP-2–dependent conversion of big ET-1 (Fernandez-Patron et al., 1999). 
 
 
1.5.2  Chymase 
Incubation of big ET-1 with purified human connective tissue mast cell chymase (a 
chymotrypsin-like serine protease) produced ET-1[1 – 31] by cleaving at the Tyr
31 – Gly32 
bond of big ET-1 (Nakano et al., 1997). In endothelium-denuded human umbilical 
venous smooth muscle, ET-1[1 – 31] does not bind to ET receptors at physiological 
concentrations but is converted by enzymatic activity to ET-1 (Maguire & Davenport, 
2004; Davenport & Maguire, 2006). In human bronchial smooth muscle cells ET-1[1 – 
31] is hydrolysed by ECE-1 and NEP-24.11 and is a trachea and vascular smooth muscle 
constricting peptide. 
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1.6  Factors regulating ET-1 biosynthesis in endothelial cells   
ET-1 biosynthesis is dependent on regulation and transcription of ET-1 mRNA (Rubanyi 
& Polokoff, 1994).  Transcriptional factors that are involved in the regulation of ET-1 
gene expression with relevance to atherosclerosis and diabetes include activator protein-
1 (AP-1), hypoxia inducible factor-1 (HIF-1), nuclear factor κB (NFκB), vascular 
endothelial zinc finger 1 (Vezf1), GATA binding protein-2 (GATA-2) and GATA-4, 
and nuclear factor of activated T-cells (NFAT) (Stow et al., 2011). Moreover, DNA 
methylation and histone modifications as well as post-transcriptional modifications that 
affect mRNA stability also modulate EDN1 expression (Stow et al., 2011). 
Transcriptional factors can be activated by stimuli such as thrombin (Yanagisawa et al., 
1988; Marsen et al., 1995), angiotensin II (Ang II)  (Emori et al., 1991; Imai et al., 
1992), growth factors [transforming growth factor-β (TGF-β)] (Lee et al., 2000; 
Rodríguez-Pascual et al., 2003), cytokines [tumour necrosis factor-α (TNF-α)], insulin 
(Oliver et al., 1991; Hattori et al., 1991; Hu et al., 1993), hypoxia (Kourembanas et al., 
1991; Kang et al., 2011), reactive oxygen species (ROS) (Kahler et al., 2001; Ruef et 
al., 2001), low density lipoprotein (LDL) (Boulanger et al., 1992), epinephrine, and 
phorbol ester enhances the secretion of ET-1. By contrast, mediators like calcium 
ionophore (Corder et al., 1993b; Brunner et al., 1994), nitric oxide (NO) (Boulanger & 
Lüscher, 1990), cyclic guanosine monophosphate (cGMP) (Wort et al., 2000), ANP (Hu 
et al., 1992), and prostacyclin (PGI2) (Prins et al., 1994) reduce the release of 
endogenous ET-1. Consensus sequences for these regulators (including shear stress, 
TGF-β, insulin, thrombin, epinephrine, interleukin-1, and Ang II,) are also found in the 
human ECE-1 gene (Valdenaire et al., 1995). 
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1.6.1  Fluid shear stress 
Fluid shear stress regulates ET-1 mRNA in a biphasic manner (Yoshizumi et al., 1989; 
Malek et al., 1999). ET-1 gene expression is stimulated at low shear stress (4 – 5 
dyn/cm2) (Harrison et al., 1998). In contrast, fluid shear stress at physiological 
magnitude (6 h, 20 dyn/cm2) suppressed ET-1 mRNA expression by 5 – 10-fold in 
cultured BAEC (Malek et al., 1993) and HUVEC (Sharefkin et al., 1991). Exposing 
primary cultures of HUVEC to laminar shear stress transiently upregulated ppET-1 
mRNA, reaching its maximum after 30 min. When HUVEC were exposed to long-term 
laminar shear stress (24 h), ppET-1 mRNA and ECE-1a mRNA levels (most abundant 
ECE-1 isoform in HUVEC) were downregulated (Morawietz et al., 2000). 
Downregulation of ppET-1 mRNA and ET-1 release occurs in a shear stress magnitude 
dependent manner (Morawietz et al., 2000). Protein kinase C (PKC) inhibitor calphostin 
C (1 µM) did not hinder shear-induced downregulation of ET-1 and forskolin (10 µM) 
an activator of adenylate cyclase (AC) had no significant effect on cyclic adenosine 
monophosphate (cAMP) levels in response to shear stress of up to 60 min (20 dynes/cm2) 
and resulted in significant downregulation of ET-1 mRNA (Malek et al., 1993). These 
data suggest that the regulation of ET-1 by shear stress (of magnitude 20 dynes/cm2) in 
aortic endothelium is independent of PKC and cAMP (Malek et al., 1993). HUVEC 
were not affected by PKC, cAMP or tyrosine kinase inhibition (Morawietz et al., 2000). 
Steady laminar shear stress (20 dyn/cm2) increased endothelial nitric oxide synthase 
(eNOS) mRNA levels (Malek et al., 1999). The mechanism of this effect could result 
from shear stress induced activation of Ca2+ dependent eNOS, which inhibits ET-1 
(Malek et al., 1999). Inhibition of eNOS (by L-NAME, 500 μM) prevented the 
downregulation of ppET-1 mRNA by shear stress (Morawietz et al., 2000). 
 
Increase in ET-1 release following short periods of mechanical stretch was demonstrated 
in ECs (Macarthur et al., 1994; Hishikawa et al., 1995) and in human atherosclerotic 
coronary arteries in vivo (Hasdai et al., 1997). 
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1.6.2  Krüppel-like factor 2 (KLF2) 
The most important mechanism regulating ET-1 gene expression in ECs in response to 
fluid shear stress is through the activation of a transcription factor, Krüppel-like factor 
2 (KLF2). Expression of KLF2 is specific for ECs where it mediates the effect of fluid 
shears on ET-1 expression. This response is blocked by siRNA for KLF2 (Parmar et al., 
2006). Inhibition of flow-induced upregulation of KLF2 in ECs caused significant 
decrease of the regulation of upregulated genes such as eNOS (Parmar et al., 2006). 
Downregulation of interleukin-8 (IL-8), Ang-II, and ET-1 was abolished at the mRNA 
level (Parmar et al., 2006). Overexpression of KLF2 in HUVEC potently induces eNOS 
and inhibits the induction of key adhesion molecules such as vascular cell adhesion 
molecule 1 (VCAM-1) and E-selectin (through NFκB-dependent pathway), but not 
intracellular adhesion molecule-1 (Feinberg et al., 2004). 
 
KLF2 inhibits activation of pro-inflammatory cytokines including TNF-α, LPS, and 
thrombin (Atkins & Jain, 2007). KLF2 inhibits protease-activated receptor-1 (PAR-1), 
which is the principal receptor of thrombin. Therefore, KLF2 inhibits thrombin-induced 
activation of cytokine/chemokine such as IL-6, IL-8, and monocyte chemoattractant 
protein-1 (MCP-1) (Atkins & Jain, 2007). 
 
1.6.3  Calcium (Ca2+) ionophores 
Stimulation of ECs with Ca2+ ionophores for short periods increase ppET-1 mRNA 
expression (Tasaka & Kitazumi, 1994) while longer stimulation suppress ET-1 synthesis 
(Corder et al., 1993b). Calcium ionophore, A23187, inhibited ET-1 release from 
cultured HUVEC (Russell et al., 1998). The inhibitory effect of A23187 was unaffected 
by NOS inhibitor NG-monomethyl-L-arginine (0.2 mM) or COX inhibitor indomethacin 
(10 µM). Therefore, inhibition of ET-1 release by A23187 was independent from NO or 
prostacyclin synthesis in BAEC and EA.hy 926 cells (Corder et al., 1993b). Calphostin 
(PKC inhibitor) suppressed basal ppET-1 expression in ECs (Malek et al., 1993), 
indicating a role of specific PKC isoforms in the regulation of ET-1 gene expression.  
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1.6.4  Thrombin 
Thrombin stimulates ppET-1 gene expression and ET-1 release in macrovascular 
[HUVEC and bovine pulmonary artery endothelial cells (BPAEC)] and microvascular 
cells [human endothelial cell line (HMEC-1)] with highest induction occurring at 4 U/ml 
after 2 h (Marsen et al., 1995). Thrombin stimulated ppET-1 mRNA and ET-1 peptide 
induction was mediated by phosphorylation and activation of protein tyrosine kinase 
(PTK) through PKA and PKC-independent pathway (Marsen et al., 1995). This 
conclusion was reached using selective PTK inhibitors herbimycin A (1 μmol/L for 6 h) 
and genistein (6 μg/ml for 30 min) before thrombin stimulation, which reduced ppET-1 
mRNA expression and thrombin-stimulated ET-1 peptide synthesis to control levels in 
HUVEC and HMEC-1, and below control levels in BPAEC (Marsen et al., 1995). 
Phorbol ester (an activator of PKC) transiently induced ppET-1 mRNA but had no effect 
on ET-1 peptide synthesis. Thrombin stimulated ppET-1 mRNA was unaffected by 
inhibition of PKC using sangivamycin (0.1 μmol/L for 30 min) and calphostin C (0.1 
μmol/L for 30 min). Forskolin (20 μmol/L for 2 h) had no effect on thrombin stimulated 
ppET-1 mRNA levels and ET-1 peptide synthesis.  
 
In contrast, thrombin stimulated ppET-1 mRNA in porcine aortic ECs can be mediated 
by PKC (Kitazumi & Tasaka, 1993) and immunoreactive (ir) ET-1 release was inhibited 
by PKC inhibitors H7 [91-(5-isoquinolinesulphonyl)-2-methylpiperazine)] and 
staurosporin (Kohno et al., 1992). 
 
 
1.6.5  Bacterial lipopolysaccharide (LPS) 
Treatment of BAEC with bacterial lipopolysaccharide (LPS) (10 µg/ml) resulted in a 
concentration-dependent increase in ET-1 release and increased ppET-1 mRNA 
expression (Douthwaite et al., 2003). Increase in ppET-1 mRNA transcription was 
relatively small in comparison to increase in ppET-1 mRNA levels and the degree of 
induction of ET-1 release (Douthwaite et al., 2003). Therefore, decreased mRNA 
degradation and increased stability were more likely to be the key contributing factors 
to the increased mRNA levels. LPS increased ppET-1 mRNA stability by approximately 
2-fold (Douthwaite et al., 2003). Jersmann et al., 2001 also stated that TNF-α and LPS 
act synergistically to upregulate expression of endothelial cell adhesion molecules such 
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as intercellular adhesion molecule-1 (ICAM-1), E-selectin and VCAM-1, which are 
important mediators in the regulation of leukocyte trafficking from the blood to the site 
of inflammation.  
  
 
1.6.6  Insulin 
Insulin stimulated ET-1 levels (2-fold) in the conditioned medium from BAEC (Potenza 
et al., 2005). Pre-treatment with a PI3K inhibitor, wortmannin, had no significant effect 
on insulin-stimulated ET-1 secretion while MAPK (MEK1/MEK2) inhibitor PD-98059 
abolished this effect of insulin. Therefore, suggesting MAPK-dependent pathways (but 
not PI3-kinase-dependent pathways) are involved in insulin mediated ET-1 secretion in 
BAEC. 
The mRNA expression of ppET-1 and ET receptors was increased in diabetic rats (STZ-
induced diabetic rats) when compared to age-matched controls (Matsumoto et al., 2004). 
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1.7 Regulation of ET-1 synthesis in other cell types: vascular 
smooth muscle cells, cardiomyocytes, airway epithelial 
cells and expression in cancer cells 
Although ECs are the primary source of vascular ET-1 production, other cell types such 
as VSMC, cardiomyocytes, macrophages (Ehrenreich et al., 1990), leukocytes, and 
fibroblasts can also synthesise ET-1 (Nunez et al., 1990). In addition to cardiovascular 
system, tubular epithelial cells, mesangial cells and podocytes of the kidney also 
synthesise ET-1 (Kohan, 1997). In non-ECs, ET-1 synthesis is low, if any, but in 
pathological conditions, it can be induced by several stimuli (as described in the previous 
section 1.6 for ECs).  
 
1.7.1  Vascular smooth muscle cells 
In contrast to ECs, ppET-1 mRNA was not constitutively expressed in quiescent cultures 
of rat aortic VSMC. Nevertheless, vasoconstrictor peptides [Ang II, arginine-
vasopressin (AVP) and ET-1 itself], growth factors [TGF-β, platelet derived growth 
factor AA (PDGF-AA) and epidermal growth factor (EGF)] induced ppET-1 mRNA 
expression in rat (Hahn et al., 1990) and human VSMC (Resink et al., 1990). This was 
rapid but with transient kinetics (peak at 3 – 5 h and return to basal within 7 h) (Resink 
et al., 1990). Thrombin induced ppET-1 mRNA expression in rat aortic SMC with 
maximal effects at 4 U/ml after 80 min incubation (Lepailleur-Enouf et al., 2000). In 
addition, glucocorticosteroids can also increase ET-1 secretion in VSMC. A pure 
glucocorticoid agonist, RU 28362 at 100 nM increased ET-1 secretion by 3.3-fold after 
1 h (Morin et al., 1998). 
In healthy saphenous and mesenteric veins, and mesenteric and internal mammary 
arteries, ET staining in medial SMC was undetectable (Howard et al., 1992). This 
suggested that in VSMC, there is very low ET-1 synthesis, if any. However, cultures of 
VSMC explanted from diseased human coronary artery, thoracic aorta, left internal 
mammary artery, saphenous vein, and HUVSMC (human umbilical vein vascular 
smooth muscle cells) secreted ET-1 (Yu & Davenport, 1995). In HUVSMC, the level of 
release was lower than ECs (Yu & Davenport, 1995).   
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TNF-α (maximal stimulation with 10 ng/ml) and interferon-γ (IFN-γ) (fixed 
concentration at 1000 U/ml) incubated in combination over 48 h significantly increased 
ppET-1 mRNA and the expression of ET-1 in human VSMC derived from internal 
mammary artery and saphenous vein (Woods et al., 1999). IL-1β, (up to 10 ng/ml), IL-
6 (up to 10 ng/ml), and bacterial endotoxin (up to 10 ng/ml) did not produce an additional 
increase in ET-1 production (Woods et al., 1999). 
 
1.7.2  Pulmonary arterial smooth muscle cells (PASMC)  
ET-1 is synthesised from pulmonary arterial smooth muscle cells (PASMC) and plays a 
key role in the pathology of vascular remodelling in pulmonary artery hypertension 
(PAH) (Tchekneva et al., 2000; Wort et al., 2001). ET-1 upregulates proliferation of 
human primary PASMC only in the presence of stimuli such as serum (Lambers et al., 
2013) through an ETA receptor-mediated mechanism (Panettieri et al., 1996). Davie et 
al., 2002 showed increased ir-ET-1 with 10% foetal bovine serum (FBS) or TGF-β1 (10 
ng/ml), while cicaprost (10−10 – 10−7 mol/L for 24 h), a PGI2 analogue, inhibited the 
proliferation of PASMC. TGF-β1 (10 ng/ml), as well as increasing ir-ET-1, it also 
increased PASMC proliferation (Davie et al., 2002). In this study, ET-1 reduced the 
inhibitory effects of cicaprost and forskolin on DNA synthesis (Davie et al., 2002). In 
contrast to TGF-β1 (1 – 10 ng/well for 24 h), hypoxia (exposure to 0% O2 for 24 h) did 
not increase ppET-1 mRNA or ET-1 production in PASMCs (Markewitz et al., 2001).    
  
ET-1 also increased the de novo synthesis and deposition of extracellular matrix (ECM) 
components; collagen type-I and fibronectin, which involved TGF-β1 and connective 
tissue growth factor (CTGF), respectively (Lambers et al., 2013).  Inhibition of ETA 
receptor (with BQ-123) or ET-1 synthesis using phosphoramidon decreased serum 
induced proliferation of human PASMC, confirming an autocrine role for ET-1 (Wort 
et al., 2001). 
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 1.7.3  Cardiomyocytes 
Cultured neonatal rat cardiomyocytes incubated with ET-1 (10-7 M) over 6 h induced 
muscle-specific gene expression [myosin light chain 2 (2.6-fold), α-actin (1.6-fold) and 
troponin I (3.6-fold)], in a dose dependent manner and the actions lasted up to 24 h (Ito 
et al., 1991). ET-1 transiently induced transcriptional activation of proto-oncogene c-
fos, however the levels were undetectable after 6 h. These results supported the notion 
that ET-1 may function as a hypertrophic factor for cardiomyocytes.  
 
Ang II (10-6 M) upregulated ppET-I mRNA by 3-fold over control levels as early as 30 
min (Ito et al., 1993). After 2 h, ppET-1 gene expression had returned to basal levels and 
remained constant during 24 h (Ito et al., 1993). Ang II incuded ET-1 release was both 
concentration- and time-dependent.  
 
Phorbol ester, tetradecanoylphorbol-acetate (TPA) (10-7), which is a PKC activator, and 
a Ca2+ ionophore, ionomycin similarly induced the expression of muscle specific genes 
(Ito et al., 1991). Both TPA and ionomycin mimicked the effects of Ang II and ET-1 
(Ito et al., 1993). Ang II-induced ppET-1 gene expression was completely inhibited by 
a PKC inhibitor, H-7 (10-5 M). An antisense oligonucleotide used against the coding 
region of ppET-1 mRNA inhibited the Ang II-stimulated ppET-l mRNA and protein 
synthesis (Ito et al., 1993). This supported the role of endogenous ET-1 to Ang II-
induced cardiac hypertrophy. 
 
 
1.7.4   Airway epithelial cells  
Human bronchial epithelial cells stimulated with LPS and various inflammatory 
mediators, such as IL-1 (IL-1r3, IL-Iα) and TNF-α, increased ppET-I mRNA expression 
and ET-I release (Nakano et al., 1994; Michael & Markewitz, 1996). After a 24 h 
incubation of cultured guinea pig tracheal epithelial cells LPS (1, 5, 10 µg/ml), TNF-α 
(5, 10 ng/ml), and IL-1β (1, 5 ng/ml) enhanced basal ET-1 release (Yang et al., 1997). 
Pre-treatment with dexamethasone (100 nM, over 24 h), a corticosteroid that is 
commonly used in the treatment of asthmatic patients, reduced LPS- (10 µg/ml), TNF-
α- (10 ng/ml) and IL-1β- (1 ng/ml) mediated ET-1 release by 48%, 31%, and 38%, 
respectively (Yang et al., 1997). Dexamethasone (100 nM) also reduced FBS (10%) and 
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IL-2-stimulated and basal ET-1 release in adenocarcinomic human alveolar epithelial 
cells (A549) (Calderón et al., 1994).  
Human bronchial epithelial cells derived from asthmatic patients express higher ET-1 
levels, while ppET-1 mRNA expression (determined by in situ hybridisation) was 
undetectable and low in healthy controls and chronic bronchitis, respectively (Vittori et 
al., 1992). Hydrocortisone (10-6 M) treatment of asthmatic bronchial epithelial cells for 
48 h reduced ET-1 release (Vittori et al., 1992). 
 
1.7.5  Cancer cells  
Human cervix (HeLa) and larynx (Hep-2) derived epithelial carcinoma cell lines express 
ppET-1 mRNA under basal conditions in which LPS (10%) stimulated ET-1 release by 
62 and 8.5-fold, respectively (Shichiri et al., 1991). ET-1 stimulated (10-3_10-9 M, 72 h) 
proliferation of HeLa and Hep-2 cells was inhibited by nicardipine (10-7 M), a 
dihydropyridine calcium-channel blocker (Shichiri et al., 1991). 
Androgens downregulate ET-1 synthesis in androgen-sensitive prostate adenocarcinoma 
cells (LNCaP), while TGF-β-1, IL-1α and EGF upregulated ET-1 gene expression in 
androgen-insensitive PC-3 and DU145 cells (Granchi et al., 2001). In contrast, neither 
of factors had an effect on ECE-1 gene expression (Granchi et al., 2001). These suggest 
that ET-1 might have a role in the progression of prostate cancer. Higher ET-1 and ETA 
receptor expression but lower ETB receptor expression detected in advanced prostate 
cancer further supports this role (Nelson et al., 1996). 
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1.8  Endothelin receptors 
Two ET receptor subtypes, ETA and ETB, have been identified, cloned and sequenced 
(Arai et al., 1990; Sakurai et al., 1990; Saito et al., 1991). Both receptors belong to the 
seven-transmembrane domain, G protein-coupled rhodopsin-type receptor superfamily. 
ET-1 has similar affinity for both ETA and ETB receptors. ET-1 and ET-2 have equal 
binding affinity and efficacy at the ETA receptors while ET-3 is less potent (Arai et al., 
1990; Sakurai et al., 1990; Davenport, 2002) (Table 1.3). All ET isoforms have equal 
affinity for ETB receptors (de Nucci et al., 1988; Rubanyi & Polokoff, 1994; Love et al., 
2000).  
Table 1.3: Affinity of ET peptides for ETA and ETB receptors.  
ET receptor ET peptide selectivity  
ETA ET-1 = ET-2 ≫ ET-3  
ETB ET-1 = ET-2 = ET-3 
 
ETA receptors predominate on VSMC mediating vasoconstriction (pressor response) 
(Davenport et al., 1995; Maguire & Davenport, 1995; Love et al., 2000).  A small 
density (<15%) of ETB receptors are also expressed on VSMC, where their activation 
contributes to vasoconstriction (Clozel et al., 1992; Maguire & Davenport, 1995). ETB 
receptors are mainly expressed on the vascular ECs (Summer et al., 1992), where their 
activation results in vasodilatation (depressor response). This is mediated by the release 
of endothelium-derived vasodilators NO and PGI2 (de Nucci et al., 1988; Verhaar et al., 
1998) (Figure 1.2, page 36). ETB receptors mediate anti-proliferative and anti-
inflammatory actions by releasing NO. They were also shown to stimulate apoptosis in 
rat aortic VSMC (Cattaruzza et al., 2000). 
Distribution of ET receptors shows species, regional, and developmental differences 
(Fukuroda et al., 1994b). Thereby, based on this difference, vasoconstrictor responses 
mediated by ET receptors vary depending on the vascular bed (Davenport & Maguire, 
1994). Contractile activities of ET isoforms were in the order of ET-1 > ET-2 = ET-3 in 
human isolated bronchus (Advenier et al., 1990). In human arteries and veins ET-2 as a 
vasoconstrictor was equipotent with ET-1 (Maguire & Davenport, 1995). 
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In contrast to ETA receptors being more prevalent in cardiovascular system, ETB 
receptors are expressed at high densities particularly in the lung, kidney and liver (Kuc 
et al., 1995; Johnström et al., 2002) where they mediate clearance of ET-1 from the 
circulation (Fukuroda et al., 1994a). In the kidney, ETB receptors comprise 70% of the 
receptors present in both cortex and medulla (Neuhofer & Pittrow, 2009). Collecting 
duct (CD) is the main renal site of ET-1 production and a CD-specific epithelial cell KO 
of ETB receptor gene (CD ETB KO) caused sodium (Na
+) retention and thereby salt-
sensitive hypertension (Ge et al., 2006). In contrast, endothelial cell specific ETB 
receptor KO (with preserved CD ETB expression) had impaired endothelium-dependent 
vasodilatation (EDD) without altering BP, even with increased plasma ET-1 
concentrations (Bagnall et al., 2006). Thus, these investigations suggested that ETB 
receptors in the CD are important in the control of BP and mediate natriuretic effects of 
ET-1. More recently the epithelial sodium channel (ENaC), which is the main regulator 
of Na+ reabsorption in the CD, has been shown to be regulated mainly via the ETB 
receptors (Bugaj et al., 2012). 
The effects of blocking ETB receptor system was investigated in wild-type and ETB 
receptor KO using a mouse model of vascular remodelling (induced by blood flow 
cessation in the carotid artery). This demonstrated worsening of vascular remodelling in 
ETB receptor KO mice after injury (Murakoshi et al., 2002). 
In disease states, expression of ET receptors shows regional differences. Some of these 
findings are as follows: in a rabbit model of diabetes mellitus (DM), kidneys had 
increased ETA receptor binding sites, but not ETB in the cortex and medulla (Khan et al., 
1999). In chronic HF patients, ETA receptors were upregulated in hearts (Pönicke et al., 
1998), while ETB receptors can be downregulated (Zolk et al., 1999). This in turn results 
in reduced clearance of ET-1 and increased circulating levels, which together with 
increased ETA receptor sites contributes to pathological changes. In pulmonary arteries 
of patients with PAH, the expression of both ET receptors were upregulated (Davie et 
al., 2002). Both receptors can mediate vasoconstrictor action of ET-1 (McCulloch et al., 
1998). In atherosclerotic arteries Bacon et al., 1996 reported increased expression of ET-
1 without altered expression of ET receptors in ischaemic heart disease. 
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1.8.1  ET receptor antagonists and clinical trials 
Although there is strong evidence that ET-1 expression is increased and likely plays a 
pivotal role in vascular pathologies, ET receptor antagonists (ERAs) have been 
disappointing in clinical trials of HF and hypertension (Packer et al., 2005). However, a 
non-selective ERA bosentan (Tracleer, Actelion Pharmaceuticals) (Rubin et al., 2002), 
and an ETA selective antagonist ambrisentan (Letairis, Volibris, GlaxoSmithKline) 
(Vatter & Seifert, 2006) have been approved for the treatment of pulmonary arterial 
hypertension (PAH).   
There are four structural classes of ERAs. These are peptides, sulphonamides, 
carboxylic and myceric acids (Palmer, 2009). Sitaxentan (highly ETA selective) and 
bosentan (non-selective) both belong to a sulphonamide group of ERAs and sitaxentan 
due to hepatotoxicity was withdrawn from the market (Galiè et al., 2011) after receiving 
regulatory approval for PAH in Europe in 2007.  
In human clinical trials of hypertension and HF, ERAs had little or no benefit. Instead 
they were associated with adverse effects including fluid retention (Weber et al., 2009; 
Battistini et al., 2006; Mann et al., 2010) and liver toxicity (Galiè et al., 2011). Fluid 
retention was indicated by weight gain, reduction in haemoglobin and increased 
incidence of oedema, which occurred in spite of diuretic use. Hypotension, renal 
dysfunction and reduction in arterial oxygen saturation were other important side effects 
observed in acute HF (Coletta et al., 2002).  
Table 1.4 summarises clinical trials of ERAs in patients with HF. In the REACH-1 trial, 
long-term effects of bosentan were investigated in patients with chronic HF for 
improvement in clinical symptoms. Patients treated with a higher dose of bosentan had 
dose-dependent worsening of chronic HF and renal insufficiency (Packer et al., 2005) 
(Table 1.4, a). Short term administration of bosentan (1 g, twice daily) to 36 patients 
with symptomatic HF over 2 weeks improved systemic and pulmonary haemodynamic 
(decreased mean arterial pressure and vascular resistance, increased cardiac output but 
heart rate was unchanged) (Sütsch et al., 1998). After bosentan treatment, plasma levels 
of ET-1 were increased while baseline levels of other hormones (norepinephrine, plasma 
renin activity, and Ang II) were unchanged. Increase in plasma ET-1 levels was a 
consequence of blocking clearance of ET-1 via ETB receptors (Kelland et al., 2010). 
This effect of bosentan was a common feature of dual ETA/B antagonism and it was 
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observed in other studies including in patients with PAH (Hiramoto et al., 2009). 
Moreover, ETB gene mutations were also associated with an increase in ET-1 
concentration (Gariepy et al., 2000). A lower dose of bosentan evaluated in ENABLE-
1 and -2 trials (Table 1.4, b), and darusentan investigated in HEAT and EARTH trials 
(Table 1.4, c and d) were all associated with side effects.   Darusentan (50, 100 and 300 
mg/day) (DORADO-AC trial) administered over 14 weeks in patients (n = 734) with 
resistant hypertension, with existing co-morbidities [type-2 DM and chronic kidney 
disease (CKD)] produced greater decreases in SBP and DBP but the treatment was 
unable to achieve the target BP goal (change from baseline to week 14) (Weber et al., 
2009; Bakris et al., 2010).   
ET antagonists have also been evaluated in cancer. Zibotentan, an ETA selective 
antagonist (10 and 15 mg/day) was used in 312 patients with metastatic castration-
resistant prostate cancer over ~4 months. Time to progression (165 progression events) 
was evaluated as the primary end-point. There was an improvement in overall survival 
time. However, the primary outcome was unchanged and peripheral oedema (placebo 
vs. zibotentan; 11% vs. 45%), dyspnoea, and cardiac failure were reported as adverse 
effects (James et al., 2010). 
A possible limitation of these trials could be evaluation criteria of treatment 
outcomes/primary end-points. As such, achieving a target BP may be difficult due to 
compensatory mechanisms. A more reliable measurement criterion is required to 
investigate the effects of these treatments, as well as monitoring adverse effects. 
Moreover, whether ERAs add further benefit to those already achieved with commonly 
used ACE inhibitors or whether beneficial effects can be sustained, have not been 
evaluated fully due to incomplete investigations. In general, clinical investigations 
suggested that selective ETA receptor antagonists in which beneficial effects of ETB can 
be preserved, may be superior to non-selective ETA/B antagonists. 
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Table 1.4: Failed clinical trials of ERAs investigating clinical outcomes in patients with heart failure. Modified from Kohan et al., 2012. 
Table 1.4 cont: 
Study & 
Disease 
ERA & Dose Receptor Number 
of 
patients 
Duration  Primary end-point Observations 
(a) REACH-1 
Chronic HF 
Bosentan   
500 mg b.i.d 
ETA/B 369 ~6 m 
Change in clinical 
symptoms (NYHA  
class or worsening of 
HF) 
- No clinical benefit with bosentan 
- Higher risk of worsening in the placebo 
group 
- Increase in hepatotoxicity and  decrease in 
haemoglobin with bosentan 
(b) ENABLE 1 
& 2 
Chronic HF 
Bosentan   
125 mg b.d 
ETA/B 1611 18 m 
Death and chronic HF 
hospitalisation  
- Fluid retention. Weight gain (approx. 0.6 
kg) and reduction in haemoglobin 
- Increase in liver enzymes 
(c) HEAT 
Chronic HF 
Darusentan 
10, 25, 50, 
100, or 300 
mg/day 
ETA 157 3 w 
Change in cardiac 
index and wedge 
pressure at the end of 
treatment 
- More adverse events (including death and 
worsening of HF) at higher doses without 
further improvements on haemodynamics 
in comparison to lower doses.  
(d) EARTH 
Chronic HF   
Darusentan 
10, 25, 50, 
100, or 300 
mg/day 
ETA 642 24 w 
Change in LV end-
systolic volume at 24 
w from baseline 
- Cardiac remodelling, clinical symptoms or 
outcomes were not improved 
- Worsened  HF in 11% and death of 5% of 
patients  
 (e) RITZ-1 
Acute HF 
Tezosentan  
24 – 72 h, 
50 mg/h (i.v.) 
ETA/B 669 ~1 m 
Symptoms of 
dyspnoea, death or 
worsening HF 
- No improvement of symptoms of 
dyspnoea 
- Worsening of HF 
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Abbreviations: (a) Packer et al., 2005; (b) Coletta et al., 2002; (c) Lüscher et al.,2002; (d)Anand et al., 2004; (e)Coletta & Cleland, 2001; (f)Louis et 
al., 2001; (g) Teerlink et al., 2005; (h) Mann et al., 2010; (i) Prasad et al., 2006, m = months, w = weeks, ERA = endothelin receptor antagonist, 
NYHA = New York Heart Association, b.d/b.i.d = twice daily, i.v.= intra-venous, SDP = systolic blood pressure, DBP = diastolic blood pressure, 
ESRD = End-stage renal disease, DM = Diabetes mellitus.  
Study & 
Disease 
ERA & Dose Receptor Number 
of 
patients 
Duration  Primary end-point Observations 
(f) RITZ-2 
Severe chronic 
HF 
Tezosentan 
24 h, 50 – 
100 mg/h 
(i.v.) 
ETA/B 285 ~1 m Haemodynamics 
- Improved dyspnoea score at 24 h 
- Fewer worsening HF events with 50 mg 
dose but clinical outcomes unchanged 
- Adverse hypotensive events 
- Renal function 
(g) VERITAS-1 
& -2 
Acute HF 
Tezosentan   
5 mg/h for 30 
m, then 1 
mg/h for 24 – 
72 h) 
ETA/B 1760 1 m 
Change in dyspnea 
over the first 24 h of 
treatment death or 
worsening of HF at 7 
days  
- Improved haemodynamics without a 
change in mortality 
(h) ASCEND 
Type-2 DM  
Avosentan  
25 or 50 mg 
ETA 1329 ~4 m 
Serum creatinine, 
ESRD, or death 
- Fluid retention and plasma volume 
expansion. Increased risk of developing 
HF and worsening renal function 
- Reduced BP and mirco-albuminuria 
(i)  LV  systolic 
dysfunction 
Enrasentan 
60 – 90 
mg/day 
ETA/B 72 6 m 
Change in  left 
ventricular end 
diastolic volume index  
- Adverse ventricular remodelling despite 
an increase in the resting cardiac index 
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Despite the fact that ET receptor antagonists have been mainly disappointing in human 
clinical trials of HF, upregulation of ET-1 in the renal system is also evident (Benigni et 
al., 1991; Orisio et al., 1993; Sørensen et al., 1994), as demonstrated with increasing 
ET-1 levels and reductions in urinary Na+ excretion. Generally, cortical vasoconstrictor 
actions of ET-1 are mediated by the ETA, while medullary vasodilatation is mediated by 
the ETB receptors (Rubinstein et al., 1995). Hence, selective ETA antagonism was 
suggested to be superior to ETB and ETA/B (Neuhofer & Pittrow, 2009). Indeed, CD was 
also shown to be of major importance for regulation of BP (Ge et al., 2006).  ETA 
blockade using sitaxentan improved cardiovascular risk factors (e.g. proteinuria, BP, and 
arterial stiffness) in patients with CKD (Dhaun et al., 2011, 2013). Therefore, CKD was 
proposed to be a promising target for ERAs (Dhaun et al., 2006). A summary of pre-
clinical and clinical studies showing reductions in proteinuria is provided by Barton, 
2008.  
 
 
1.9  Evolutionary perspective of ET-1 and ET receptors 
Sequence conservation of human ET family genes is restricted to the ET-1 sequence 
(80% homology) and the endothelin-like domain (Arinami et al., 1991). Interestingly, 
the positions of four cysteine residues are completely conserved in the endothelin-like 
domain. The homology between human ET-1 and endothelin-like domain is ~38%. 
Endothelin-like domain is likely to result from exon duplication in an ancestral ET gene 
(Bloch et al., 1989). The sequence of each peptide is highly conserved throughout 
evolution (Table 1.5 and 1.6). Endothelin-like domain therefore, might have an 
important physiological function. However, previous attempts failed to show biological 
activity for ppET-1[110 – 130] when tested at concentrations of 10
-10 – 10-5 M (Cade et al., 
1990).  
ET peptides also share a striking sequence homology with sarafotoxins (S6a, S6b, S6c, 
and S6d) (Table 1.5), a snake venom toxin from Atractaspis engaddensis (Kloog et al., 
1988; Landan et al., 1991; Takasaki et al., 1992). Sarafotoxins, like ET peptides, are 21 
amino acids long, contain two disulphide bridges and have a hydrophobic C-terminal 
sequence. In sarafotoxins, the disulphide bridges are essential for binding to ET 
receptors (Rubanyi & Polokoff, 1994), where they mediate vasoconstrictor activities. 
S6b has similar potency for both ET receptors while S6c is a highly selective ETB agonist 
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(Sokolovsky, 1994). Different amino acid residues are substituted with closely related 
residues with the exception of Lys (K) at position 4 and Glu (E) at position 9. S6c differs 
from S6a and S6b as it is the least toxic and has the lowest vasoconstrictor activity. At 
the end of its C-terminal, S6c lacks the characteristic cleavage site of ECE. Furthermore, 
the characteristic dibasic amino acid pair upstream of the first residue in all ET peptides 
was not conserved in the sarafotoxins (Rubanyi & Polokoff, 1994). Therefore, although 
the presence of high sequence homology (60%) led to suggestions of a common 
evolutionary origin (Kloog et al., 1988), sarafotoxins are more likely the result of 
convergent evolution.  
 
Two ET receptors, ETA and ETB, are found only in vertebrates (Hyndman & Evans, 
2007) and are distantly related to G-protein coupled receptor 37 (Hyndman et al., 2009). 
The cDNA sequences show considerable homology (>90%) between human, bovine and 
rat ETA receptor whereas ETB receptors share ~88% homology between human and rat 
(Arai et al., 1993). Despite the high homology in species, they have differences in their 
ligand binding characteristics. As such, S6c, which is more selective for ETB than it is 
for ETA, showed differences in its affinity in human and rat left ventricle (Russell & 
Davenport, 1996). ETA and ETB receptors share ~55% homology in human and other 
species. In human, amino acid sequences of ETA and ETB display only 59% similarity 
(Davenport, 2002). A third ET receptor gene encodes an amphibian-specific receptor 
ETC, expressed in Xenopus (Karne et al., 1990). Evolution of vertebrate ET genes and 
their receptors is illustrated in detail in Braasch et al., 2009.   
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Table 1.5: Comparison of the amino acid sequences of human ET-1 and the sarafotoxins. Homologous residues to human ET-1 are represented 
as hyphens (-). Cysteine residues at positions 1 – 15 and 3 – 11 form disulphide bridges and are completely conserved in evolution. The C-terminal 
hydrophobic region is also highly conserved across species. Data from Ensemble (http://www.ensembl.org/index.html). 
ET-1 peptide 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
Human  C S C S S L M D K E C V Y F C H L D I I W 
Mouse - - - - - - - - - - - - - - - - - - - - - 
Opossum  - - - - - - L - - - - - - - - - - - - - - 
Platypus  - - - - - - L - - - - - - - - - - - - - - 
Chicken  - - - - - - L - E - - - - - - - - - - - - 
Lizard - - - - - - - - - - - - - - - - - - - - - 
Frog  - - - - - - - - - - - - - - - - - - - - - 
Zebrafish - - - - - - - - - - - - - - - - - - - - - 
 
S6A - - - K D M T - - - - L N - - - Q - V - - 
S6B - - - K D M T - - - - L - - - - Q - V - - 
S6C - T - N D M T - E - - L N - - - Q - V - - 
S6D - T - K D M T - - - - L - - - - Q - - - - 
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Table 1.6: Comparison of the EDN1 gene derived endothelin-like domain during evolution. Homologous residues to human endothelin-like 
domain are represented as hyphens (-). Similar to ET-1, cysteine residues at positions 1, 3 and11, 15 are completely conserved in evolution.  
 
Endothelin-
like domain 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Human  C Q C A S Q K D K K C W N F C Q A G K E L R 
Mouse - - - - H - - - - - - - - - - - - - - - - - 
Opossum  - - - - - R - - - - - - V - - - - - - - - - 
Platypus  - - - - N - - - - - - - D - - - - - - - - - 
Chicken  - - - - - - R - - - - L - - - - - - - - - - 
Lizard - - - T N L - - - - - A - - - K - E - - I W 
Frog  - - - - - - - - - - - - - - - - - - - - - - 
Zebrafish - K - - D S Q - - T - S S - - Q D S A - - Q 
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1.10  Vascular actions of ET-1 
1.10.1  Signal transduction and downstream effectors  
ET-1 binding to ETA and ETB receptors stimulates a calcium influx through activation 
of phospholipase C (PLC)-mediated membrane-bound diacylglycerol (DAG) and 
cytosolic inositol triphosphate (IP3) production (Figure 1.2). IP3 initiates the release of 
Ca2+ from intracellular stores (iCa2+) of sarcoplasmic reticulum (SR) and membrane Ca2+ 
channels [L-type voltage dependent Ca
2+ (VOC)] to stimulate Ca2+ flux from 
extracellular space (Hirata et al., 1988). DAG activates PKC, which along with increased 
iCa2+ phosphorylates and activates calmodulin-dependent myosin light chain (MLC) and 
mediates ET-1 induced vasoconstriction (Figure 1.2, a). 
Vasodilatation mediated by activation of ETB receptors on ECs involve eNOS-derived 
NO release. Activation of eNOS is Ca2+-calmodulin-dependent. Once produced, NO 
diffuses to the underlying SMC, it activates cytosolic soluble guanylate cylase (sGC), 
which leads to the formation of cyclic guanosine monophosphate (cGMP) (Figure 1.2, 
b). This in turn inhibits the contractile process (Vanhoutte, 2004).  
Increases in iCa2+ activate phospholipase-A2 (PLA2) to produce arachidonic acid (AA), 
which activates the main cyclooxygenase (COX) product PGI2 in ECs (Moncada & 
Vane, 1979). Diffusion of PGI2 to SMC activates adenylate cyclase (AC), which 
produces cAMP and activation of voltage-dependent potassium (K+) channels (Tirapelli 
et al., 2005) result in vasodilatation (Figure 1.2, c).   ETA receptors can lead to activation 
of phospholipase D (PLD), facilitating PKC activation and cellular contraction (Goto et 
al., 1996) and PLA2 releasing AA and prostaglandins such as prostaglandin E2 (PGE2), 
which can contribute to vasoconstrictor responses. 
 
ET-1 mediated activation of signalling cascades involving MAPK and PI3K activate 
transcriptional factors that are involved in regulation of growth/proliferation and 
hypertrophy.
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Figure 1.2: ET-1 mediated signal transduction pathways. cGMP = cyclic guanosine monophosphate, cAMP =  cyclic adenosine monophosphate, 
CaM = calmodulin, GTP = guanosine triphosphate, ATP = adenosine triphosphate, sGC = soluble guanylyl cyclase, AC = adenyl cyslase, PLC 
= phospholipase C, DAG = diacylglycerol, IP3 = inositol triphosphate, ROC = receptor operated Ca
2+ channel, VOC = L-type-voltage operated 
Ca2+ channel, Ca2+ = calcium, iCa2+ = intracellular calcium, eNOS = endothelial nitric oxide synthase, NO· = nitric oxide, AA = arachidonic 
acid, COX = cyclooxygenase 1 and 2, PGI2 = prostacyclin, PKC = protein kinase C, SR = sarcoplasmic reticulum,  MAPK = mitogen activated 
protein kinases. MLC = myosin light chain, IP= prostacyclin receptor, and IP3R = inositol trisphosphate receptors. 
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1.10.2  Mitogenic actions   
On VSMC, ET-1 stimulates c-fos and c-myc expression and has proliferating effects in 
response to stimuli such as Ang II, TGF-β, and PDGF (Komuro et al., 1988). It can also 
act as a mitogen for VSMC by potentiating the actions of other mitogens including EGF 
(Battistini et al., 1993). Moreover, low concentrations of ET-1 (10-9 M), potentiated the 
effects of other vasoconstrictor such as serotonin and norepinephrine, in mammary and 
in coronary arteries (Yang et al., 1990).  In general, the mitogenic action of ET-1 is 
mediated by the ETA receptors (Eguchi et al., 1992; Yang et al., 1999).  
Infusion of Ang II (200 ng/kg/min) stimulated both vascular and renal ET-1 expression, 
and increased ECE activity in vivo. Haemodynamic and proliferative effects were 
completely blocked by ETA receptor antagonism (LU135252, 50 mg/kg/day) (Barton et 
al., 1997b). Thus, ET-1 acting mainly by the ETA receptors mediates vascular 
remodelling. All these studies supported the notion that ET-1 could have a significant 
role in the initiation and development of atherosclerosis. 
  
1.10.3  Inflammatory effects    
Increases in ET-1 levels are associated with elevations in plasma concentrations of pro-
inflammatory cytokines (TNF-α, IFN-γ, IL-1β) (Warner & Klemm, 1996).  In turn, 
inflammatory and pro-thrombotic mechanisms stimulate ET-1 synthesis (Corder et al., 
1995a; Corder, 2001). In cultured macrophages ET-1 stimulated the synthesis of TNF-
α and this was blocked by ETA receptor antagonists BQ-123 or BQ-485. Thus indicating 
an ETA mediated mechanism of action (Ruetten & Thiemermann, 1997). 
Intravenous (i.v.) administration of TNF-α (4 µg/kg) to anesthetised rats resulted in a 
rapid increase in arterial ET-1 levels, reaching maximum levels within 15 min (Klemm 
et al., 1995). Hearts were isolated after treatment with TNF-α (4 µg/kg) and perfused in 
vitro by the Langendorff technique. This was associated with a remarkable coronary 
vasoconstriction (Klemm et al., 1995). Similarly, infusion of TNF-α to healthy 
volunteers increased plasma levels of ET-1 (Patel et al., 2002). These have strongly 
suggested that activation of vascular ET-1 is associated with growth and pro-
inflammatory effects and therefore contribute to the progression of vascular pathologies. 
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1.10.4  Endothelial function 
Transgenic (TG) mice overexpressing human ppET-1 specifically in the endothelium 
(generated using promoter/enhancer regions of the endothelium-specific tyrosine kinase 
receptor Tie-2) showed hypertrophic remodelling, endothelial dysfunction, increased 
vascular NADPH oxidase activity (measured as p67phox and gp91phoxexpression) and 
inflammation in mesenteric small arteries in comparison to non-TG wild-type littermates 
(Amiri et al., 2004). TG mice also had a 3-fold increase in aortic ppET-1 mRNA and a 
7-fold increase in plasma ET-1 levels. This study demonstrated the first in vivo evidence 
for overexpression of endothelial-specific ET-1 with altered vascular structure 
(increased media thickness of mesenteric resistance arteries in TG mice) and function 
(impaired vasoconstrictor responses to ET-1 and impaired vasodilatation of resistance 
arteries in TG mice) without any significant changes in BP. This model had increased 
ETB mRNA and protein levels in TG mice while ETA mRNA and protein levels were 
unaltered. 
 
Endothelium-dependent vasodilatation in human internal mammary arteries was 
improved following acute ET receptor antagonism. As such, a mixed antagonist 
bosentan (3 μM for 20 min) showed the greatest beneficial effect on endothelial function 
[assessed using Acetylcholine (ACh)-induced vasodilatation] while both ETA [BQ-123 
(1 μM for 20 min)] and ETB [BQ-788 (1 μM for 20 min)] receptor antagonists had 
similar, but slightly reduced, effects on maximum relaxation (Verma et al., 2001).   
 
Acute ETA blockade with BQ-123 produced a modest vasodilatation of the coronary 
microcirculation and improved endothelial dysfunction in coronary artery disease 
(CAD) (Halcox et al., 2001). This study measured epicardial diameter and Doppler flow 
velocity (measured coronary blood flow) and calculated coronary vascular resistance 
(CVR) (arterial pressure ÷ coronary blood flow) as parameters to assess endothelial 
dysfunction. In patients with early atherosclerosis, long-term administration (6 months) 
of ETA antagonist atrasentan (10 mg) improved endothelial function (Reriani et al., 
2010a). Furthermore, non-selective blockade of ET receptors in patients with essential 
hypertension increased forearm blood flow (FBF), which was unaffected in controls 
(Cardillo et al., 2002).  All studies supported the role of ET-1 in the regulation of 
endothelial function both in early coronary atherosclerosis and in essential hypertension. 
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1.11 The role of ET-1 in the pathophysiology of cardiovascular 
disease 
ET-1 is highly implicated in various cardiovascular pathologies including 
atherosclerosis, hypertension, PAH, chronic HF as well as CKD. Endogenous ET-1 
production contributes to the maintenance of basal vascular tone and BP (Haynes & 
Webb, 1994; Haynes, 1995). The precise role of ET-1 in the pathogenesis of 
cardiovascular disease was evaluated following treatments with ERAs. The effects of 
ET-1 have been discussed in previous sections but here, existing evidence for the 
upregulation of ET system and the role of ET-1 in the pathogenesis of atherosclerosis, 
hypertension, and chronic HF is briefly highlighted. 
 
1.11.1  Atherosclerosis  
The role of ET-1 in the pathogenesis of atherosclerosis became evident after detection 
of ir-ET-1 (using immunohistochemistry) in VSMC as well as in ECs (Lerman et al., 
1991). Jones et al., 1996 have shown localisation specifically to ECs overlying 
atherosclerotic plaques and fatty streaks without detectable ET-1 in VSMC. A number 
of observations further supported the role of ET-1 in atherosclerosis. These include the 
findings of increased expression of ET-1, big ET-1 and ECE-1 in atherosclerotic arteries 
(Lerman et al., 1991; Zeiher et al., 1995; Bacon et al., 1996; Maguire & Davenport, 
1998); and detection of ET receptors in vasa vasorum of normal blood vessels and at 
regions of neovascularisation of atheromatous vessels (Dashwood et al., 1993). 
Inflammatory and prothrombotic mechanisms elevate ET-1 synthesis (Corder, 2001) 
and consistent with mitogenic actions, these further contribute to ET-1 mediated 
atheroma formation. Such evidence for remodelling after angioplasty was shown by 
Haynes & Webb, 1998. Mechanical pressure and stretch increased ET-1 levels in 
atherosclerotic coronary arteries with the levels correlating with the extent of mechanical 
stress (Hasdai et al., 1997). Macrophages and fibroblasts (Martin-Nizard et al., 1991; 
Ihling et al., 1996; Zeballos et al., 1991), which are abundant in atheromatous plaques, 
also secrete ET-1. In addition to increased ET-1 synthesis, ET receptor density is also 
increased in SMC during remodelling (Dashwood et al., 1998). 
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1.11.2  Hypertension 
In experimental models of hypertension [deoxycorticosterone acetate (DOCA) and Dahl 
salt-sensitive rats], ET-1 induced vascular hypertrophy and increased BP (Larivière et 
al., 1993; Deng et al., 1996), which were reversed by ETA/B antagonist bosentan (Li et 
al., 1994). However, the role of ET-1 in spontaneously hypertensive rats (SHR) has been 
controversial. Interestingly, hypertensive patients have either normal (Davenport et al., 
1995) or low ET-1 levels with the exception of black Africans (Ergul et al., 1996). In 
contrast, patients with pulmonary hypertension had increased ET-1 gene expression with 
an inverse relation with eNOS and the degree of ir-ET-1 in the lungs (Giaid & Saleh, 
1995). 
 
Mice with CD-specific KO of the ET-1 gene (CD ET-1 KO) are hypertensive on a 
normal-Na+ diet and this is exacerbated by high Na+ intake (Ahn et al., 2004). Further 
gene targeting studies that investigated the physiological role of ET-1 and ET receptors 
are described in more detail in Chapter 6, section 6.1.2. 
 
1.11.3             Chronic heart failure 
Plasma levels of ET-1 are elevated in HF (Stewart et al., 1992). Chronic treatment with 
an ETA antagonist BQ-123 (Sakai et al., 1996) or ETA/B antagonist bosentan (Muller et 
al., 1997) improved the survival and haemodynamic parameters in rats with chronic HF. 
However, the beneficial effects were not extrapolated to patients (see Table 1.4, page 
29).  
Cardiomyocyte-specific EDN1 overexpressing mice [generated as α-myosin heavy 
chain promoter-dependent cardiac-specific tetracycline-regulated gene expression 
system (Tet-OFF)] featured activated inflammatory pathway (e.g. NFκB activation and 
IL-6 expression) that was associated with cardiac hypertrophy and premature death 
(Yang et al., 2004). However, combination of ETA and ETA/B receptor antagonists were 
unable to prevent the lethal HF caused in this model (Yang et al., 2004). As a result, the 
role of ET-1 in HF has been controversial.  
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1.12 The area of unmet clinical need and requirement of 
biomarkers 
1.12.1  Endothelial dysfunction 
Endothelial dysfunction is a general term referring to the disruption of normal function 
of the vascular endothelium by impaired production of endothelium-derived relaxing 
factors (EDRF) (NO and PGI2) and increased synthesis of endothelium-dependent 
contracting factors (EDCF) (ET-1) (Vanhouette et al., 2009). 
Dyslipidaemia/hypercholesterolemia, diabetes, hypertension and smoking are 
cardiovascular risk factors that contribute to endothelial dysfunction. It is also closely 
linked to vascular aging with a loss of endothelium-dependent vasodilatation (EDD) 
from middle age to the elderly. Endothelial dysfunction is a key mediator and implicated 
in early stages of progression to atherosclerosis. It is independently associated with 
increased cardiovascular risk (Suwaidi et al., 2000; Endemann & Schiffrin, 2004). 
The mechanism of endothelial dysfunction is characterised by reduced NO 
bioavailability, which could be resulting from either reduced production of NO by eNOS 
or increased breakdown by ROS (Versari et al., 2009). NO is the best described 
vasodilator, which increases its protective role also by inhibiting platelet aggregation, 
adhesion and penetration of macrophages, SMC migration and proliferation, and 
suppression ofET-1 synthesis. Impaired NO production and elevated ET-1 are early 
features of endothelial dysfunction. Greater dysfunction leads to activation of pro-
coagulant and pro-inflammatory mechanisms that initiate a sequence of reactions that 
predispose to atherosclerosis and CAD (Vanhoutte et al., 2009).  
Under physiological conditions, NO is produced by the enzymatic conversion of eNOS 
in presence of substrate L-arginine and the co-factor, tetrahydrobiopterin (BH4) 
(Ghafourifar et al., 2005). Under pathological conditions, reduced bioavailability of BH4 
and a deficiency in L-arginine result in uncoupling of eNOS (Touyz & Schiffrin, 2004), 
and this contributes to the generation of ROS [e.g. superoxide anion (O2
.−) and hydrogen 
peroxide (H2O2)] (Vásquez-Vivar et al., 2003). Elevated O2
.− can reduce NO 
bioavailability by reacting with NO to form peroxynitrite (ONOO-), a strong oxidant 
which can damage cell membranes.   ONOO- oxidises the essential co-factor of eNOS, 
BH4 to its inactive form (Vásquez-Vivar et al., 2001), which together result in a further 
decline in NO production and increased O2
.− formation by eNOS. In addition, increases 
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in endogenous competitive inhibitor of eNOS, N
G NG-dimethyl-L-arginine (ADMA) 
(Vallance et al., 1992) and arginase activity (which converts L-arginine to urea and 
ornithine) also cause eNOS uncoupling.  
 
There are other factors that modulate NO release by the endothelium.  Shear stress 
activates Ca2+-dependent eNOS via increased iCa2+ and activated protein kinases (PKs) 
(Vanhoutte et al., 2009). Also in ECs, elevated iCa2+ and PKs activate PLA2, which 
releases AA from membrane-bound phospholipids and then becomes available for 
metabolism by COX. Peroxidase activity on COX transforms AA into endoperoxides, 
which are converted into PGI2, thromboxane A2, prostaglandin D2, prostaglandin E2 
and/or prostaglandin F2a by their selective synthases (Vanhoutte et al., 2009).   
 
The release of NO can be increased by oestrogen, vasopressin, substance P, bradykinin, 
histamine, thrombin and products formed during platelet aggregation [serotonin, 
adenosine diphosphate (ADP)] (Vanhoutte, 2004).  Hypercholesterolemia is a major risk 
factor for human atherosclerosis and increased LDL, especially oxidised-LDL (ox-
LDL), reduces the production of NO, by decreasing the gene expression of eNOS and 
may enhance ET-1 secretion (Ridker et al., 2004). 
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1.12.2 Changes in vascular function with age, predictive of cardiovascular 
disease risk 
Aging is associated with increased vascular stiffness (increased elastase and collagen 
production by VSMC), vascular wall intimal thickness (Virmani et al., 1991) and 
impaired endothelial function (Celermajer et al., 1994). These factors may be the result 
of (1) increased formation of ROS (O2
.−), (2) alteration in the expression and/or activity 
of eNOS, (3) decrease in L-arginine/NO bioavailability (Boulanger & Lüscher, 1990), 
due to increased production of O2
.− and (4) impaired EDD due to reduced endothelium-
mediated relaxation and increased production of vasoconstrictors such as ET-1 
(Goettsch et al., 2001) and COX-2 derived prostanoids (Vessières et al., 2013). These 
have all been suggested as potential mechanisms underlying the impaired endothelium-
dependent vasodilator responses that occur with aging (Küng & Lüscher, 1995; Barton 
et al., 1997a), but the precise triggers have yet to be defined. Other vasoactive factors 
that are affected during ageing also regulate EDN1 gene expression and together could 
contribute to age-dependent changes in vascular function. These include Ang II (Imai et 
al., 1992), TGF-β1 (Hahn et al., 1990) and oestrogen (Morey et al., 1998). 
In response to ACh and Ca2+ ionophore A23187, endothelium-dependent relaxations 
were reduced in the aorta of old rats, with reduced basal release of NO and lower 
expression of eNOS mRNA (Barton et al., 1997a). In the aortas of old rats, contractions 
to norepinephrine were increased while ET-1-mediated contractions were reduced 
(Barton et al., 1997a). Neither endothelium-dependent relaxations nor contractions were 
affected by aging in the femoral artery (Barton et al., 1997a). Age-related impairment in 
ACh-mediated EDD (analysed by FBF) was also reported in man by Westby et al., 2011.  
Co-infusion of ACh with an ETA selective antagonist, BQ-123, improved ACh-mediated 
EDD in older men and this suggested that impairment in age-related vasodilatation is 
partly due to increased vasoconstrictor tone, which is mediated by increased ET-1 levels 
with age. 
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1.12.3  Current methodologies measuring endothelial function 
Endothelial dysfunction affects resistance and conduit vessels in the forearm and in the 
coronary circulation. The forearm vascular bed is commonly accepted as a surrogate for 
assessing endothelial function in the coronary arteries (Wilkinson & Webb, 2001). 
Endothelium-dependent vasodilatation is evaluated with use of pharmacological stimuli 
(including ACh, bradykinin, substance P, and 5-hydroxytryptamine) or mechanical 
stimuli by inducing a shear stress response. Flow-mediated dilatation (FMD) uses 
increased shear stress to stimulate the release of NO and induce EDD of the brachial 
artery (Behrendt & Ganz, 2002).  
Alternatively, the functional integrity of the vascular endothelium can be assessed with 
FBF responses to intra-arterial agonists such as ACh (Heitzer et al., 2001). ACh 
stimulates a receptor-mediated increase in NO synthesis and release from the vascular 
endothelium and as a result, can be used to monitor EDD responses (Versari et al., 2009). 
Both FMD and FBF responses to ACh are assessed using a strain-gauge 
plethysmography (mainly mercury-in-rubber, but alternatively indium-gallium gauges 
can also be used). 
Endothelial dysfunction in the microcirculation can be evaluated by the assessment of 
the change in epicardial coronary artery diameter in response to ACh concentrations 
using quantitative coronary angiography and in the microcirculation intravascular 
ultrasound is used to monitor changes in flow (Versari et al., 2009). Additionally, 
Doppler flow velocity measurements in response to ACh can be used to evaluate 
endothelial function. Non-invasive techniques include positron emission tomography 
(PET), which can be used to assess myocardial blood flow in response to vasodilator 
agents such as adenosine, and adenosine triphosphate (Reriani et al., 2010b). 
The advantages and disadvantages of some techniques used for the assessment of 
endothelial function are summarised in Table 1.7. A methodology of an ideal test should 
be non-invasive, reproducible, repeatable, and cheap and it should be specific, provide 
prognosis of subclinical disease processes and risk stratification.   
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Table 1.7: Methods used in the assessment of vascular endothelial function. Data from Coretti et al., 2002, Deanfield et al., 2007 and Reriani 
et al., 2010b. 
Test Vascular bed Outcome measured 
(e.g. change in diameter or 
blood flow) 
Equipment  
 
Advantages Disadvantages 
Coronary 
endothelial 
function testing 
Coronary 
arteries. 
Diameter and BF in 
response to ACh. 
Quantitative coronary 
angiography and 
coronary Doppler flow.  
“Gold standard” 
Reproducible. 
Invasive 
Expensive  
Procedural risks. 
Venous occlusion 
plethysmography 
Forearm 
resistance 
vessels. 
Forearm circumference 
indicative of forearm BF 
Can be coupled with 
brachial artery 
administration of 
vasoactive peptides and 
drugs (e.g. ET-1). 
Strain-gauge 
plethysmography. 
Accurate. 
Reproducible. 
Invasive (requires 
arterial cannulation).   
Unrepeatable.  
Difficult to 
standardise results. 
Procedural risks. 
FMD 
 
Mainly 
brachial, but 
radial and 
femoral arteries 
can also be 
used. 
Diameter of a conduit 
artery in response to shear 
stress. 
 
Ultrasound with Doppler 
and electrocardiogram 
(ECG) monitor. 
  
 
Non-invasive. Require technical 
expertise.  
May not be 
reproducible. 
Expensive equipment. 
Limited for risk 
stratification.  
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Table 1.7 cont: 
Test Vascular bed Outcome measured 
[e.g. change in diameter 
or blood flow (BF)] 
Equipment  
 
Advantages Disadvantages 
Brachial artery 
reactivity test 
Brachial artery. Diameter of brachial 
artery in response to 
shear stress. 
Measures FMD. 
Ultrasound with Doppler 
and electrocardiogram 
(ECG) monitor. 
Non-invasive. 
Easy to use. 
Operator variability. 
Difficulty to 
standardise results. 
Peripheral 
arterial 
tonometry 
(PAT) 
Peripheral 
arteries. 
Post-occlusion pulse 
wave amplitude in 
relation to the baseline. 
Tonometer. Non-invasive. 
Automated/easy to 
use, automatic 
analysis, reliable 
and reproducible. 
Expense of disposable 
finger probes. 
Positron emission 
tomography 
(PET) 
Coronary 
microcirculatory 
vasculature. 
Myocardial BF in 
response to 
adenosine/dipyridamole. 
Tomography. Non-invasive. 
High sensitivity. 
Limited specificity for 
endothelial function. 
Use of isotopes. 
Pulse-wave  Radial, brachial, 
and femoral 
artery.  
Changes in peripheral 
pressure waveform in 
response to β-2 receptor 
agonist (inhaled 
albuterol/salbutamol). 
Tonometry used for 
measurements and 
augmentation index 
(AIx) for quantification. 
Non-invasive. 
Simple and 
portable 
instrumentation can 
be adapted to large 
studies. 
Unpredictable of 
outcome. 
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1.13  Proposed Biomarker(s)  
1.13.1  ET-1 as a biomarker of cardiovascular disease risk     
Plasma levels of ET-1 are elevated in various pathological conditions (McMurray et al., 
1992; Pousset et al., 1997; Goddard & Webb, 2000; Selvais et al., 2000) with the levels 
correlating with disease progression. Despite the strong evidence that shows a role of 
ET-1 in disease development/progression and all the factors that increase ET-1 synthesis 
in disease states, plasma concentrations of ET-1 in healthy subjects are low, ranging 
between <0.3 pg/ml and 3 pg/ml in most studies (Battistini et al., 1993).  
ET-1 is unstable, and due to its short half-life in plasma (Gasic et al., 1992; Corder & 
Vane, 1994) the significance in diagnosis has been controversial. Studies of cultured 
ECs indicate that ET-1 is mainly released abluminally and mediates its actions as a 
paracrine/autocrine factor on smooth muscle cells (Wagner et al., 1992). This likely 
targets ET-1 to ETA receptors on the underlying VSMC, which further decreases the 
amount of ET-1 escaping into the circulation. Particularly in the pulmonary vascular 
bed, ET binding to ETB receptors results in clearance, which further decreases the 
circulating levels of ET-1 (Wagner et al., 1992; Dupuis et al., 1996b). Moreover, ET-1 
is degraded by endopeptidases such as NEP-24.11, which is highly expressed on venous 
ECs (Llorens-Cortes et al., 1992; Abassi et al., 1992).  
All immunoassays for ET-1 required a solid-phase extraction step prior to immunoassay. 
This could result in variations of ET-1 measurements due to differences in recovery, 
type of immunoassay employed and the specificity of the antisera (Davenport & Kuc, 
2002). As a result of the above factors ET-1 is a poor biomarker of vascular ET-1 
production. The levels are likely to reflect a spillover that has not bound to ET receptors. 
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1.13.2  Plasma measurements of big ET-1 and C-Terminal fragment 
Proteolytic processing of big ET-1 produces ET-1 and CTF of big ET-1 in equimolar 
amounts. Slower clearance of big ET-1 (Hemsén et al., 1995; Burkhardt et al., 2000) 
and the inactive CTF were assessed as alternative markers for estimation of ET-1 release. 
Plasma levels of big ET-1 were strongly correlated with prediction of 1 year mortality 
in patients with severe HF to a greater degree than ANP (Pacher et al., 1996). The 
radioimmunoassay (RIA) for CTF of big ET-1[1 – 38] was based on an extraction 
methodology and had cross-reactivity of around 82% between the CTF and big ET-1[22 
– 38] and <1% with ET isopeptides (Pacher et al., 1996).  
Cross-reactivity of big ET-1 in RIA often resulted from recognition of the ET[1 – 15] loop 
region (Corder, 1996). At high concentrations there was less cross-reactivity, which 
could suggest equilibrium between an unfolded conformation recognised by antibodies 
specific for ET-1 and a folded conformation where the C-terminal sequence of big ET-
1 folds over ET-1[1 – 15] thereby inhibiting antibody detection. CTF could not be measured 
with sandwich-ELISA due to the presence of only one of the two epitopes necessary to 
generate a signal (Plumpton et al., 1995).  
Changes in plasma big ET-1 levels may not reflect alterations in ET-1 synthesis because 
big ET-1 is cleaved at the tissue level not only into active ET-1, but also into ET-1[1 – 31] 
by the action of chymase (Nakano et al., 1997). These factors limit the use of big ET-1 
and CTF of big ET-1 as sensitive biomarkers of ET-1 synthesis.  
 
1.13.3  ProET-1 derived peptides as alternative markers of ET-1 synthesis 
Sandwich immunoassays were developed covering six positions of the ppET-1 (18 – 53, 
32 – 109, 32 – 181, 94 – 148, 136 – 181 and 168 – 212) and only three ir-proET-1 regions 
(18 – 53, 94 – 148 and 168 – 212) were detected in control subjects and septic patients 
(Struck et al., 2005). As a result, CT-proET-1 was proposed as an alternative to 
indirectly assess ET-1 release (Struck et al., 2005; Papassotiriou et al., 2006).  
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1.13.4  Other biomarkers of vascular function and risk 
Clinical parameters of cardiovascular disease risk include Framingham Risk Score 
(FRS), New York Heart Association (NYHA) and high-sensitivity C-reactive protein 
(hsCRP). However, classifications are imprecise and limited. In order to contribute to a 
better classification, a biomarker should exhibit independent prediction of disease risk 
from conventional parameters and, at the same time, it should provide sensitivity and 
specificity for the underlying disease.  
 
Two commonly used imaging techniques coronary artery calcium (CAC) score, 
measured using computed tomography (CT) and carotid intima-medial thickness 
(cIMT), measured using B-mode ultrasound can discriminate between risk groups and 
are used as subclinical disease biomarkers for CAD risk stratification.  Although CAC 
is simple, fast, and accurate for identification of CAD stenosis severity, extent, and 
distribution, it is associated with low but tolerable radiation exposure. Measuring 
thickening of the intima-media as an early feature of atherosclerosis with cIMT is also 
non-invasive and simple. Nevertheless, there is a need for reclassification improvement 
where circulating biomarkers may provide better risk stratification of cardiovascular 
disease. Biomarkers of vascular disease can be grouped into six main categories  as listed 
in Figure 1.3 (Ridker et al., 2004; Cohn et al., 2004; Iqbal et al., 2012).An overview of 
these biomarkers in relation to disease and associated methodological issues is provided 
in a review by Vasan, 2006. 
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Figure 1.3: Main categories of key cardiovascular biomarkers. 
 
A. Neurohormones: N-terminal-pro B-type natriuretic peptide (NT-proBNP) and 
midregional pro-adrenomedullin (MR-proADM)]; provasopressin or copeptin 
(CT-proAVP); and midregional pro-atrial natriuretic peptide (MP-proANP). 
These neurohormones are released in response to strain on cardiomyocytes, 
haemodynamical stress and to volume expansion, respectively. 
B. Tissue markers of cardiomyocyte injury/necrosis: Troponins (cTnT and 
cTnI). 
C. Inflammatrory and adhesion molecules: hsCRP, IL-6, E-selectin, P-selectin, 
MCP-1, growth differentiation factor 15 (GDF-15), galectin-3, ICAM-1, and 
VCAM-1. 
D. Fibrosis and collagen turnover: CTGF, collagen as an important 
compartment of myocardial ECM and MMPs (particularly MMP-9), which 
degrade collagen are markers of fibrosis and collagen turnover. In addition, 
vWF, tissue plasminogen activator (t-PA), fibrinogen, and D-dimer are possible 
markers of thrombosis. 
E. Oxidative stress related biomarkers: oxLDL. 
F. Lipid metabolism: Apolipoprotein B100 (Apo-B100), Apo-AI. 
 
A. 
Neurohormones
B. 
Cardiomyocyte 
injury/necrosis
C. Inflammatrory 
and adhesion 
molecules
D. Fibrosis and 
collagen turnover
E. Oxidative stress 
F. Lipid 
metabolism
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Although these biomarkers may reflect active disease, they are not sufficiently sensitive 
or specific to identify cardiovascular disease in asympomatic patients (Ridker et al., 
2004; Vasan, 2006). Currently the stable fragment of brain natriuretic peptide (BNP), 
NT-proBNP is the strongest predictor and it is used for the diagnosis and risk 
stratification of patients with HF (Maisel et al., 2002; Masson et al., 2006; McMurray 
et al., 2012). Similarly, in asympomatic patients with HF, high sensitivity cTnT was 
associatied with cardiovascular mortality risk (deFilippi et al., 2010). However, the 
prognostic utility of BNP and troponin measurements in the diagnosis of asymptomatic 
HF patients has yet to be fully evaluated. The ability of NT-proBNP, adhesion and 
inflammatory markers (CRP, soluble ICAM-1, sVCAM-1 sUL-1Ra, IL-6 and 
fibrinogen) in predicting cardiovascular events was evaluated previously and as a result, 
only NT-proBNP provided incremental value for cardiovascular risk prediction over 
traditional markers such as FRS (Blankenberg et al., 2006). Another study compared the 
relationship between neurohormonal markers (MR-proADM, MR-proANP, NT-
proBNP, CT-proET-1, copeptin, neopterin) and vascular function parameters [FMD and 
PAT] in 5,000 individuals (Gutenberg Health Study). Baseline vascular function showed 
strong associations for MR-proANP and baseline pulse amplitude; as well as MR-
proANP and NT-proBNP with brachial artery diameter. For hyperaemic response 
variables, CT-proET-1, MR-proADM, and MR-proANP were related to PAT ratio, 
which is a representative measure of microvascular circulation (Schmabel et al., 2012). 
A number of comparative studies investigated the ability of CT-proET-1[168 – 212] and 
these are summarised in Table 1.8. In general, CT-proET-1 was an independent 
biomarker, as such in acute myocardial infarction (MI), both NT-proBNP and CT-
proET-1 were independent predictors of death and HF (Khan et al., 2007). In diabetic 
patients, Maier et al., 2009 showed a correlation between endothelial markers MR-
proADM, CT-proAVP, CT-proET-1, and MR-proADM and cardiovascular events with 
MR-proANP being the strongest predictor in this patient group. Boyer et al., 2012 
investigated the changes in MR-proADM, MR-proANP and CT-proET-1 during the first 
2 – 4, and 12 – 24 h after therapy in 48 patients with acute decompensated heart failure 
(ADHF). Changes in MR-proANP levels occurred more commonly at 2 – 4 after 
therapy. Changes in CT-proET-1 showed a relation with ejection fraction, heart rate and 
BNP. CT-proET-1 over 2 – 4 h after therapy also positively correlated with Na+ 
concentration.  
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Table 1.8: The prognostic significance of CT-proET-1 in comparison to other cardiovascular biomarkers.  
Study & 
Reference 
Patients Biomarkers Results Conclusion 
Struck et al., 
2005 
Sepsis  Sandwich 
immunoassays  
for ppET-1 
peptide 
sequences 18 – 
53, 32 – 109, 
32 – 181, 94 – 
148, 136 – 181 
and 168 – 212    
Only ppET-1 sequences 18 – 53, 94 – 148 and 168 – 
212 showed strongly elevated ir-proET-1 in sepsis. 
These proET-1 peptides were also detected in normal 
subjects. 
Immunoreactivities of 3 
ppET-1epitopes suggest 3 
proET-1 derived peptides. 
Papassotiriou 
et al., 2006 
Chronic HF (n = 
77), sepsis (n = 116) 
and healthy (n = 
326) 
CT-proET-1  
Big ET-1  
CT-proET-1 significantly correlated with age. 
Elevated CT-proET-1 levels in chronic HF and sepsis 
patients. CT-proET-1 correlated with bigET-1 
measurements. 
The CT-proET-1 assay 
without extraction and lack of 
cross-reactivity may be a 
useful biomarker. 
LAMP study 
Khan et al., 
2007 
Acute MI 
(n = 983) 
CT-proET-1  
NT-proBNP 
Both NT-proBNP and CT-proET-1 were independent 
predictors of death and HF. AUC was 0.76 for both 
NT-proBNP and CT-proET-1. 
CT-proET-1 is a strong 
predictor of adverse 
outcomes. 
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Table 1.8 cont: 
Study & 
Reference 
Patients Biomarkers Results Conclusion 
Behnes et al., 
2008 
Acute ST elevation 
MI or non-ST 
elevation MI  
(n = 30) 
MR-proADM 
CT-proET-1 
 
3 days after MI median CT-proET-1 in event vs. no-
event group was significantly higher (72.9 vs. 54.4 
pmol/L). MR-proADM levels were 0.69 vs. 0.59 
nmol/L.  AUC for MR-proADM and CT-proET-1 
was 0.71 and 0.76. 
Both MR-proADM and CT-
proET-1 may predict acute 
phase of MI. 
Adlbrecht et 
al., 2009 
Chronic HF 
(n = 786) 
CT-proET-1 
MR-proADM 
BNP 
MR-proADM better predictor of mild to moderate 
HF. ADM is not superior to NT-proBNP in 
predicting outcome. 
BNP can be a better 
biomarker of prognosis at a 
later disease stages. 
Dieplinger et 
al., 2009 
 
Acute destabilised 
HF (n = 137) 
CgA 
CT-proET-1 
NT-proBNP 
Decedents (n = 41) had higher median plasma 
concentrations of CgA (9.7 vs. 6.0 nmol/L), CT-
proET-1 (120 vs. 72 pmol/L), and NT-proBNP (5112 
vs. 2610 ng/L) at baseline than survivors. 
CT-proET-1 added 
independent prognostic 
information in addition to 
NT-proBNP measurement. 
Maier et al., 
2009 
 
Type 2-DM  
(n = 781)  
Median follow up of 
15 months 
 
MR-proADM, 
CT-proET-1 
CT-proAVP 
MR-proANP 
Creatinine 
GFR 
All biomarkers increased in future CV events, 
independently correlated to serum creatinine. 
MR-proANP was the strongest predictor of CV 
events (AUC 0.80), while CT-proET-1 (AUC 0.65) 
was the weakest. MR-proADM and CT-proET-1 also 
correlated with GFR and serum creatinine. 
CT-proET-1 unable to add 
additional value to predict 
future CV events. All 4 
neurohormonal biomarkers 
were related to both kidney 
function and CV events. 
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Table 1.8 cont: 
Study & 
Reference 
Patients Biomarkers Results Conclusion 
GISSI-HF  
 
Masson et 
al., 2010  
 
Chronic and stable 
HF (n = 1,237) 
Median follow-up of 
3.9 years 
MR-proANP, 
MR-proADM, 
CT-proET-1 
and CT-
proAVP or 
copeptin 
All markers were higher in elderly, in patients with 
more severe HF symptoms and reduced eGFR.  MR-
proANP was unable to improve reclassification based 
on clinical risk factors    
AUC for MP-proANP, NT-proBNP, and CT-
proproET-1 was 0.74, 0.73, and 0.71, respectively.  
Although all markers had 
significance independent of 
NT-proBNP, the most 
powerful predictor of 
outcome was MR-proANP. 
GENOA 
study 
 
Habib et al., 
2010 
Hypertensive 
African Americans 
(n = 981) and non-
Hispanic whites  
(n = 812)  
CT-proET-1 
urinary ACR 
Higher CT-proET-1 levels in African Americans in 
comparison to non-Hispanic whites. African 
Americans had a higher prevalence of diabetes, lower 
use of statins, and higher eGFR, SBP, and DBP, and 
greater urinary ACR. 
CT-proET-1 independently 
associated with lower target-
organ damage measures 
(urinary ACR). 
Jankowska et 
al., 2011 
Systolic chronic HF 
(91% men) 
(n = 491) 
CT-proET-1 
NT-proBNP  
Higer CT-proET-1 levels in patients with chronic HF 
when compared to healthy controls.   
CT-proET-1 levels were positively associated with 
age and the disease severity (NYHA class). 
CT-proET-1 increased 
prognostic value of CHF and 
added value to 12-month CV 
mortality in patients with 
CHF. 
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Table 1.8 cont: 
Study & 
Reference 
Patients Biomarkers Results Conclusion 
GISSI-AF  
Lattini et al., 
2011  
 
Hypertensive 
(84.8%, 59.7% AF) 
(n = 382) 
1 year follow-up 
MR-proANP 
MR-proADM 
CT-proET-1 
Copeptin/CT-
proAVP  
NT-proBNP 
hsTnT 
Baseline NT-proBNP, MR-proANP and hsTnT 
were higher in patients older than 70 years, in 
those with HF or LVEF, and those with CAD.  
Highest correlation was between NT-proBNP 
and MR-proANP, which also showed an inverse 
relationship with recurrence of AF. CT-proET-1 
was also associated with the risk of first 
recurrence of AF. 
hsTnT, MR-proANP, NT-
proBNP and CT-proET-1 had 
a modest but statistically 
significant predictive power 
for recurrence of AF. 
KORA F4 
study 
Seissler et 
al., 2012 
Type 2-DM and 
MetS (n = 1,590) 
CT-proET-1 
MR-proADM 
CT-proET-1 and MR-proADM significantly 
elevated in patients with MetS. 
 
PEACE trial 
Sabatine et 
al., 2012 
Stable CAD and 
preserved LVEF 
(n = 3,717) 
MR-proANP 
MR-proADM 
CT-proET-1 
Copeptin 
MR-proANP, MR-proADM, and CT-proET-1 
were independently associated with the risk of 
CV death or HF. 
Increased levels of 
biomarkers may be useful to 
identify patients at higher risk 
of CV death and HF and aid 
selection of responsive 
patients to therapy.  
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Table 1.8 cont: 
Study & 
Reference 
Patients Biomarkers Results Conclusion 
Drion et al., 
2012 
 
Type 2-DM  
(n = 1,225) 
Median follow-up of 
3 or 10 years 
CT-proET-1 
Albuminuria 
 
CT-proET-1 was associated with fatal 
cardiovascular events, all-cause mortality, and 
new-onset albuminuria 
CT-proET-1 improved 
prediction of fatal 
cardiovascular events. 
 
Abbreviations: IR = immunoreactivity, AF = atrial fibrillation, CAD = coronary artery disease, MI = myocardial infarction, Type 2-DM = Type 
2-diabetes mellitus, MetS  = metabolic syndrome, LVEF = left ventricular ejection fraction, LLD = lower limit of detection, NYHA = New York 
Heart Association Class, CV = Cardiovascular, GFR = glomerular filtration rate, CgA = Chromogranin A, CT-proET-1 = C-terminal-
proendothelin-1, HsTnT = high sensitivity troponin T, MR-proADM = midregional proadrenomedullin, NT-proBNP = N-terminal-pro B-type 
natriuretic peptide.  ACR = albumin:creatinine ratio. MR-proANP, MR-proADM, CT-proET-1, Copeptin/CT-proAVP  were all measured using 
chemiluminescence immunoassays (CIA) (BHRAMS), NT-proBNP and HsTnT were measured using electrochemiluminescence immunoassay 
(Elecys), and big ET-1 was measured using ELISA. 
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Cardiovascular disease occurs frequently in patients with renal disease (e.g. CKD) 
(Foley et al., 2005). Similarly, CKD is an independent risk factor for cardiovascular 
morbidity and mortality (Jones et al., 2004). Renal function is assessed using estimated 
glomerular filtration rate (eGFR) but cystatin C and proteinuria are other renal markers. 
Serum creatinine is used to estimate eGFR. However, it is a poor biomarker of early 
CKD. This is because detection of renal dysfunction occurs after extensive tissue 
damage (Hewitt et al., 2004). Thus, there is an unmet clinical need for more sensitive 
biomarkers that will provide earlier detection of renal impairment and potentially reflect 
effectiveness of therapy. Since there is interplay between cardiovascular and renal 
dysfunction, biomarkers investigated in predicting cardiovascular disease risk have also 
been evaluated in renal disease. As such, cardiovascular biomarkers (NT-proBNP, 
hsTnT, proANP, copeptin and proADM) were associated with renal function in patients 
with systolic HF (Bosselmann et al., 2013). 
  
Increased ET-1 production in patients with renal disease and its relation to impaired 
renal function (as a measure of eGFR), through which contributes to the progression and 
maintenance of hypertension and arterial stiffness, has been evident (Dhaun et al., 2006; 
Goddard et al., 2007). Urinary ET-1 excretion is well correlated with renal ET-1 
production (Benigni et al., 1991) and thus it was suggested as a potential biomarker for 
renal injury (Ohta et al., 1991). The diagnostic or prognostic utility of CT-proET-1 in 
patients with CKD has yet to be described.  
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1.14  Hypothesis and aims of this thesis 
1.14.1  Hypothesis 
There is a clinical need for sensitive markers for early diagnosis in both cardiovascular 
and renal pathologies that would reflect changes in progression and treatment outcomes. 
Current methods measuring EDD and the effects of treatments in BP have limited 
diagnostic value. ET-1 is an early contributor to endothelial dysfunction and plays a vital 
role in regulation of BP. However, ET-1 has a short circulating half-life and its 
measurement has limitations.  
The work described in this thesis investigated the hypothesis that other ppET-1-derived 
peptides co-released with ET-1 are more stable in circulation and thus could serve as 
alternative biomarkers of elevated ET-1 synthesis in cardiovascular and renal 
pathologies. ProET-1-derived peptides may be clinically useful as diagnostic biomarkers 
and may provide improved risk assessment. Moreover, their measurement could be 
beneficial for monitoring treatment outcomes of ET receptor antagonists.    
 
1.14.2  Aims 
The general aim of this thesis was to characterise ppET-1 synthesis and to develop 
specific immunoassays for the measurement of proET-1 peptide fragments. Specific 
aspects of the research were: 
(1) To evaluate the release of ET-1 and proET-1 peptides from endothelial 
(EA.hy 926) and epithelial (A549) cell lines (Chapter 3), which were 
identified using immunoassays optimised in Chapter 2. The aim of this 
investigation was to define whether proET-1 peptide fragments released into 
the condition media were stable and whether inhibiting ET-1 synthesis using 
an ECE inhibitor phosphoramidon and/or protease inhibitors had an effect on 
the release of proET-1 peptides. 
(2) These investigations were also required to find optimal conditions for 
collection of conditioned media samples from EA.hy 926 and A549 cells for 
pursuing the purification and characterisation of proET-1 peptides (Chapter 
4). 
(3) To provide sequence identities of the endogenous proET-1 peptides using 
mass spectrometry (Chapter 5). This chapter provides evidence for the 
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identity of a novel ppET-1 derived peptide, which contains an endothelin-like 
domain. 
(4) (A) Evaluate the clearance rates of identified proET-1 peptide fragments in 
the circulation of rats and study their metabolism in whole blood and plasma. 
(B) Using patient samples assess whether stable proET-1 peptides may be 
potential biomarkers of vascular and renal pathologies (Chapter 6). 
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2.1  MATERIALS  
2.1.1  Reagents and Solutions 
1. 0.2 µm filter paper (Whatman, UK). 
2. 24-well plates cell culture (VWR, UK). 
3. 25G needle (BD MicrolanceTM, USA). 
4. Acetic acid, glacial (CH3COOH) (Analar grade: BDH Laboratory supplies, UK). 
5. Acetonitrile (CH3CN) HPLC grade (Rathburn Chemicals Ltd., Scotland). 
6. Ammonium bicarbonate (NH4HCO3) (Analar grade: BDH Laboratory supplies). 
7. Ammonium sulphate (NH4)2SO4 (Merck, Germany). 
8. Anhydrous sodium sulphate (Analar grade: BDH Laboratory supplies, UK). 
9. Bacitracin, prepared fresh in DMEM (10 mM) and 0.2 µm filter sterilised before 
use (Sigma, UK). 
10. Benzamidine HCl (anhydrous basis) (MWt = 156.61). A reversible inhibitor of 
trypsin, trypsin-like enzymes, and serine proteases (Sigma, UK). 
11. Bio Gel P-30, 100 g fine 45 – 90 µm (wet) (Bio-Rad, Germany). 
12. Bovine serum albumin (BSA) (Sigma, UK). 
13. Carboxymethyl Fractogel, EMD COO- 650 (M) (500 ml) (Merck, Germany). 
14. Centrifugal filter devices Amicon Ultra (MWt cut-off 100 kD) (Millipore, 
Ireland). 
15. Clear 96-well plate (Sterlin, UK). 
16. CNBr activated Sepharose (1 g makes ~3.5 ml) (Amersham-Pharmacia, UK). 
17. Dimethyl formamide (DMF) (Sigma, UK).   
18. Dimethyl sulfoxide (DMSO) (Sigma, UK).   
19. Dulbecco’s Modified Eagle’s Medium - high glucose (DMEM) with 4500 mg/L 
glucose, L-glutamine, sodium pyruvate, and sodium bicarbonate (D6429, Sigma, 
UK). For use 500 ml DMEM is supplemented with 5 ml antibiotics (100 Units/ml 
Penicillin and 100 µg/ml streptomycin) and 12.5 ml HEPES (25 mM) (DMEM+). 
20. Dulbecco’s Phosphate Buffered Saline (without CaCl2 and MgCl2) (Sigma, UK). 
21. Endopeptidase Inhibitors: leupeptin, chymostatin and pepstatin A (Sigma, UK). 
Inhibitor stock solutions chymostatin 100 mM (MWt = 600, 25 mg dissolved in 
417 µl of DMSO, stored at -20°C); 10 mM pepstatin A (MWt = 685.9, 5 mg 
dissolved in 729 µl of DMSO, stored at -20°C); 100 mM leupeptin  (MWt = 426.5, 
100 mg dissolved in 2.344 µl of H2O, stored at -20°C). Peptide inhibitor mix was 
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prepared in DMEM diluting chymostatin and leupeptin at 10 µM, and pepstatin A 
at 10 µM. 
22. Ethanolamine (Analar grade: BDH Laboratory supplies, UK). 
23. EDTA (Ethylenediaminetetraacetic acid) (Sigma, UK). 
24. EDTA solution, 0.5 M (pH 8.0) (Promega, USA). 
25. Ethanolamine-hydrochloride (Sigma, UK). 
26. EZ-Link Iodoacetyl-PEG-Biotin, 50 mg (Pierce reagent 21334, USA). 
27. EZ-Link NHS-LC-LC-Biotin (Pierce reagent 21343, USA). 
28. Falcon tubes, 15 and 50 ml (Beckman, UK). 
29. Float A-Lyser G2 (MWt cut-off 8 – 10 kD) (Spectrum, USA). 
30. Foetal calf serum (FCS) (Sigma, UK). 
31. Formic acid (BDH Laboratory supplies, UK). 
32. Freund`s adjuvant (complete, F5881; incomplete, F5506; Sigma, UK). 
33. Gamma globulins from bovine blood (Sigma, UK). 
34. Glutaraldehyde, 25% (G6257, Sigma, UK). 
35. Guanidine hydrochloride (G-HCl) (Sigma, UK). 
36. HAT Media Supplement (50×) (H0262, Sigma, UK). 
37. Heparin sodium (5,000 Units/ml) (Wockhardt, UK). 
38. HEPES 1M (N-2-Hydroxyethylpiperazine-N′-2-ethanesulfonic Acid), free acid 
(H3375, Sigma, UK). 
39. High-binding, flat bottom 96-well plates, black clear bottom polystyrene (Costar, 
Corning, USA). 
40. High-binding, flat bottom 96-well plates, white solid bottom polystyrene (Costar, 
Corning, USA). 
41. Hydrochloric acid (HCl) 10 M stock (Analar grade: BDH Prolabo, UK). 
42. Imject Mariculture Keyhole limpet Hemocyanin (mcKLH; 2 x 20 mg vials Pierce 
product# 77600, USA). 
43. Lo-Binding ultracentrifugation tubes (Eppendorf, USA). 
44. Low nonspecific binding dialysis membranes (MWt cut-off 10,000, Spectra/Por 
Biotech Cellulose Ester, 8 mm width; 131261, Spectrum, Perbio Science, UK). 
45. Luminex® 100/200 Calibration Kit LX200-CAL (Luminex Corporation, USA). 
46. Luminex® 100/200 Performance verification kit LX200-CON (Luminex 
Corporation, USA). 
47. Luminex® 100/200 Sheath fluid (Luminex Corporation, USA). 
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48. Magnetic beads for NT-proET-1, ELDP, CT-proET-1 immunoassays (Luminex 
Corporation, USA). 
49. Mercaptoethanol (BDH Laboratory supplies, UK). 
50. Methanol (HPLC grade: BDH Prolabo, France). 
51. MTT [1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan Thiazolyl blue 
formazan] powder dissolved in DMEM (0.4 mg/ml) (M2003, Sigma, UK). 
52. Natural slick-seal tubes 0.2 ml, 1.5 ml (Bioquote, USA). 
53. Neutravidin-horeradish peroxidase (N-HRP) (Pierce, USA). 
54. Penicillin/Streptomycin: 10,000 Units/ml Penicillin and 10,000 µg/ml 
streptomycin (Gibco®, Invitrogen, USA). 
55. Peptide mix solution: Prepared at 1 nmol/ml as a mixture of the three peptides, 
NT-proET-1, ELDP and CT-proET-1, in 0.2 µm filtered 0.9% NaCl/0.1% BSA. 
The interim dilution was prepared from a fresh stock in freshly prepared 0.9% 
NaCl/0.1% BSA. 
56. pH indicator strips (non-bleeding), pH 0 – 6 and pH 7.5 – 14 (BDH Laboratory 
supplies, UK). 
57. Phosphate buffered saline (PBS) tablets (P4417-100TAB, Sigma, UK). 
58. Phosphate-buffered saline (PBS): dissolve 1 PBS tablet (Sigma, UK) in 200 ml 
uhq-H2O. 0.01 M phosphate buffer: 0.0027 M KCl, 0.137 M NaCl, pH 7.4, at 
25°C. 
59. Phosphoramidon 100 mM (Peptide Institute, Japan) (MWt = 543.5): 25 mg 
dissolved in 460 µl of sterile PBS, 100 µl aliquots stored at -20°C). Diluted in 
DMEM on the day of experiments. 
60. Polyethylene catheters (PE-50) (BD MicrolanceTM, USA). 
61. Polypep bovine protein digest low viscosity (Sigma, UK). 
62. Polypropylene tubes (5 ml, 75 x 13 mm) (Sarstedt, Germany). 
63. ProClin 300 (SuperCo Analytical, USA). 
64. PTFE porous membrane filter, 40 µm pore size (Alltech, Fisher Scientific). 
65. Q-Sepharose Fast Flow (300 ml) (GE Healthcare Bio-Sciences AB, Sweden). 
66. Rabbit anti-sheep IgG (H+L)-HRP labelled (Immunopure, Pierce Lot# 
1D1062475, USA). 
67. Sep-Pak® 3cc (500 mg) C2 cartridges (Waters, USA). 
68. Sintered glass funnel. 
69. Sodium azide (BDH/Merck, UK). 
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70. Sodium bicarbonate (Analar grade: BDH Laboratory supplies). 
71. Sodium carbonate anhydrous (Sigma, UK). 
72. Sodium chloride (NaCl) (Sigma-Aldrich Chemical Company, UK). 
73. Sodium thiopentone: The anaesthetic was purchased fresh from the supplier and 
made up at the time of surgery (Intraval Sodium, 120 mg/kg i.p.; Merial Animal 
Health Ltd., UK). 
74. Streptavidin (5 mg) (Immunopure, Thermo Science, USA). 
75. Streptavidin-R-Phycoerythrin (Steptavidin-RPE) (Invitrogen, Life Technologies, 
UK). 
76. Succinimidyl 4-[p-maleimidophenyl]butyrate (SMPB) (10 mg, MWt = 356) 
(Thermo Scientific, Pierce, USA). 
77. SulfoLink Coupling Resin (Thermo Scientific, Pierce, USA) (Iodoacetyl-activated 
crosslinked 6% beaded agarose, slurry in 50% glycerol, 10 mM EDTA with 
sodium azide). 
78. Sulfo-succinimidyl 4-(N-maleimidomethyl) (Thermo Scientific/Pierce, USA). 
79. Supersignal ELISA Pico chemiluminescence substrate 250 ml kit (Pierce, USA). 
80. Syringes, sterile, 10 ml (Sherwood medical, UK). 
81. Tissue culture T25 and T175 cm2 flasks (VWR, UK). 
82. TopTip Carbon+ (Graphite) C18 spintips (10 – 200 µl) (Glygen Corp, USA). 
83. Trifluoroacetic acid (TFA) (Rathburn Chemicals Ltd., Scotland). 
84. Tris (base) molecular biology grade (Calbiochem, Germany). 
85. Tris (hydroxymethyl) methylamine (BDH Laboratory supplies, UK). 
86. Triton X-100 (Sigma, UK). 
87. Trypsin, Sequencing Grade Modified (20 µg) (Promega, PRV5111). Trypsin 
Resuspension Buffer (V542A) (supplied with V5111): is composed of 50 mM 
acetic acid.  
88. Trypsin-EDTA Solution (10x) 5.0 g porcine trypsin and 2.0 g EDTA●4Na/L in 
0.9% NaCl (Sigma, UK). 
89. Tween-20 (Sigma, UK).  
90. Urea (VWR, UK). 
91. Vectaspin Micro Anopore 0.2 µm centrifugation tubes, 1.5 ml (Whatman, USA). 
92. White clear bottom Costar 96-well plates (Costar, Corning, USA). 
93. Wistar male rats (Charles River Limited, UK).  
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2.1.2  Equipment 
1. 96-well plate liquid scintillation counter and luminometer (Wallac 1450 
MicroBeta Trilux). 
2. Alltech 24-port vacuum manifold (Grace Davison Discovery Sciences, USA). 
3. Berthold microplate luminometer (Berthold Technologies, GmbH & Co. KG). 
4. ELx405™ Microplate Washer (BioTek). 
5. High-performance liquid chromatography system (HPLC): MERCK Hitachi L-
6200 Intelligent Pump with 2 ml injection loop, with gradient elution capability, 
Shimadzu SPD-6A UV detector that measured absorbance at A280 or A215, and 
Pharmacia LKB Helifrac fraction collector. HPLC columns: ACE C4 (Part 
number: ACE-223-2546); ACE C18 (Part number: ACE-221-2546) with 5 µm 
particle size, 300 Å pore size and 4.6 x 250 mm dimensions; and Jupiter C4 
(Phenomenex, Part Number: 00G-4169-N0) with 15 µm particle size, 300 Å pore 
size and 1 x 25 cm dimensions. 
6. Infinite 200 PRO series (TECAN plate reader). 
7. LTQ Orbitrap XL mass spectrophotometer (Thermo Fisher Scientiﬁc). 
8. Luminex 100/200 system (Luminex Corporation, USA).   
9. Techne sample concentrator (Bibby Scientific Limited, UK). 
10. Ultracentrifuge (Beckman Coulter). 
 
2.1.3  Preproendothelin-1 peptides   
ProET-1 peptide fragments NT-proET-1 (ppET-1[18 – 50]), ELDP (ppET-1[93 – 166]) and 
CT-proET-1 (ppET-1[169 – 212]) were chemically synthesised by the University of Geneva. 
Each peptide was initially dissolved in uhq-H2O at a nominal concentration of 100 
nmol/ml. The purity of each peptide was confirmed by HPLC (ACE C4 column, with 
absorbance measured at 280 nm). The concentration of each peptide was determined 
from peak area on HPLC (at A280), and quantified using standard concentrations of 
tyrosine and tryptophan as reference depending on the relative number of tyrosine and 
tryptophan residues in the peptide. Peptide sequences of proET-1 peptides are shown in 
Table 2.2. 
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2.1.3.1  Direct infusion of proET-1 peptides on Orbitrap 
Stock concentrations of synthetic NT-proET-1, ELDP and CT-proET-1 at 70, 85 and 59 
nmol/ml, respectively were diluted in 25% acetonitrile containing 0.1% formic acid at 1 
pmol/µl prior to LC-MS analysis on Orbitrap XL mass spectrophotometer (MS) 
(Thermo Fisher Scientiﬁc). NT-proET-1 was injected at a flow rate of 2 µl/min while 
ELDP and CT-proET-1 were injected at a flow rate of 1 µl/min over 5 min. 
Comparison of average masses (monoisotopic) of each proET-1 peptide obtained from 
Orbitrap [NT-proET-1 (3,429.797); ELDP (8,637.348); and CT-proET-1 (5,289.660)] 
(Table 2.1) with the monoisotopic masses calculated from ProteinProspector [NT-
proET-1 (3,429.787); ELDP (8,637.367) and CT-proET-1 (5,289.670)] (see Table 2.2 
for amino acid composition), showed mass errors of <0.02 Da. Therefore, the masses of 
synthetic proET-1 peptides were in agreement with the calculated monoisotopic masses. 
This indicated that amino acid sequences of proET-1 peptides corresponded correctly 
with the synthetic peptides. 
 
Table 2.1: Characterisation of proET-1 synthetic standards by direct infusion onto 
Orbitrap. The monoisotopic mass is calculated from the formula: [(m/z) x z] n-1 x H+, 
where m/z = mass-to-charge ratio, (m is the ion mass in atomic mass units in Daltons 
(Da) and z is the number of  elemental charge units), n = number of charges, H+ = mass 
of a proton (1.008 Da). 
ProET-1 peptide 
Observed ion 
(MH+) mass, m/z 
Charge 
Monoisotopic 
Mass 
NT-proET-1 
(ppET-1[18 – 50]) 
1,143.938 3 3,429.798 
858.205 4 3,429.798 
686.766 5 3,429.800 
ELDP 
(ppET-1[93 – 166]) 
720.704 12 8,637.360 
665.340 13 8,637.326  
617.890 14 8,637.358 
CT-proET-1 
(ppET-1[169 – 212]) 
882.450 6 5,289.662 
756.528 7 5,289.651 
662.090 8 5,289.667 
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2.1.4  Preproendothelin-1 antibodies  
Preparation of antibodies for ET-1 and big ET-1 immunoassay were described 
previously (Corder, 2002). Antibodies for proET-1 peptides were also produced 
following described methodologies (Corder, 2002). Details of the proET-1 peptide 
antibodies used in immunoassays are shown in Table 2.1. For assay use all antibodies 
were prepared as affinity purified IgG (Corder, 2002). Synthetic peptide antigens used 
for raising proET-1 antisera and for the affinity purification of IgG were purchased from 
Bachem GmbH (Germany). 
Underlined sequences in Table 2.2 indicate peptides used as antigens to raise specific 
antisera for the development of capture and detection antibodies. Specific IgG were 
purified from antisera using the same antigen coupled to SulfoLink Coupling Resin or 
CNBr-Sepharose; except for ET-1/big ET-1 where the detection antibody IgG was 
purified using ppET-1[54 – 63] coupled to Sulfolink Coupling Resin (Corder, 2002). To 
enable maleimide conjugation of ppET-1[18 – 30] and ppET-1[169 – 186] a C-terminal Cys-
NH2 residue was included in the synthetic peptide used for these antigens. 
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Table 2.2: Antibodies used for proendothelin-1 immunoassays. Amino acid numbering is based on the 212 amino acid sequence for 
preproendothelin-1 (ppET-1) (Bloch et al., 1989). Underlined sequences indicate peptides used as antigens to raise specific antisera for the 
development of capture and detection antibodies. 
ProET-1 peptide sequences 
Capture 
Antibody/ 
Protein 
Conjugate 
Species 
Detection 
Antibody/ 
Protein 
Conjugate 
Species 
ET-1 (ppET-1[53 – 73]): 
CSCSSLMDKECVYFCHLDIIW 
ppET-1[68 – 73]/ 
Glutaraldehyde 
Sheep 
ppET-1[54 – 63]/ 
Carbodiimide 
Rabbit 
Big ET-1 (ppET-1[53 – 90]): 
CSCSSLMDKECVYFCHLDIIWVNTPEHVVPYGLGSPRS 
ppET-1[74 – 90]/ 
Glutaraldehyde 
Rabbit 
ppET-1[54 – 63]/ 
Carbodiimide 
Rabbit 
NT-proET-1 (ppET-1[18 – 50]): 
APETAVLGAELSAVGENGGEKPTPSPPWRLRRS 
ppET-1[18 – 30]/ 
Maleimide 
Rabbit 
ppET-1[42 – 50]/ 
Glutaraldehyde 
Rabbit 
ELDP (ppET-1[93 – 166]): 
ALENLLPTKATDRENRCQCASQKDKKCWNFCQAGKEL
RAEDIMEKDWNNHKKGKDCSKLGKKCIYQQLVRGRKI 
ppET-1[93 – 109]/ 
Maleimide 
Sheep 
ppET-1[155 – 166]/ 
Maleimide 
Sheep 
CT-proET-1 (ppET-1[169 – 212]): 
SSEEHLRQTRSETMRNSVKSSFHDPKLKGKPSRERYVTH
NRAHW 
ppET-1[169 – 186]/ 
Maleimide  
Sheep 
ppET-1[204 – 212]/ 
Glutaraldehyde 
Rabbit 
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2.2  METHODS 
2.2.1  Cell culture 
EA.hy 926 is a hybridoma cell line generated by fusing A549 cells (human 
adenocarcinoma-derived alveolar epithelial cells) with primary human umbilical vein 
endothelial cells (HUVEC), which has characteristics of cultured endothelial cells (ECs) 
(Edgell et al., 1983). Previous studies have shown this is a suitable cell line for studying 
ET-1 synthesis (Saijonmaa et al., 1991; Corder et al., 1993a; Waxman et al., 1994). 
Conditioned media released from EA.hy 926 and A549 cells were used to study the 
effects of protease inhibitors on ET-1 and proET-1 peptide release (Chapters 3) and as 
source of proET-1 peptides for purification and characterisation of proET-1 peptides 
(Chapter 4). 
2.2.2  Chemiluminescence immunoassays 
2.2.2.1  Assay buffers  
A. IgG Coating buffer:  50 mM bicarbonate buffer, pH 9.5 (85 mg Na2CO3, 143 mg 
NaHCO3 in 50 ml uhq-H2O). 
B. Blocking buffer (10x): IgG coating buffer containing 0.5% BSA and 0.05% 
polypep. 
C. Neutralisation-buffer for cell culture media (N-SAB 6.9x conc): 363 mg Tris 
base (0.05 mM), 944 mg HEPES free acid (0.02 mM), 690 mg BSA (0.03 mM), 
276 mg IgG (0.07 mM), 276 mg polypep (0.07 mM), 69 µl Triton X-100 in 19.5 
ml uhq-H2O with phenol red. 5 ml aliquots were stored at -20
oC. 
D. Sandwich assay buffer (SAB, pH 7.5): 1 PBS tablet, 1 g BSA (0.5%), 0.4 g IgG 
(bovine gamma globulin) (0.2%), 0.4 g polypep (0.2%), 100 l Triton X-100, 
0.05 g sodium azide in 200 ml uhq-H2O. Filter sterilised (0.2 µm) and 50 ml 
aliquots were stored at -20oC. 
E. Sandwich assay buffer for plasma samples (nSAB, pH 7.5): 0.6 g 
NaH2PO4.2H2O, 5.76 g Na2HPO4.12H2O, 1.17 g NaCl, 1 g BSA, 0.4 g IgG, 0.05 
g sodium azide, 0.01 g heparin sodium salt, 0.1 ml ProClin, 6 ml 0.5 M pH 8.0 
EDTA, 0.4 ml Triton X-100 in 193.5 ml uhq-H2O.  
F. SAB with ProClin: 0.1 ml ProClin in 200 ml SAB. 
G. Wash buffer (PBS with 0.05% Tween-20): 1 PBS tablet and 100 l Tween-20 in 
200 ml uhq-H2O. 
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2.2.2.2  Immunoassays for ET-1 and big ET-1 
Step 1: Black clear bottom and high-binding Costar 96-well plates were coated with 
capture antibodies: 100 l/well of sheep anti-ET-1[16 – 21] IgG (ppET-1[68 – 73]) at 3 g/ml 
in coating buffer, or rabbit anti-human big ET-1[22 – 38] (ppET-1[74 – 90]) at 2 g/ml for big 
ET-1. Plates were incubated overnight at 4°C. 
 
Step 2: Next day, coating buffer was decanted and plates were blocked by adding 250 
µl/well blocking buffer (1x) and incubating for a further 2 h at room temperature. 
 
Step 3: ET-1 standards were prepared at 2000 fmol/ml in sandwich assay buffer (SAB) 
followed by 1 in 4 serial dilutions over the range 1.9 – 2000 fmol/ml. Human big ET-1 
standards were diluted to 300 fmol/ml followed by 1 in 3 serial dilutions over the range 
1.2 – 300 fmol/ml.  
 
Step 4: After blocking, plates were washed 3 times with wash buffer and 50 l of 
biotinylated antibody rabbit anti ET-1[2 – 11] IgG (ppET-1[54 – 64]) was added to all wells. 
100 l of each ET-1 or big ET-1 standard or samples were added to corresponding wells. 
100 l of SAB was also added for non-specific binding and 0 fmol/ml wells. Plates were 
then incubated overnight at 4°C.  
 
Step 5: End-point detection was then carried out after washing plates 3 times with wash 
buffer followed by addition of 100 µl of neutravidin-HRP diluted in wash buffer 
containing 0.5% BSA and incubated for 1 h at room temperature. Plates were then 
washed 4 times with wash buffer and 100 µl of supersignal ELISA Pico 
chemiluminescence substrate mixed at 1:1 ratio was added to all wells. The plates were 
covered and mixed for 1 min on a plate mixer and read using a scintillation/luminescence 
counter (protocol: Isoplate Tropix- reads 1 sec/well).  
 
Both ET-1 and big ET-1 immunoassays are highly specific with a negligible cross-
reactivity (<0.01%) in each assay (Corder, 2002).  
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2.2.2.3  Immunoassays of NT-proET-1, ELDP and CT-proET-1 
Chemiluminescent double-recognition site sandwich ELISAs for NT-proET-1, ELDP 
and CT-proET-1 were performed as described above for ET-1 and big ET-1 using 
antibodies indicated in Table 2.1. Affinity purification and biotinylation of IgG were 
prepared following well-established methods (Corder, 2002).  
Plates were coated with 100 µl of capture antibody at a concentration of 1 µg/ml. ProET-
1 standards were prepared at 1000 fmol/ml in SAB followed by 1 in 3 serial dilutions 
over the range 1.4 – 1000 fmol/ml. After blocking (as in step 2), 25 l of SAB was added 
to all wells. After adding 50 µl of standard or samples plates were mixed at room 
temperature for 30 min. 25 l of biotinylated antibody was added before an overnight 
incubation at 4°C. End-point detection was then carried out in the same way as described 
above for ET-1 and big ET-1 immunoassays (step 5). 
 
2.2.2.4 Immunoassay of ELDP and CT-proET-1 for plasma and urine 
measurements 
White solid bottom and high-binding Costar 96-well plates were coated with the capture 
antibodies (1 µg/ml) specific for ELDP and CT-proET-1. After an overnight incubation, 
plates were blocked (as in step 2) and 25 µl of plasma samples or 100 µl of urine samples 
were added in wells containing 75 µl of nSAB or 50 µl of 3 times concentrated nSAB. 
Standards were prepared in the range 0.09 – 200 fmol/ml in nSAB and 50 µl or 100 µl 
per well was added for plasma or urine measurements, respectively. Following an 
overnight incubation detection of bound peptide was achieved with biotinylated IgG for 
ELDP (ppET-1[155 – 166]) or CT-proET-1 (ppET-1[204 – 212]), respectively. This was in 
conjunction with neutravidin-HRP and chemiluminescent substrate detection as 
described above (step 5). The plate was read using Berthold microplate luminometer (1 
s/well). The lower limit of detection for ELDP was 0.09 fmol/ml in urine and 0.30 
fmol/ml in plasma. The detection limit for CT-proET-1 in plasma was 0.60 fmol/ml.  
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2.2.3 Magnetic bead-based multiplex assays for proET-1 
peptides 
Magnetic beads (Bio-Rad) were coated with corresponding capture antibodies for NT-
proET-1, ELDP and CT-proET-1 (see Table 2.2, page 68) following standard protocols 
(Luminex Corporation).  
(1) White clear bottom Costar 96-well plates were washed with a microplate washer 
(ELx405, BioTek). Magnetic beads for NT-proET-1, ELDP and CT-proET-1 
were prepared as a combination (and protected from light) by diluting stock 
solutions in wash buffer at 1 in 50 for NT-proET-1 and 1 in 100 for ELDP and 
CT-proET-1. A 10 µl volume of the diluted bead combination was added to each 
well (and protected from light). 
(2) 135 µl nSAB was added to the sample wells and to the nSAB standard curve, 
while for the plasma standard curve 120 µl nSAB and 15 µl rat plasma was added 
and mixed on an orbital plate mixer. Standards were prepared in the range 2.1 – 
1500 fmol/ml. 15 µl of standards or plasma samples were added (total volume 
per well 150 µl) and the plate was incubated overnight at 4°C on an orbital plate 
mixer.  
(3) On the next day, after washing plates on the ring magnet plate washer, 25 µl of 
combined biotinylated antibodies were added to all wells and incubated for 2 h 
at room temperature mixing on the orbital plate shaker.  
(4) After washing three times on the plate washer end-point detection was carried 
out by incubating 25 µl/well of 1 in 10 diluted Streptavidin-RPE (Invitrogen) for 
30 min at room temperature on orbital plate shaker. After washing plate 3 times 
on the ring magnet 100 µl/well sheath fluid was added and mixed before reading 
on a Luminex 200 System, which was set to analyse magnetic beads at regions 
45 (NT-proET-1), 36 (ELDP) and 27 (CT-proET-1) in a volume of 50 µl/well 
and to count 50 beads/region. 
 
  
Chapter 2  General materials & methods 
 
 
73 
 
2.2.4 Production of new capture and detection antibodies for 
CT-proET-1 immunoassay 
Initially, the N-terminal sequence SSEEHLRQTRSETMRNSV corresponding to ppET-
1[169 – 186] was used to raise specific antisera for CT-proET-1 immunoassay. The human 
sequence has four homologous residues with the sheep sequence (Table 2.3). This may 
result in some cross-reactivity of sheep CT-proET-1 with the sheep antibodies resulting 
in increased non-specific binding. Therefore, the non-homologous region 
SSEEHLRQTRS (ppET-1[169 – 179]) was used as the new antigen sequence to raise 
specific antisera with the aim of increasing assay sensitivity and specificity. 
 
Table 2.3: Comparison of human and sheep N-terminal sequence of CT-proET-1 
peptide. Bold indicates CT-proET-1 sequence used to raise antisera/purify IgG, hyphens 
(-) represents missing residues where there is no corresponding amino acid residue in 
the sequence for these residues and italics indicates non-homologous residues in the 
sheep sequence. 
  
 
169          179       186 
Human S S E E H L R Q T R S E T M R N S V 
Sheep - - - - - - - - - - L E T I S N S I 
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2.2.4.1  Reagents and solutions  
2.2.4.1.1 Custom synthesised CT-proET-1 peptides 
N-terminal CT-proET-1 (ppET-1[169 – 179])-Cys: H-Ser-Ser-Glu-Glu-His-Leu-Arg-Gln-
Thr-Arg-Ser-Cys-NH2 (SSEEHLRQTRSC) trifluoroacetate salt, MWt = 1431.55 (>95% 
pure, 75% peptide content) (Bachem lot# 3008326, UK).  
Cysteine-amide is added to the C-terminus of the N-terminal sequence to facilitate 
coupling of this peptide to KLH carrier protein (using the maleimide method) and for 
biotinylation of this peptide-antigen with EZ-Link Iodoacetyl-PEG-Biotin. 
C-terminal CT-proET-1 (Lys203-ppET-1[204 – 212]): H-Lys-Tyr-Val-Thr-His-Asn-Arg-
Ala-His-Trp-OH (KYVTHNRAHW) trifluoroacetate salt, MWt = 1311.47 (>97% pure, 
71.8% peptide content) (Bachem lot# 3008325, UK).  
Lysine at the N-terminal of the C-terminal CT-proET-1 sequence is added to improve 
coupling efficiency of the peptide sequence to KLH carrier protein using glutaraldehyde 
and for biotinylation of this peptide-antigen with EZ-Link NHS-LC-LC-Biotin. 
 
2.2.4.1.2 Conjugation buffers 
1. Phosphate Buffer (0.1 M, pH 7.2): 0.19 g KH2PO4 and 0.64 g Na2HPO4 in 50 ml 
uhq-H2O. 
2. Phosphate Buffer with EDTA (0.2 M, pH 7.2/10 mM EDTA): 0.39 g KH2PO4, 
1.27 g Na2HPO4 and 0.19 g Na2EDTA in 50 ml uhq-H2O. 
3. Reaction buffer for CNBr Sepharose: 0.2 M NaHCO3 and 0.5 M NaCl, pH 8.0. 
4. Coupling buffer: 0.5 M sodium bicarbonate (NaHCO3) buffer, pH 8.5 (2.1 g 
NaHCO3 in 50 ml uhq-H2O). 
5. Reaction buffer for SulfoLink coupling resin: 0.1 M Tris-HCl (pH 8.5)/10 mM 
EDTA: 0.22 g Tris-HCl, 0.44 g Tris and 0.186 g Na2EDTA in 50 ml. 
6. Blocking buffer for CNBr Sepharose: 50 mM ethanolamine-HCl in coupling 
buffer, pH 8.0. 
7. Blocking buffer for SulfoLink coupling resin: 10 mM mercaptoethanol. 
8. 5 mM EDTA: 0.09 g EDTA in 50 ml. 
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2.2.4.1.3 Biotinylation of CT-proET-1 peptides and purified IgG 
N-terminal CT-proET-1 peptide: 1.6 mg of SSEEHLRQTRSC (MWt = 1432; peptide 
content 75%; ~838 nmol) was dissolved in 750 µl of 5 mM EDTA. 18 µl of peptide (20 
nmol) was diluted in 1 ml 0.2% formic acid and injected onto HPLC with detection of 
peptide peak by absorbance (A215; ACE C18, 4.6 x 250 mm; eluted with a gradient of 
8% to 24% CH3CN containing 0.1% TFA over 40 min at a flow rate of 1 ml/min; elution 
time 19.1 min). 5.2 mg of EZ-Link Iodoacetyl-PEG-Biotin (MWt = 542) was dissolved 
in 2.28 ml of Tris-HCl pH 8.5/EDTA (2.28 mg/ml). To characterise the HPLC elution 
position of the biotinylation reagent and to facilitate identification of reaction products, 
5 µl of biotinylation reagent (21 nmol) was diluted in 1 ml of 0.2% formic acid and 
injected onto HPLC (conditions as above for synthetic peptide; elution time 34.8 min). 
The biotinylation reagent was reacted with 25% excess over peptide; 250 µl of the 
biotinylation reagent (1.05 µmol) was added to the remaining peptide, and a further 500 
µl of 0.1 M Tris-HCl pH 8.5/10 mM EDTA was added to the reaction mixture before 
incubation at room temperature in the dark for 1 h. The efficiency of biotinylation 
reaction was evaluated after 1 h by injecting 20 µl from the reaction mix onto HPLC 
(conditions as above; elution time of biotinylated peptide product 30.8 min, no unreacted 
peptide). After verification of the successful reaction the biotinylated peptide was 
purified by acidifying the reaction mixture with 6 µl 98% formic acid, and loading the 
entire sample onto HPLC using the same elution conditions as those used for monitoring 
reaction. The purified biotinylated peptide was retained for subsequent antibody 
evaluation. 
C-terminal CT-proET-1 peptide: 6.2 mg of KYVTHNRAHW peptide (MWt = 1311; 
peptide content 71.8%; ~3.4 µmol) was dissolved in 680 µl of H2O (5 µmol/ml), and 0.1 
ml (0.5 µmol) was placed on ice. The pH was adjusted to 8.5 by adding 50 µl of 0.5 M 
NaHCO3, pH 8.5. 1 µl of the C-terminal peptide (5 nmol) was injected onto HPLC with 
detection of peptide peak by absorbance (A215; ACE C4, 300 Å pore size, 4.6 x 250 mm; 
eluted with a gradient of 8% to 24% CH3CN containing 0.1% TFA over 40 min at a flow 
rate of 1 ml/min; elution time 8.4 min). 2.5 mg of NHS-LC-LC-Biotin reagent (MWt = 
568) was dissolved in 176 µl dimethyl formamide (DMF) in a glass tube, and kept on 
ice (4.4 µmol = 25 µmol/ml). 1 µl of biotinylation reagent (25 nmol) was diluted in 0.2% 
formic acid and injected onto HPLC with the elution conditions indicated above (elution 
time 12.8 min). For comparison a sample of biotinylation reagent was hydrolysed in 0.1 
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M NaHCO3 for 1 h at room temperature and then subjected to HPLC (elution position 
of hydrolysed reagent 9.8 min). For biotinylation of the C-terminal peptide, 25 µl of 
biotinylation reagent in DMF (0.625 µmol; 25 % excess) was added to 100 µl of peptide 
(0.5 µmol)  and the reaction mixture was gently mixed and allowed to react on ice for 
20 – 30 min and then at room temperature for 2 h. The efficiency of biotinylation reaction 
was evaluated by HPLC of 1.5 µl samples at A215 and A280 with the elution conditions 
described above (elution time for main biotinylated product 18.7 min). The biotinylated 
peptide was purified by HPLC and retained for subsequent antibody evaluation. 
Peptide specific purified IgG: After affinity purification (section 2.2.4.6) of C-terminal 
(Lys203-CT-proET-1[204 – 212]) peptide specific IgG, the fractions containing the highest 
affinity peptide-specific IgG were determined using the ELISA methodology described 
in section 2.2.4.5. Highest affinity IgG were determined on the basis of highest binding 
peptide-specific IgG to the Sepharose gel. Fractions E – F, H – J and I showed highest 
affinity for the C-terminal peptide. These fractions were concentrated and then subjected 
to dialysis to remove contaminating reagents that could interfere in the biotinylation 
reaction; as described in section 2.2.4.6.3 (step 7).  
Biotinylation of C-terminal peptide specific IgG was carried out as follows. The pH of 
IgG samples were adjusted to 8 by adding 0.5 M NaHCO3 (typically 1 in 10 dilution for 
a post-dialysis IgG solution in 0.9% saline) and then chilled on ice. Biotinylation reagent 
was added at a 100-fold molar excess based on IgG concentrations (0.15 mg IgG = 1 
nmol) determined by Bio-Rad protein assay (section 2.2.5). 5.4 mg of NHS-LC-LC-
Biotin reagent (9512 nmol) was dissolved in 288 µl DMF (33 nmol/µl), and 20 µl was 
added to fractions E – F (1 mg in 150 µl), and 10 µl was added to IgG fractions H – J 
and I and (both 0.5 mg IgG). The biotin-IgG reaction mixture was kept on ice for 1 h 
and then reacted for 2 h at room temperature. Biotinylated IgG was dialysed using a 10 
kD cut-off membranes against 5 L 0.15 M NaCl/0.05 M sodium phosphate buffer pH 
7.2 for 16 – 18 h to remove excess and unbound biotinylation reagent from the 
biotinylated-IgG. Based on post dialysis sample volumes, biotinylated IgG 
concentrations were 1.67, 1.0 and 1.25 mg/ml for E – F, H – J and I respectively. 
Biotinylated IgG were tested at dilutions of ~7.5, 15 and 30 ng/well with 25 µl of the 
appropriate dilution added per well. 
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2.2.4.2 Coupling of synthetic N-terminal peptide of CT-proET-1 to an 
immunogenic carrier protein 
1. 40 mg of Imject Mariculture Keyhole limpet Hemocyanin (mcKLH) (± 0.4) 
(~450 – 13,000 kD) was dissolved in 6 ml 0.1 M phosphate buffer (pH 7.2) and 
chilled on ice. 
2. 10 mg of succinimidyl 4-[p-maleimidophenyl]butyrate (SMPB) (MWt = 356) 
was dissolved in 250 μl DMF. 120 µl of SMPB solution was added to 6 ml of 
mcKLH solution (~5 mg of SMPB) and chilled on ice to 4°C (0.35 µmol/mg 
protein). 
3. The tube containing the reaction mix was covered in foil and incubated at room 
temperature for 2 h to allow the reaction to take place while gently mixing on a 
flat-bed roller mixer. Then to remove any free SMPB the conjugate 
mcKLH/SMPB solution was dialysed (MWt cut-off 10 kD) against 10 mM 
phosphate pH 7.2 in 0.2 M NaCl (5 L) in the dark at 4°C for 2 x 24 h, i.e. changing 
the dialysis buffer after 24 h. On completion of dialysis mcKLH was centrifuged 
for 10 min at 3000 rpm to remove any protein that had become insoluble after 
SMPB reaction. 
4. 6.4 mg of SSEEHLRQTRSC (75% peptide by weight, ~5 mg pure peptide) was 
dissolved in 0.2 M phosphate buffer pH 7.2 containing 10 mM EDTA pre-chilled 
on ice. The peptide was then added to mcKLH, gently mixed and incubated at 
room temperature for 2 h. 
5. To confirm successful conjugation of peptide to mcKLH carrier protein, a 15 µl 
aliquot from the reaction mix was diluted in 0.5 ml 0.2% formic acid, subjected 
to filtration through a 10 kD cut-off filter (Microcon YM-10, Amicon), and the 
filtrate was injected onto HPLC to demonstrate absence of free unreacted peptide 
(detection by absorbance A215; column: ACE C18, 5 µm, 4.6 x 250 mm; eluted 
with a gradient of 8% to 24% CH3CN containing 0.1% TFA over 40 min at a 
flow rate of 1 ml/min). 
6. CT-proET-1/mcKLH conjugate was dialysed overnight at 4°C using 10 kD MWt 
cut-off dialysis membranes against 500 ml of 0.9% NaCl. 
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2.2.4.3 Coupling of synthetic C-terminal peptide of CT-proET-1 to an 
immunogenic carrier protein  
1. KYVTHNRAHW was conjugated to mcKLH with glutaraldehyde. A 20-fold 
molar excess of glutaraldehyde (95 µl of 0.8 M) was added to 7.1 mg of 
KYVTHNRAHW (~5 mg pure peptide = 3.8 µmol) dissolved in 1 ml 0.1 M 
phosphate buffer, and placed in the dark for 30 min at room temperature. 
2. mcKLH (20 mg) was dissolved in 4 ml of 0.1 M phosphate buffer and added to 
the glutaraldehyde activated KYVTHNRAHW peptide. The reaction mixture of 
mcKLH and glutaraldehyde–KYVTHNRAHW was left in the dark for 1 h at 
room temperature. Unreacted glutaraldehyde was quenched by the addition of 6 
mg glycine dissolved in 5 ml of 0.1 M phosphate buffer. 
 
2.2.4.4  Sheep immunisation protocol 
To raise antisera conjugated peptides were sent to Ig-Innovations (Llandysul, Wales). A 
standardised immunisation procedure was used with pre-immune sera being collected 
from each sheep before immunisation. For the initial immunisation peptide conjugates 
were diluted with an equal volume of Complete Freund’s adjuvant. Two sheep were 
immunised with each antigen: N-terminal or C-terminal peptide of CT-proET-1. Booster 
injections were administered every 4 weeks over a 4 – 5 month period. Test bleeds were 
collected 2 weeks after each booster injection and evaluated for antigen binding by 
ELISA. Each new antiserum sample was compared to the previous bleed and pre-
immunisation sample. 
 
2.2.4.5  ELISA methodology to evaluate the affinity of antisera   
Black, high-binding 96-well plates were coated with 5 µg/ml streptavidin (Thermo 
Science) and stored at 4°C overnight. On the next day, the plates were blocked with 
blocking buffer. After washing, 100 µl of the biotinylated peptides for N-terminal CT-
proET-1 (ppET-1[169 – 179]) or C-terminal CT-proET-1 (ppET-1[204 – 212]) (see section 
2.2.4.1.3) diluted to 200 pmol/ml were incubated for 4 h at room temperature (N.B. 
previous studies had established that 10 pmol/well gives maximum signal with this 
streptavidin-biotin-peptide-IgG complex). Plates were washed 3 times and incubated for 
24 h with 100 µl antisera dilutions prepared in assay buffer. Plates were washed 5 times 
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and end-point detection was carried out by incubating plates for 1 h with rabbit anti-
sheep IgG-HRP conjugate, followed by 5 washes before incubation with 
chemiluminescence substrate.  
 
2.2.4.6  Affinity purification of IgG  
2.2.4.6.1 Coupling of N-terminal peptide of CT-proET-1 to Agarose 
1. 8.2 mg of SSEEHLRQTRSC (4.3 µmol pure peptide) was dissolved in 2 ml of 5 
mM EDTA. An aliquot (10 µl, 21.5 nmol) was retained for HPLC 
characterisation and for comparative estimation of coupling efficiency. 
2. SulfoLink coupling resin (10 ml, 50% slurry = 5 ml gel bed volume) was 
transferred to a column and washed three times with 5 ml reaction buffer (0.1 M 
Tris-HCl pH 8.5 containing 10 mM EDTA). The gel was vacuum dried after 
washing, transferred to a 15 ml tube, and then 2 ml peptide and 5 ml reaction 
buffer was added to react for 1 h at room temperature.  
3. The reaction mix (11 ml including gel) was allowed to settle for 10 min. 200 µl 
of the gel supernatant was transferred to a microcentrifuge tube and centrifuged 
for 3 min at 14000 rpm to remove all fine gel particles. A sample [110 µl (43 
nmol) – equivalent to twice the retained reference sample in step 1] of the 
resultant supernatant was diluted in 500 µl 0.2% formic acid, the pH adjusted to 
3.0 by adding formic acid (98 – 100%), and subjected to HPLC with detection 
by absorbance (A215; column: ACE C18, 5 µm, 4.6 x 250 mm; eluted with a 
gradient of 8% to 24% CH3CN containing 0.1% TFA over 40 min at a flow rate 
of 1 ml/min). The reaction efficiency was determined by comparison of the peak 
area with that obtained with initial sample of reconstituted peptide measured at 
A215. This showed >95% peptide had been coupled to the gel.  
4. Unreacted iodo-groups on the SulfoLink gel were blocked by adding 10 mM 
mercaptoethanol, and reacting at room temperature for 1 h.  
5. The column was washed with 3 – 4 column volumes of sterile-filtered PBS. 
Vacuum dried gel was transferred to a new tube and stored in 10 ml of PBS 
containing 0.02% azide at 4°C until affinity purification of IgG. 
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2.2.4.6.2 Coupling of C-terminal peptide of CT-proET-1 to Sepharose 
1. CNBr Sepharose was prepared according to the protocol described in Corder, 
2002. Briefly, 1.3 g CNBr Sepharose was weighed in a sintered glass funnel with 
a 40 µm porous filter. 1 mM HCl was added to swell the gel, and it was then 
rinsed four times with 50 ml of 1 mM HCl. Using a clean spatula, the swollen 
gel was immediately transferred to a 15 ml Falcon tube. 
2. 9.2 mg of KYVTHNRAHW was dissolved in 1 ml of H2O (~5 µmol pure 
peptide). A sample (1 µl, 5 nmol) was retained for HPLC. The remaining peptide 
solution was transferred to the swollen gel and 6 ml of 0.2 M NaHCO3 containing 
0.5 M NaCl, pH 8.0 was added to initiate the reaction. The gel and the peptide 
were mixed on a roller-bed mixer at room temperature for 2 h.  
3. The reaction efficiency of the 10 ml reaction mix (0.5 nmol/µl) was determined 
as described above (step 3) by HPLC with monitoring of peptide peaks at A280. 
No unreacted peptide was detected, indicating 100% coupling efficiency. 
4. After coupling of the peptide, the gel was blocked by the addition of 
ethanolamine-HCl, pH 8.0, to 50 mM, and then incubated at room temperature 
for 1 h to react.  
5. The gel was poured into sintered glass funnel and the tube was washed with 2 
mM HCl, and followed by sterile PBS as described in the previous section (step 
5). The gel was stored in PBS with 0.02% azide until used for purification of 
IgG. 
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2.2.4.6.3 Sodium Sulphate Precipitation 
Antisera (2 x 40 ml) were measured into 50 ml Falcon tubes. Anhydrous Na2SO4 was 
added to produce an 18% weight per volume (w/v) solution (e.g. 1.8 g per 10 ml 
antiserum). The tube was inverted immediately several times and then mixed on a roller-
bed mixer until all Na2SO4 had dissolved. The serum IgG fraction was precipitated by 
centrifugation at 2000 g for 15 min at 20°C. The supernatant was aspirated and the IgG 
precipitate was reconstituted in PBS to the same volume as the initial antiserum sample 
volume. Affinity purification of antisera protocol was adapted from the previously 
described methodologies (Corder, 2002).  
1. After precipitation of the antiserum with sodium sulphate as described above, the 
N-terminal CT-proET-1 Agarose and C-terminal CT-proET-1 Sepharose gels 
were gently mixed on a roller-bed mixer. Using a glass pipette, the gels were 
transferred to columns fitted with porous PTFE filters and washed three times 
with PBS. 
2. The reconstituted IgG solutions were passed through the corresponding peptide 
gel. The gels were washed four times with 5 ml PBS, and then with 5 ml of 0.5 
M NaCl to remove non-specifically bound proteins. 
3. Specifically bound IgG was eluted into tubes containing 300 µl 0.8 M NaHCO3 
per tube for neutralisation with the following elution conditions: (A) 3 ml 50 mM 
NaCH3COO adjusted to pH 4.5 with acetic acid; (B) 2 ml 50 mM NaCH3COO 
adjusted to pH 4.0 with formic acid; (C) 2 ml 50 mM NaCH3COO adjusted to 
pH 3.5 with formic acid; (D) 2 ml C + 1 M Urea; (E) 2 ml C + 2 M Urea; (F) 2 
ml C + 4 M Urea; (G) 2 ml C + 8 M Urea; (H) 2 ml C + 8 M Urea; (I) 2 ml C + 
2 M G-HCl + 10% CH3CN; (J) 2 ml C + 4 M G-HCl + 10% CH3CN; (K) 2 ml 
C + 6 M G-HCl + 10% CH3CN; (L) 2 ml C + 6 M G-HCl + 10% CH3CN; (M) 2 
ml C + 6 M G-HCl + 10% CH3CN; (N) 2 ml C + 6 M G-HCl + 10% CH3CN; 
(O) 2 ml C + 6 M G-HCl + 10% CH3CN; (P) 2 ml C + 6 M G-HCl + 10% 
CH3CN; (Q) 2 ml C + 6 M G-HCl + 10% CH3CN. 
4. 50 µl PBS containing 1% azide was added to each tube as a preservative and 
mixed gently. 
5. Furthermore, 100 µl of each eluate was diluted in tubes containing 1 ml PBS with 
azide for evaluation of protein/IgG concentration using Bio-Rad protein assay 
(section 2.2.5) and antigen binding.  
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6. The gels were washed with 40 ml of PBS with azide and stored at 4°C. 
7. Peak fractions from step 5 were pooled and concentrated using centrifugal filter 
devices (Amicon Ultra, MWt cut-off 100 kD), and then IgG was dialysed against 
0.9% NaCl using Float A-Lyser G2 (MWt cut-off 8 – 10 kD) to remove salts that 
could interfere with biotinylation of IgG or lead to denaturation of IgG on 
storage. 
8. IgG from dialysed fractions were tested as capture antibodies using sandwich 
ELISA methodology to ensure low non-specific binding and high assay 
sensitivity. Black, high-binding 96-well plates were coated with 100 µl/well of 
N-terminal or C-terminal CT-proET-1 specific IgG at 2 µg/ml and stored at 4°C. 
On the next day, plates were blocked with blocking buffer. CT-proET-1 synthetic 
standard was prepared in the range 25 – 200 fmol/ml. After washing, 50 µl of 
standards or SAB (to determine non-specific binding) were added to the N-
terminal CT-proET-1 (ppET-1[169 – 179]) specific IgG coated wells and mixed at 
room temperature for 30 min. 25 µl of rabbit anti ppET-1[204 – 212] biotinylated 
IgG (Table 2.2) was added to all wells and stored at 4°C. C-terminal CT-proET-
1 (ppET-1[204 – 212]) specific IgG was evaluated with 100 µl/well of the 
biotinylated-peptide antigen at 10 pmol/ml (section 2.2.4.5). The plate was 
mixed at room temperature for 30 min and stored at 4°C for end-point detection 
on the following day. 
 
2.2.5  Bio-Rad protein assay 
The protein concentration of the affinity purified fractions was measured from an IgG 
standard curve as a representative protein solution. IgG was prepared at 1 mg/ml in PBS 
and the standard curve (concentration range 7.8 – 500 µg/ml) was prepared by 1:2 serial 
dilutions in PBS. Stock solution of Bio-Rad reagent was prepared at 1:4 dilution of dye 
reagent concentrate in uhq-H2O, which was then filtered using a 0.2 µm filter paper and 
stored at 4°C. In a clear 96-well plate (Sterlin), 50 µl of standards or samples were added 
in duplicate and 200 µl of the 1:5 diluted (in uhq-H2O) Bio-Rad reagent was added to 
all wells. The plate was incubated at room temperature mixing on orbital mixer for 5 
min. The absorbance was then measured at 595 nm using a spectrophotometer (Infinite, 
TECAN). 
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Release of ET-1 and proET-1 peptide fragments from 
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3.1  INTRODUCTION 
Endothelin-1 is produced from the inactive intermediate big ET-1 by the hydrolysis of 
Trp21 – Val22 bond of big ET-1. This process is catalysed by the physiological endothelin 
converting enzyme (ECE) (Figure 3.1). The first clear evidence of this was provided by 
inhibition of ET-1 release with high concentrations of a metallopeptidase inhibitor 
phosphoramidon. This resulted in accumulation of the big ET-1 (Ikegawa et al., 1990). 
Similarly, in circulation and in isolated vessels, phosphoramidon inhibited the 
conversion of big ET-1 to ET-1 (McMahon et al., 1991; Corder & Vane, 1995; Battistini 
et al., 1995). Along with ET-1 a biologically inactive C-terminal fragment (CTF) of big 
ET-1 is also produced. Phosphoramidon reduced immunoreactive-ET-1 and CTF of big 
ET-1 (22 – 39) (Ikegawa et al., 1990). This proteolytic step can occur in the extracellular 
medium and intracellularly in the secretory vesicles prior to its release (Corder et al., 
1995b; Harrison et al., 1995). Therefore, big ET-1 can be secreted alone or co-secreted 
with ET-1 (Plumpton et al., 1994). 
Endothelial (EA.hy 926) and epithelial (A549) cells were previously used to study the 
intracellular biosynthesis of ET-1 as they express ET-1 mRNA and secrete big ET-1 and 
ET-1 into the culture media in a phosphoramidon-sensitive manner (Saijonmaa et al., 
1991; Corder et al., 1995b; Corder et al., 2002). A phosphoramidon-sensitive ECE 
activity with the characteristics of ECE-1 is localised predominantly in the plasma 
membrane of EA.hy 926 cells and A549 cells (Waxman et al., 1994; Corder et al., 
1995b; Deprez-Roy et al., 2000). However, localisation of ECE-1 to the membranes of 
Golgi apparatus indicated that ET-1 biosynthesis is primarily intracellular (Gui et al., 
1993; Xu et al., 1994) requiring much higher (~10-fold) concentrations of 
phosphoramidon than those required to inhibit membrane bound ECE-1 (Isaka et al., 
2003; Corder et al., 1995b). Thus, phosphoramidon is a more potent inhibitor of 
exogenous big ET-1 cleavage than the endogenous big ET-1 (Corder et al., 1993a). 
EA.hy 926 cells express high NEP-24.11 activity (Waxman et al., 1994), which was 
shown to degrade ET-1 in vitro (Vijayaraghavan et al., 1990) and in vivo (Abassi et al., 
1992). At lower levels (1 µg/ml), NEP-24.11 resulted in the degradation of secreted ET-
1, while at higher levels it resulted in the total cleavage of ET-1 by the Trp21 – Val22 
bond of big ET-1 (Abassi et al., 1993a).  
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Inhibitory effects of phosphoramidon alone and in combination with thiorphan (NEP-
24.11 inhibitor) on the conversion of exogenous big ET-1 to endogenous ET-1 synthesis 
was studied in human cells using HUVEC, EA.hy 926 and A549 cells (Corder et al., 
1995b). While thiorphan (1 µM) had no inhibitory effect on the ECE activity of BAEC, 
in EA.hy 926 cells thiorphan reduced ECE activity by 30% and when used in the 
presence of low concentrations of phosphoramidon (up to 0.1 µM), the ECE activity was 
reduced by 63% (Corder et al., 1995b). In comparison to EA.hy 926 cells, approximately 
25% of the ECE activity of HUVEC was attributed to NEP-24.11. Immunoblot analysis 
identified ECE-1 in the membrane fraction of A549 cells (Deprez-Roy et al., 2000). 
However, in contrast to EA.hy 926 cells, ECE-1b/c, but not NEP-24.11 is involved in 
ET-1 production in A549 cells (Aubert et al., 1998). 
Although ECE-1 and NEP-24.11 have similar structures (see Table 1.2) (Malfroy et al., 
1988) thiorphan, a specific inhibitor of NEP-24.11 has no inhibitory effect on ECE-1 
activity. Therefore, it was suggested that NEP-24.11 is unlikely to function as a 
physiologically relevant ECE-1 activity (Abassi et al., 1993a; Murphy et al., 1994). 
Processing of proET-1 at double basic amino acid residues has the potential to produce 
further peptides that are co-released with ET-1, and which may serve as alternative 
biomarkers of ET-1 synthesis, or have biological actions that complement those of ET-
1. Pilot studies have identified three proET-1 peptides, namely NT-proET-1 (ppET-1[18 
– 50]), Endothelin-like Domain Peptide – ELDP (ppET-1[93 – 166]), and CT-proET-1 ppET-
1[169 – 212] (see description of assays in Chapter 2 and Figure 3.1). These proET-1 peptides 
were shown to be present in conditioned media samples from EA.hy 926 and A549 cell 
lines using specific immunoassays. However, the effects on regulation of their synthesis 
with protease inhibitors have not been investigated. Therefore, the goal of this chapter 
was to examine the effects of phosphoramidon on the synthesis of NT-proET-1, ELDP 
and CT-proET-1. In addition, the effects of other protease inhibitors were also 
investigated. Synthetic peptides corresponding to the identified peptides NT-proET-1, 
ELDP and CT-proET-1 were chemically synthesised and immunoassays were used to 
measure the release of these peptides in the conditioned media samples of EA.hy 926 
and A549 cells. 
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Figure 3.1: Scheme for ppET-1 processing and antibody recognition sites for the 
detection of proET-1 peptides: NT-proET-1, ELDP and CT-proET-1.  Specific 
antisera was raised for NT-proET-1 (ppET-1[18 – 50]); Endothelin-like Domain Peptide–
ELDP (ppET-1[93 – 166]); and CT-proET-1 (ppET-1[169 – 212]). Synthetic peptides 
corresponding to the identified peptides were chemically synthesised. 
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3.2  METHODS  
3.2.1  Cell culture 
EA.hy 926 cells were grown to confluence in T75 cm2 flasks in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 4500 mg D-glucose/L with 10% (v/v) foetal 
calf serum, 2% HAT medium supplement (50x) (100 μM sodium hypoxanthine, 0.4 μM 
aminopterin, and 16 μM thymidine) and incubated at 37°C in a humidified CO2 
incubator (8% CO2, 92% air). HAT supplement was also routinely added to DMEM for 
all incubations with EA.hy 926 cells. A549 cells were cultured under the same 
conditions, except that HAT supplement was excluded from the DMEM. 
Subcultures were prepared by treating confluent flasks using 10% trypsin prepared in 
warm PBS and seeded into 2 x 24-well plates (2 cm2 growth area per well/ 2.5 x 105 
cells per cm2) in the relevant culture medium containing 10% FCS to give approximately 
70 – 80% confluence on the following day. On the next day, protease inhibitors were 
prepared as described in the next section and incubated on the confluent cells over 6 h 
and 24 h as described in section 3.2.3. Experiments were performed in DMEM without 
serum or penicillin/streptomycin. 
 
3.2.2  Protease inhibitor study 
The protease inhibitors used to study the stability of ET-1 and proET-1 peptides released 
from EA.hy 926 and A549 cells included phosphoramidon and an inhibitor cocktail that 
was composed of 1000 µM bacitracin, 10 µM chymostatin, 10 µM leupeptin, and 1 µM 
pepstatin A (Table 3.1). Phosphoramidon was prepared as a stock concentration of 100 
mM in PBS.  Stock solutions of protease inhibitors were prepared by reconstituting 
leupeptin at 100 mM in uhq-H2O, chymostatin at 100 mM in DMSO and pepstatin A at 
10 mM in DMSO. Furthermore, 1:10 interim dilutions of the stocks were made up in the 
same solutions and they were stored at -80°C. Bacitracin was prepared fresh on the day 
of experiment (MWt = 1,422.7) in DMEM. Confluent cells were initially washed with 
serum-free DMEM and incubated with protease inhibitors (phosphoramidon or inhibitor 
cocktail) in DMEM without FCS. 
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Table 3.1:  The protease inhibitors used in inhibitor cocktail. 
Protease Inhibitor Protease Family 
Targeted 
Inhibitor 
Type 
Concentration 
(µM) 
Bacitracin Proline endopeptidases Reversible 1000 
Chymostatin 
Chymotrypsin-like 
serine/(cysteine) 
Reversible 10 
Leupeptin 
Typsin-like serine and 
some cysteine proteases 
Reversible 10 
Pepstatin A Aspartic acid proteases Reversible 1 
Phosphoramidon Metalloprotease Reversible 1 – 1000 
 
3.2.3  Cell culture incubations with protease inhibitors 
Before the incubation period, confluent cells were rinsed with warmed DMEM (500 
µl/well) and then treated with 300 µl/well of the conditions containing protease 
inhibitor(s). Initial experiments investigated the effect of varying concentrations of 
phosphoramidon from 1 – 1000 µM on the intracellular processing of ET-1 and proET-
1 peptides. The effect of inhibitor cocktail was studied using 10 µM leupeptin, 10 µM 
chymostatin, 1 µM pepstatin A, and 1000 µM bacitracin. Cells were treated in triplicate 
with each test condition using 2 x 24-well plates and incubated in a 37°C humidified cell 
culture incubator with 8% CO2 for 6 h and 24 h.  
 
3.2.3.1  Collection of conditioned media and treatment before immunoassay 
After 6 h and 24 h incubation periods, 270 µl of the conditioned media/well were 
collected into 1.5 ml microcentrifuge tubes. Samples were neutralised by adding 25 µl 
0.295 M HCl (prepared from a 100 M stock in fume hood) and heat-treated at 80°C for 
10 min with caps open. After cooling, 50 µl N-SAB (Chapter 2, section 2.2.2.1) was 
added, re-capped and vortexed prior to storing at -20°C for subsequent immunoassay. 
The remaining medium was aspirated from the 24-well plates and the viability of cells 
was investigated by an MTT assay as described in section 3.2.4.  
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3.2.4  Cell viability (MTT) assay 
Endothelial cell viability was evaluated using the 3-[4, 5-dimethyliazol-2-yl]-2, 5-
diphenyltetrazolium bromide (MTT) colorimetric assay. MTT indicates mitochondrial 
respiration by quantifying cell-dependent mitochondrial dehydrogenase activity. This 
assay assesses whether any protease inhibitors have cytotoxic effects on endothelial 
cells. A stock solution of MTT (M2003, Sigma) was prepared at 2 mg/ml in DMEM 
containing 10 mM antibiotics (100 Units/ml penicillin and 100 µg/ml streptomycin) and 
25 mM HEPES.  
On the day of assay, MTT was diluted to 0.4 mg/ml in DMEM, and 300 l/well (24-
well plate) was added immediately after aspiration of conditioned media residues. MTT 
was incubated with cells for 1 h at 37°C. The medium was then aspirated and the cells 
were solubilised in 300 µl of dimethyl sulfoxide (DMSO). The absorbance was 
determined at 550 nm using a 96-well plate reader (Infinite, TECAN). 
 
3.2.5 Immunoassays of ET-1, big ET-1 and proendothelin-1 
peptides  
Immunoassays of ET-1 and proET-1 peptides are described in detail in Chapter 2 
sections 2.2.2.2 and 2.2.2.3, respectively. Primary amino acid sequences in which these 
specific sandwich immunoassays were developed are shown in Chapter 2, Table 2.2. 
Briefly, antibody recognition sites used for the detection of ppET-1 derived peptides 
were illustrated in Figure 3.1. 
 
3.2.6  Data handling and statistical evaluation 
The effect of protease inhibitors on ET-1 and proET-1 peptide fragments were expressed 
as fmol/ml released per 6 h and 24 h. Error bars in the graphs are shown for mean and 
standard error of mean (s.e.m). Statistical analyses were performed using one-way 
ANOVA with Fisher`s protected least significant difference (PLSD) as a post-hoc test. 
In the figures and tables P values less than 0.001 are indicated by ***, P values from 
0.001 to 0.01 are indicated by **, P values from 0.01 to 0.05 are indicated by *. P values 
greater than 0.05 are non-significant and indicated by ns. 
Chapter 3                Release of ET-1 and proET-1 peptides from the conditioned media of EA.hy 926 and A549 cells    
 
 
90 
 
3.3  RESULTS  
Human endothelial EA.hy 926 and epithelial A549 cell lines are well established 
systems for studying ET-1 biosynthesis. Phosphoramidon is a metalloprotease inhibitor 
that inhibits ECE and NEP-24.11. This produces a concentration dependent inhibition 
of the conversion of big ET-1 to ET-1. To investigate the stability of secreted proET-1 
peptides, EA.hy 926 and A549 cells were incubated with phosphoramidon alone and in 
combination with inhibitor cocktail, which is composed of endopeptidase inhibitors at 
10 µM leupeptin, 10 µM chymostatin, 1 µM pepstatin A, and 1 mM bacitracin.  
 
3.3.1  EA.hy 926 conditioned medium  
3.3.1.1 Effect of phosphoramidon on the biosynthesis of ET-1 and big ET-1  
EA.hy 926 cells were incubated for 6 h and 24 h with increasing concentrations of 
phosphoramidon from 1 – 1000 µM. Phosphoramidon inhibited endogenous ET-1 
production. This was biphasic with a dramatic increase in ET-1 release at low 
concentrations (1 – 10 µM) and decreased release at higher concentrations (>10 µM) 
(Figure 3.2).   
In comparison to basal ET-1 release, incubation with 10 µM phosphoramidon over 6 h 
and 24 h increased the amount of ET-1 present in the medium by 1.4 and 4-fold, 
respectively. Incubation with phosphoramidon (1 – 10 µM) therefore, prevented 
degradation of released ET-1 into the culture medium by NEP-24.11. Therefore, the 
effect of increasing phosphoramidon concentrations on ET-1 synthesis was compared to 
ET-1 levels at 10 µM phosphoramidon (to reflect basal release without degradation). As 
a result, at concentrations above 10 µM phosphoramidon, ET-1 synthesis was inhibited 
to a similar degree over 6 h and 24 h incubation. As such, decrease in ET-1 release at 
1000 µM was 78% at 6 h and 80% at 24 h.  
Inhibition of ET-1 resulted in the accumulation of big ET-1 at phosphoramidon 
concentrations >30 µM (Figure 3.2). In the concentration range of 1 – 30 µM, 
phosphoramidon did not inhibit the processing of big ET-1 to ET-1. Big ET-1 levels 
accumulated more significantly after 24 h incubation with 1000 µM phosphoramidon, 
showing a 16-fold increase over 6 h and 24-fold increase over 24 h incubation. 
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Figure 3.2: Effect of phosphoramidon on ET-1 (  ) and big ET-1 (  ) released from 
EA.hy 926 cells over (A) 6 h and (B) 24 h. Cells were grown to confluence on 24-well 
plates and incubated for 6 h and 24 h in the presence of increasing concentrations of 
phosphoramidon (0 – 1000 µM). Mean results ± s.e.m, from two experiments with 
incubations in triplicates. * = P <0.05, ** = P <0.01, and *** = P <0.001 comparison 
of means to control by ANOVA with Fisher`s PLSD. Basal release of ET-1 with no 
phosphoramidon present was 68.8 ± 2.1 fmol/ml per 6 h and 95.6 ± 15.8 fmol/ml per 24 
h. Big ET-1 basal release was 6.8 ± 1.0 fmol/ml per 6 h and 14.4 ± 1.3 fmol/ml per 24 
h. 
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3.3.1.2  Effect of inhibitor cocktail on ET-1 and big ET-1 biosynthesis  
EA.hy 926 cells were incubated with 10 µM phosphoramidon, inhibitor cocktail [10 µM 
leupeptin, 10 µM chymostatin, 1 µM pepstatin A, and 1 mM bacitracin] and a 
combination of both treatments over 6 h and 24 h. The aim was to investigate the effect 
of inhibitor cocktail on ET-1 production from endogenous precursors by EA.hy 926 
cells. 
In comparison to basal ET-1 release, all three conditions significantly elevated ET-1 
release from the conditioned medium of EA.hy 926 cells (Figure 3.3A). Incubation with 
10 µM phosphoramidon over 24 h showed a 6 – 7-fold increase in ET-1 release. 
Incubation of EA.hy 926 cells with 10 µM phosphoramidon in combination with 
inhibitor cocktail increased ET-1 release by approximately 4.6-fold, in which the effect 
of inhibitor cocktail alone resulted in a 3.7-fold increase. 
Basal release of big ET-1 over 6 h incubation (6.8 fmol/ml) was increased by 
approximately 2.1-fold over 24 h incubation (14.4 fmol/ml) (Figure 3.3B). On the other 
hand, basal release of ET-1 was only increased by approximately 1.4-fold over 24 h 
(Figure 3.3A). This suggested that big ET-1 accumulates over time while ET-1 is being 
degraded. 
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Figure 3.3: Effect of inhibitor cocktail on (A) ET-1 and (B) big ET-1 in the 
conditioned medium of EA.hy 926. Cells were grown to confluence on 24-well plates 
and incubated for 6 h and 24 h in the presence of 10 µM phosphoramidon, inhibitor 
cocktail and a combination of 10 µM phosphoramidon with inhibitor cocktail. Mean 
results ± s.e.m from two experiments with incubations in triplicates were compared to 
control by ANOVA with Fisher`s PLSD, * = P <0.05, ** = P <0.01, and *** = P 
<0.001. Basal release of ET-1 (n = 6) immunoreactivity measured in conditioned 
medium samples from EA.hy 926 was 68.8 fmol/ml per 6 h and 95.6 fmol/ml per 24 h.  
Basal release of big ET-1 was 6.8 fmol/ml per 6 h and 14.4 fmol/ml per 24 h. 
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3.3.2  A549 conditioned medium  
3.3.2.1 Effect of phosphoramidon and inhibitor cocktail on ET-1 and big ET-
1 biosynthesis 
Unlike the biphasic pattern of ET-1 release in EA.hy 926 cells, phosphoramidon 
produced a concentration-dependent inhibition of endogenous synthesis of ET-1 and an 
enhanced accumulation of big ET-1 in the conditioned medium of A549 cells (Figure 
3.4A). Incubation of A549 medium with 1000 µM phosphoramidon inhibited ET-1 
synthesis by 84% over 24 h (24 h EC50 for ET-1 = 50.9 ± 4.8 µM phosphoramidon). 
Inhibition of ET-1 synthesis was marked, even for the 6 h incubation, with 1000 µM of 
phosphoramidon treatment reducing ET-1 accumulation in the medium by 92% (data 
not shown). 
 
Compared to phosphoramidon alone the combination with inhibitor cocktail produced a 
more effective inhibition of ET-1 accumulation. The release of ET-1 was reduced by 
28% with 10 µM phosphoramidon over 24 h incubation. Phosphoramidon (10 µM) in 
presence of inhibitor cocktail inhibited the release of ET-1 by 57%, which shows a 2-
fold increase in the amount of ET-1 inhibition over 24 h. Although ET-1 released into 
the conditioned medium of A549 cells was inhibited more effectively with 
phosphoramidon in combination with inhibitor cocktail, big ET-1 accumulated to a 
lesser extent with this condition (Figure 3.4B). As such, the levels of big ET-1 
accumulated with 10 µM phosphoramidon in presence of inhibitor cocktail (41.1 
fmol/ml) were 43% less than that of 10 µM phosphoramidon alone (72.1 fmol/ml). In 
addition, big ET-1 released into the conditioned medium after 24 h incubation with 1000 
µM phosphoramidon was 1.7-fold less than the big ET-1 levels accumulated in EA.hy 
926 cells (199 fmol/ml for A549 and 343 fmol/ml for EA.hy 926 cells). 
 
Basal release of ET-1 and big ET-1 from the conditioned medium of A549 cells over 6 
h incubation was 102.3 and 8.3 fmol/ml (data not shown), while over 24 h incubation 
the levels were 557 fmol/ml and 20.1 fmol/ml, respectively. Basal ET-1 release from the 
conditioned medium of A549 cells was at a greater magnitude (5 – 6-fold) than that of 
EA.hy 926 cells (95.6 fmol/ml over 24 h incubation).  
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Figure 3.4: Stability of ET-1 (  ) and big ET-1(  ) released from A549 cells incubated 
with (A) phosphoramidon and (B) phosphoramidon in combination with inhibitor 
cocktail over 24 h. Cells were grown to confluence on 24-well plates and incubated for 
24 h in the presence of increasing concentrations of phosphoramidon (10 – 1000 µM) 
alone and in presence of inhibitor cocktail. Mean ± s.e.m, from two experiments 
performed in duplicates were expressed as fmol/ml. * = P <0.05, ** = P <0.01, and *** 
= P <0.001 comparison of means to basal release of ET-1 by ANOVA. Basal release of 
ET-1 and big ET-1 was 557 fmol/ml per 24 h and 20.1 fmol/ml per 24 h, respectively.  
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3.3.3 Stability of proendothelin-1 peptides (proET-1): NT-
proET-1, ELDP and CT-proET-1 released from EA.hy 926 
cells 
Firstly, EA.hy 926 cells were incubated with increasing concentrations of 
phosphoramidon   (1 – 1000 µM) over 6 h and 24 h. ProET-1 peptides were measured 
by immunoassays for NT-proET-1 (ppET-1[18 – 50]), ELDP (ppET-1[93 – 166]) and CT-
proET-1 (ppET-1[169 – 212]). Release of proET-1 peptides were unaffected by 
phosphoramidon, indicating that endogenously released proET-1 peptides are fairly 
stable in the conditioned medium of EA.hy 926 cells (Table 3.2).  
 
Table 3.2: Effect of phosphoramidon on NT-proET-1, ELDP and CT-proET-1 in the 
conditioned medium of EA.hy 926. Cells were grown to confluence on 24-well plates 
and incubated for 24 h in the presence of increasing concentrations of phosphoramidon 
(0 – 1000 µM). Mean results ± s.e.m (n = 3) were expressed as a percentage of the 
control values and each experiment was conditioned in triplicates. Basal release (n = 
5) of NT-proET-1, ELDP and CT-proET-1 was 294 fmol/ml, 1389 fmol/ml, and 334 
fmol/ml over 24 h incubation. 
Phosphoramidon 
(µM) 
EA.hy 926,  24 h conditioned medium (% of control) 
NT-proET-1 ELDP CT-proET-1 
0 100 ± 2.9 100 ± 8.7 100 ± 5.1 
1  92.0 ± 1.7 107.0 ± 6.6 102.9 ± 3.9 
3  95.8 ± 1.6 114.4 ± 6.7 107.1 ± 6.7 
10  91.9 ± 2.0 115.8 ± 8.9 104.9 ± 7.0 
30  95.2 ± 1.9 105.3 ± 6.7 100.1 ± 8.8 
100 103 ± 6.4 107.5 ± 8.3 109.9 ± 10.5 
300  96.0 ± 3.5 106.7 ± 8.0 111.5 ± 8.3 
1000  87.9 ± 1.7 103.1 ± 10.2 104.9 ± 8.6 
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Secondly, Table 3.3 summarises the effect of inhibitor cocktail with and without 10 µM 
phosphoramidon. Incubation with inhibitor cocktail did not show a significant effect 
over 6 h except slight inhibition of NT-proET-1 released into the conditioned medium 
of EA.hy 926 cells (data not shown). However, proET-1 peptides were inhibited to a 
greater extent over 24 h. This inhibition was greatest for NT-proET-1, followed by 
ELDP and CT-proET-1 at approximately 28% (P <0.001), 23% (P <0.001) and 9%, 
respectively. Similarly, 10 µM phosphoramidon in combination with inhibitor cocktail 
inhibited NT-proET-1 and ELDP release at a similar magnitude to that of inhibitor 
cocktail alone. However, CT-proET-1 levels were unaffected by 10 µM 
phosphoramidon with inhibitor cocktail and the levels were relatively close to control. 
Interestingly, proET-1 peptides accumulated slightly with 10 µM phosphoramidon, 
which increased NT-proET-1, ELDP and CT-proET-1 levels by 8% (P = 0.02), 5% and 
11%, respectively.  
Table 3.3: Effect of phosphoramidon and inhibitor cocktail on NT-proET-1, ELDP 
and CT-proET-1 in the conditioned medium of EA.hy 926. Cells were grown to 
confluence on 24-well plates and incubated for 24 h in the presence of treatment 
conditions (10 µM phosphoramidon, inhibitor cocktail, and a combination of 10 µM 
phosphoramidon and inhibitor cocktail). Mean results ± s.e.m from two experiments that 
were conditioned in triplicates was expressed as a percentage of the control values. * = 
P <0.05 comparison of means to control by ANOVA.  
 
Although some of these reductions reached significance, the synthesis or degradation of 
proET-1 peptides was largely unaffected with either of incubations with 
phosphoramidon, inhibitor cocktail with and without phosphoramidon suggesting that 
they are fairly stable in the conditioned medium released from EA.hy 926 cells.  
EA.hy 926, 24 h conditioned  
medium  (% of control) 
NT-proET-1 ELDP 
 
CT-proET-1 
 
Control, (DMEM+ only) 100 ± 1.0 100 ± 1.1 100 ± 1.1 
10 µM Phosphoramidon 107.5 ± 3.1* 104.5 ± 4.1 110.8 ± 1.6 
Inhibitor cocktail 72.3 ± 3.3* 76.7 ± 2.2* 90.9 ± 2.1 
10 µM Phosphoramidon 
and inhibitor cocktail 
72.3 ± 1.4* 81 ± 3.2* 99.7 ± 4.1 
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3.3.4 Stability of proET-1 peptides: NT-proET-1, ELDP, and 
CT-proET-1 released from A549 cells 
Once again, incubation with phosphoramidon had no effect on proET-1 peptide 
synthesis (Table 3.4). This in turn suggested that proET-1 peptides released in the 
conditioned media of both EA.hy 926 and A549 cells were fairly stable. Although 
increasing phosphoramidon concentrations (10 – 1000 µM) did not show a concentration 
dependent proET-1 inhibition, CT-proET-1 levels slightly accumulated at 10 µM 
phosphoramidon by 4% and 15% at 1000 µM over 24 h (Table 3.4).   
Table 3.4: Effect of phosphoramidon on NT-proET-1, ELDP and CT-proET-1 in the 
conditioned medium of A549 cells. Cells were grown to confluence on 24-well plates 
and incubated for 24 h in the presence of increasing concentrations of phosphoramidon. 
Mean results ± s.e.m from two experiments conditioned in duplicates were expressed as 
a percentage of the control values. Basal release (n = 4) of NT-proET-1, ELDP and CT-
proET-1 was 555 fmol/ml, 1212 fmol/ml, and 279 fmol/ml over 24 h incubation. 
Phosphoramidon (µM) 
A549, 24 h conditioned medium (% of control) 
NT-proET-1 ELDP CT-proET-1 
0 100 ± 1.2 100 ± 1.9 100 ± 3.5 
10  95.8 ± 1.6 98.5 ± 2.7 103.9 ± 3.2 
30  95.9 ± 0.7 97.9 ± 0.6 101.2 ± 3.0 
100  87.9 ± 2.4 93.2 ± 4.5 102.2 ± 2.5 
300  95.5 ± 4.2 103 ± 4.4 108.7 ± 4.5 
1000  95.8 ± 2.9 100.1 ± 3.6 115.1 ± 1.2 
 
On the other hand, incubation with inhibitor cocktail in the presence of increasing 
concentrations of phosphoramidon reduced the release of proET-1 peptide fragments. 
At 6 h incubation, while NT-proET-1 and ELDP were slightly inhibited, CT-proET-1 
levels accumulated by 50% with 10 µM phosphoramidon with inhibitor cocktail (data 
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not shown). When A549 cells were incubated with this treatment over 24 h, accumulated 
CT-proET-1 was inhibited by 14% (Table 3.5). Increasing phosphoramidon 
concentrations did not inhibit the release of CT-proET-1. In comparison, NT-proET-1 
and ELDP were inhibited more significantly by 62% and 41%, respectively.  
 
Table 3.5: Effect of phosphoramidon and inhibitor cocktail on NT-proET-1, ELDP 
and CT-proET-1 in the conditioned medium of A549 cells. Cells were grown to 
confluence on 24-well plates and incubated for 24 h in the presence of increasing 
concentration of phosphoramidon with inhibitor cocktail. Mean results ± s.e.m from two 
experiments conditioned in duplicates were expressed as a percentage of the control. * 
= P <0.05 comparison of means by ANOVA. 
Phosphoramidon             
and  inhibitor 
cocktail (µM) 
A549, 24 h conditioned medium (% of control) 
NT-proET-1 ELDP CT-proET-1 
0 
100 ± 1.3 100 ± 4.0 100 ± 1.8 
10  37.6 ± 3.8* 58.6 ± 0.4 86.1 ± 1.3 
30  41.7 ± 1.4* 62.0 ± 1.5 89.4 ± 4.7 
100  42.4 ± 3.4* 56.0 ± 0.1 94.7 ± 2.1 
300  43.2 ± 4.0* 59.0 ± 2.5 94.2 ± 2.5 
1000  43.9 ± 2.9* 62.8 ± 2.8 93.5 ± 3.5 
 
Although cytotoxic effects of phosphoramidon and inhibitor cocktail were not evaluated 
in this experiment, in other studies, incubation of A549 cells with inbibitor cocktail 
(without phosphoramidon) over 24 h resulted in 10% reduction in cell viability when 
compared to controls. The decreased proET-1 peptide levels observed with 
phosphoramidon with inhibitor cocktail may be explained by phosphoramidon 
increasing the cytotoxic effects of inhibitor cocktail. As a result, decrease in proET-1 
levels most likely resulted from cytotoxicity rather than inhibition of ECE activity or 
proET-1 processing.  
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 3.4  DISCUSSION 
The aim of this chapter was to characterise the biosynthesis of proET-1 derived peptides 
from EA.hy 926 and A549 cells. The processing of proET-1 occurs via constitutive 
secretory vesicles (Harrison et al., 1995) with release of ET-1 together with other 
fragments of proET-1 (Corder et al., 1995). Previously unpublished pilot studies by our 
laboratory had shown processing of proET-1 to three peptides: NT-proET-1, ELDP, and 
CT-proET-1 (Figure 3.1). However, their parallel secretion and stability had not been 
studied. The proteolytic processing of ET-1 and proET-1 peptide fragments was 
therefore studied by treating EA.hy 926 and A549 cells with phosphoramidon and 
inhibitor cocktail and quantifying their release in the conditioned media using specific 
immunoassays. Synthetic peptides used for NT-proET-1 (ppET-1[18 – 50]), ELDP (ppET-
1[93 – 166]) and CT-proET-1 (ppET-1[169 – 212]) peptides do not have any sequence 
homology with the corresponding sequences of proET-2 and proET-3. Therefore, the 
assays developed have the advantage of being specific for measuring increased proET-
1 synthesis.  
 
 
Endogenous ET-1 production appeared to be biphasic in EA.hy 926 cells. Lower 
concentrations of phosphoramidon increased ET-1 levels in the medium samples such 
that ET-1 release appeared highest at 10 µM showing a 3 – 4-fold increase over 24 h 
(Figure 3.3). EA.hy 926 cells express NEP-24.11, which at phosphoramidon 
concentrations <1 µM degrades secreted ET-1 (Abassi et al., 1993a). Phosphoramidon 
at 10 µM as well inhibiting ECE-1, it also inhibited NEP-24.11. It was shown to prevent 
degradation of ET-1 by NEP-24.11 at 1 µg/ml (Abassi et al., 1993a). The biphasic 
response of EA.hy 926 cells to phosphoramidon treatment was consistent with previous 
results (Corder et al., 1993b; Xu et al., 1994; Ahn et al., 1995). At higher concentrations 
of phosphoramidon there was a concentration-dependent inhibition of ET-1 release. 
Thus, at lower phosphoramidon concentrations ET-1 degradation is prevented then 
phosphoramidon starts to inhibit ET-1 synthesis at higher concentrations (>10 µM), 
when the stability of it was at its highest. Inhibition of ET-1 synthesis results in the 
accumulation of big ET-1 (Figure 3.2). In addition, phosphoramidon (0.01 – 2 mM) was 
shown to cause a biphasic alteration of ET-1 release in human aortic endothelial cells 
(Matsumura et al., 1995). Similarly, at lower concentrations increased ET-1 
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accumulation could be due to inhibition of ET-1 degradation by NEP-24.11. The 
inhibition of ET-1 synthesis at higher phosphoramidon concentrations was compared to 
10 µM phosphoramidon, at which the stability of ET-1 was at its highest. Therefore, 
when degradation of ET-1 was prevented in presence of 10 µM phosphoramidon, higher 
phosphoramidon concentrations (>10 µM) had a similar degree of inhibition of ET-1 
release over 6 h and 24 h. In addition, others also reported that higher phosphoramidon 
concentrations were required for intracellular inhibition of ECE (Corder, 2001; Woods 
et al., 1999). Thus, processing of big ET-1 is, at least in part, intracellular and occurs 
during vesicle transport from the trans-Golgi network to the cell surface by the 
constitutive secretory pathway (Harrison et al., 1995; Russel et al., 1998)). This was 
supported by findings showing localisation of ECE-1 in the membranes of intracellular 
organelles such as Golgi apparatus (Xu et al., 1994; Barnes et al., 1998; Russel et al., 
1998), where it could catalyse the endogenous synthesis of ET-1.  
 
In contrast to the biphasic behaviour of EA.hy 926 cells, phosphoramidon produced a 
concentration-dependent inhibition of ET-1 synthesis and accumulation of big ET-1 in 
the conditioned medium of A549 cells (Figure 3.4A).                  Consistent with 
phosphoramidon acting as an ECE inhibitor, inhibition of ET-1 synthesis in A549 cells 
has also been reported by Deprez-Roy et al., 2000. The absence of a biphasic response 
in this cell line is likely due to the absence of the confounding effects of NEP-24.11 
expression (Aubert et al., 1998). Phosphoramidon in combination with inhibitor cocktail 
was more effective in suppressing ET-1 levels over 24 h (Figure 3.4B). This suggested 
that inhibitor cocktail might increase the stability of phosphoramidon to have a greater 
effect in combination. This might be expected to result in a greater increase in big ET-1 
levels with phosphoramidon in combination with inhibitor cocktail. However, 
phosphoramidon alone produced a greater increase in big ET-1 in the conditioned 
medium of A549 cells (Figure 3.4A). Cell viability assay (MTT), however, showed 
cytotoxicity of inhibitor cocktail on A549 cells over 24 h incubation. Therefore, reduced 
release of ET-1 and proET-1 fragments is likely to result from cytotoxicity induced by 
inhibitor cocktail components rather than inhibition of ECE activity. 
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Immunoassay results showed that unlike ET-1; NT-proET-1, ELDP and CT-proET-1 
released in the conditioned medium of EA.hy 926 cells were unaffected by 
phosphoramidon treatment (Table 3.2). This implies that at physiological concentrations 
none of these peptides are degraded by NEP-24.11. In addition, these data suggest that 
intracellular processing of proET-1 at double basic amino acids is not affected by 
inhibition of ECE by the metalloprotease inhibitor phosphoramidon. For the three 
proET-1 peptides investigated, only NT-proET-1 showed a slight reduction whereas 
ELDP and CT-proET-1 levels were increased slightly (neither were significant changes). 
Similarly in A549 cells, phosphoramidon had no significant effect on proET-1 peptide 
levels (Table 3.4). Thus, proET-1 peptides are fairly stable in the conditioned media 
samples. Hence, phosphoramidon selectively inhibits ECE without affecting proET-1 
processing at double basic residues.  
The inhibitor cocktail alone or in combination with phosphoramidon over 24 h 
suppressed proET-1 peptide levels slightly for EA.hy 926 cells when compared to 
treatment with phosphoramidon alone. However, there was a more marked reduction 
with A549 cells. In both cell lines a greater reduction with inhibitor cocktail was 
observed for NT-proET-1 and ELDP than CT-proET-1. These results indicate that for 
proET-1 peptides released into the conditioned media of EA.hy 926 and A549 cells CT-
proET-1 is the most stable, while NT-proET-1 is the least stable peptide. Therefore, 
these peptide fragments could be alternative and more stable markers of ET-1 synthesis. 
However, another point to note is that in the conditioned media samples ELDP had the 
highest concentration of any proET-1 peptide (EA.hy 926 cells 1389 fmol/ml after 24 h, 
without inhibitors present). ET-1 (for EA.hy 926 cells in the presence of 10 µM 
phosphoramidon), big ET-1 (EA.hy 926 cells in the presence of 1000 µM 
phosphoramidon), NT-proET-1 and CT-proET-1 were of the same order of magnitude 
(~340 fmol/ml after 24 h, without inhibitors present). Whereas, ELDP concentrations 
were approximately 4-fold higher. Peptide standard concentrations had been carefully 
matched by using HPLC quantification of synthetic peptides based on A280 absorbing 
residues (Trp and/or Tyr). Therefore other factors affecting stability or clearance (e.g. 
ETB-receptor clearance of ET-1) must come into play during these prolonged incubation 
periods.  
Thus it is important to define the optimal fragments of proET-1 for development of the 
most sensitive and specific diagnostic assay for inferring an elevated level of ET-1 
Chapter 3                Release of ET-1 and proET-1 peptides from the conditioned media of EA.hy 926 and A549 cells    
 
 
103 
 
synthesis, which could then be used to guide or optimise treatment. These proET-1 
peptide fragments have been identified only by antibody cross-reactivity. Therefore, a 
detailed characterisation with HPLC and identification using mass spectrometry was 
considered essential and these studies are described in Chapters 4 and 5, respectively. In 
addition, the stability of proET-1 peptides, both in vivo and ex vivo, and their diagnostic 
utility in patient samples were evaluated in Chapter 6.  
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CHAPTER 4 
Purification and characterisation of proendothelin-1 
fragments 
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4.1  INTRODUCTION 
Initial studies showed that three proET-1 fragments: NT-proET-1 (ppET-1[18 – 50]); 
Endothelin-Like Domain Peptide, ELDP (ppET-1[93 – 166]); and C-terminal fragment, 
CT-proET-1 (ppET-1[169 – 212]) were secreted from endothelial (EA.hy 926) and epithelial 
(A549) cells (Chapter 3). This chapter focuses on purification and characterisation of 
proET-1 peptides from conditioned media collected from EA.hy 926 and A549 cells. 
 
4.1.1  Types of separation methods  
Proteins can be fractionated using different types of chromatography techniques, which 
include gel filtration (size-exclusion chromatography), ion-exchange chromatography 
(IEC), hydrophobic interaction chromatography (HIC), and high performance liquid 
chromatography (HPLC). Separations are based on their physiochemical properties such 
as molecular size, net charge, and hydrophobicity, respectively (Burgess, 2008; Queiroz 
et al., 2001). Other protein fractionation methods such as ammonium sulphate 
[(NH4)2SO4] precipitation, isoelectric point focusing, dialysis and ultrafiltration can also 
be used for separation of proteins. Ammonium sulphate precipitation, IEC and HPLC 
were among the methods that were used for protein fractionation, purification and 
characterisation, respectively. These methods are briefly explained here. 
4.1.1.1  Ammonium sulphate precipitation 
The separation of proteins by ammonium sulphate precipitation is based on their 
solubility; proteins and other macromolecules become progressively less soluble and 
tend to aggregate and precipitate out of solution with increasing salt concentration. In 
other words proteins are “salted out”. Ammonium sulphate precipitation is often 
performed as a preliminary step in protein purification either to clean up samples by 
removal of large molecular weight (MWt) poorly soluble proteins, or to prepare an 
enriched protein precipitate for chromatography. Removal of ammonium sulphate may 
be necessary before proceeding to subsequent chromatography methods for purification. 
Dialysis can be used as a desalting or buffer exchange step, but this increases the sample 
volume due to an osmotic effect, and is only useful for peptides or proteins that exceed 
the MWt cut-off for the pore size of the dialysis membrane. 
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4.1.1.2  Ion exchange chromatography (IEC) 
Separation of proteins by IEC is based on charge mainly through electrostatic 
interactions between charged amino acid side chains exposed to the surface of a protein 
that bind to oppositely charged ligands. Anion exchangers have basic functional groups, 
which can be either weak or strong.  Quaternary ammonium (Q) is an example of a 
strong anion exchanger with a functional group of –O-CH2N+-(CH3)3. Negatively 
charged side chains (aspartic acid [pKa 3.86] and glutamic acid [pKa 4.25] both with 
carboxylic acid groups) of proteins bind to anion exchangers, while positively charged 
side chains (lysine [amino group, pKa 10.79], arginine [guanadino group, pKa 12.48] 
and histidine [imidazole group, pKa 6.04]) bind to cation exchangers that contain acidic 
functional groups. These functional groups can be either weak or strong. Carboxymethy 
(CM) is an example of a weak cation exchanger with a –O-CH2COO- functional group. 
A protein that has no net charge at a pH equivalent to its isoelectric point (pI) will not 
interact with a charged medium. However, at a pH above its pI, a protein will bind to an 
anion exchanger (positively charged ligand) and, at a pH below its pI, a protein will bind 
to a cation exchanger (negatively charged ligand).  Advantages of using IEC include:  
(1) Gradient elution with use of different salt and buffer compositions. 
(2) Application to a large volume of sample, which can be used as a concentration 
step, to recover proteins from a dilute solution. 
(3) High recoveries due to carrying out separations in smaller volumes. 
(4) High resolving power (Stanton, 2004).  
 
The disadvantages of IEC include: (1) application of sample to IEC matrix at a low ionic 
strength and controlled pH; (2) buffers used for elution may not be compatible with 
further chromatographic separations or assay systems [e.g. high salt concentrations (>1 
M)] or guanidine hydrochloride (G-HCl). Thus an additional buffer exchange method 
may be required (Stanton, 2004). 
 
4.1.1.3  High performance liquid chromatography (HPLC) 
HPLC is a well-established technique that is used for purification, isolation and analysis 
of biomolecules. Separations are based on hydrophobicity, size and protein 
conformation. A high degree of selectivity can be achieved by using various modes of 
separation including reverse-phase [hydrophobic], normal-phase [hydrophilic], ion 
exchange, and size exclusion. The surface chemistry of a column is an important 
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determinant of the sample retention. In particular, characterisation of proET-1 fragments 
was performed using a reverse-phase HPLC (RP-HPLC) system, where the surface 
chemistry was based on silanol groups on the silica surface and bonded with alkyl chains 
(C4 [butyl] or C18 [octadecylsilane]). In RP-HPLC, separation of intact proteins is 
usually performed with wide pore size and shorter hydrocarbon chains in order to 
minimise protein denaturation or irreversible binding of the protein to the column. 
Hydrophobic proteins with longer amino acid sequences are retained strongly by longer 
alkyl chains and may not elute efficiently, resulting in poor recoveries. Adsorbed peptide 
or protein is eluted by the addition of an organic solvent (such as acetonitrile (CH3CN) 
containing an ionic modifier like trifluoroacetic acid [TFA]) to the mobile phase where 
the gradient can be either isocratic or gradient elution. Adsorbed peptides are eluted in 
order of increasing molecular hydrophobicity. HPLC can be used for analysing protein 
identities such as identification of protein degradation products. For example, peptides 
that have an oxidised methionine residue can be separated from the native peptide. RP-
HPLC is a very powerful technique for the analysis of peptides and proteins because of 
a number of factors that include: 
(1) High resolving power with a wide selection of conditions and choice of columns 
enabling separation of closely related molecules as well as structurally distinct 
molecules based on differences in hydrophobicity or molecular conformation. 
(2) The experimental ease with which mobile phase can be manipulated for 
selectivity.  
(3) Stability of the sorbent materials under a wide range of mobile phase conditions. 
(4) Robust and efficient systems that generally provide high recoveries with good 
reproducibility of repeated separations carried out over a long time period 
(Aguilar, 2003; Aguilar & Hearn, 1996; Benedek, 2004).   
 
However, RP-HPLC can cause the irreversible denaturation of protein samples thereby 
reducing the potential recovery of material in a biologically active form (Aguilar, 2003).   
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4.1.2  Experimental and theoretical rationale 
The aim of this chapter was to purify proET-1 peptides (NT-proET-1, ELDP and CT-
proET-1) to obtain sufficient amount of each peptide for confirmation of their identities 
by mass spectrometry. Table 4.1 shows the amino acid composition, molecular weights 
and isoelectric points of proET-1 peptides. These parameters were considered in order 
to select methods and develop a strategy for purification. The workflow for proET-1 
characterisation is summarised in Figure 4.1 and the methodology is described here; 
(1) Ion exchange chromatography: Q-Sepharose anion exchanger was used to remove 
acidic peptides and proteins as well as phenol red present in the conditioned media 
(step 1). This was followed by using a carboxymethyl cation exchanger for the 
recovery of proET-1 fragments that had passed through the Q-Sepharose anion 
exchanger without absorption (step 2). Separation in these steps is based on 
differences in isoelectric points.   
(2) After elution from the cation exchanger, CM fractions with the highest ELDP and 
CT-proET-1 immunoreactivity (section 4.3.1) were subjected to solid-phase 
extraction (SPE) for buffer exchange and concentration of these peptides prior to 
characterisation by HPLC (step 3).  
(3) However, only low NT-proET-1 immunoreactivity was detected in the CM 
fractions, requiring additional steps for recovery of NT-proET-1. For EA.hy 926 
cells, NT-proET-1 was recovered from the unadsorbed Q-Sepharose sample and 
10 mM acetic acid washings by SPE (step 3). 
(4) For A549 cells, ammonium sulphate precipitation at 20% saturation was used to 
remove impurities that blocked the column systems, described above for EA.hy 
926 conditioned medium. SPE was used for buffer exchange and concentration for 
characterisation of proET-1 peptides from A549 cells by HPLC. 
(5) Characterisation of fractionated ppET-1 peptide products by HPLC required two 
steps: semi-preparative (step 4) and analytical HPLC separation (step 5). Presence 
of proET-1 fragments and identification of fractions with the highest levels of 
immunoreactivity were achieved with sandwich immunoassays for NT-proET-1 
(ppET-1[18 – 50]), ELDP (ppET-1[93 – 166]) and CT-proET-1 (ppET-1[169 – 212]). 
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Table 4.1: Amino acid composition, molecular weights and isoelectric points of proendothelin-1 peptide fragments. Amino acid numbering is 
based on the 212 amino acid sequence for ppET-1 (Bloch et al., 1989). Molecular weights and theoretical isoelectric points were calculated from 
the online server http://web.expasy.org/compute_pi/ and net charge at pH 7.0 was calculated from 
http://vitalonic.narod.ru/biochem/index_en.html. 
Proendothelin-1 
 
Amino acid composition of proET-1 sequences 
 
Molecular 
weight, MWt 
(avg): 
Isoelectric 
point, pI 
Net 
charge at 
pH 7.0 
Number of 
residues 
NT-proET-1 
ppET-1[18 – 50] 
APETAVLGAELSAVGENGGEKPTPSPPWRLRRS 3,430.8 6.3 0.0 33 
ELDP          
ppET-1[93 – 166] 
ALENLLPTKATDRENRCQCASQKDKKCWNFCQAGKEL
RAEDIMEKDWNNHKKGKDCSKLGKKCIYQQLVRGRKI 
8,642.1 9.4 8.1 74 
CT-proET-1 
ppET-1[169 – 212] 
SSEEHLRQTRSETMRNSVKSSFHDPKLKGKPSRERYVT
HNRAHW 
5,291.9 10.5 5.4 44 
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Anion exchange:        
Q-Sepharose Fast Flow
• Removal of phenol red and 
acidic proteins 
Cation exchange: 
Carboxymethyl
• Separation of basic peptides
SPE: C2 cartridges
• Desalting, buffer exchange and 
concentrating CM fractions containing 
highest ELDP and CT-proET-1 
immunoreactivity
• Recovery of the NT-proET-1 from 
unadsorbed Q-Sepharose sample
Semi-preparative HPLC
• Initial purification and
characterisation of proET-1
fragments
Characterisation of A549 
conditioned medium  
Step 1
Analytical  HPLC
• Further characterisation of 
proET-1 fragments
Step 2
Step 3
Step 4
Step 5
Purification of EA.hy 926 
conditioned medium  
SPE: C2 cartridges
• Desalting, buffer exchange and
concentrating
Given insufficient recovery of NT-
proET-1 from IEC and blockade of
the column systems; a different
characterisation approach was
adapted for the recovery of proET-1
peptides from the A549 conditioned
medium. For this purpose,
ammonium sulphate precipitation at
20% saturation was used to reduce
impurities from the A549 conditioned
medium prior to SPE and RP-HPLC
RP-HPLC
Mainly based on 
hydrophobicity
 
Figure 4.1: Approach to purification and characterisation of proET-1 peptides from 
the conditioned media from EA.hy 926 and A549 cells collected after 48 h incubation. 
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4.2  METHODS 
4.2.1 Collection of conditioned media for purification and 
characterisation of proET-1 peptides 
Cell culture growth conditions of EA.hy 926 and A549 cells are described in Chapter 3, 
section 3.2.1. Subcultures of these human cell lines were prepared in four T175 cm2 
flasks at a 1:3 seeding dilution with DMEM supplemented with 4500 mg D-glucose/L, 
25% 1 M HEPES and 1% penicillin/streptomycin (DMEM+) and 10% FCS (total 
volume 30 ml). This resulted in 90 – 100% confluent flasks after 4 – 5 days.  
To purify and characterise ppET-1 peptide fragments, conditioned media from EA.hy 
926 and A549 cells were collected from confluent cultures of these cell lines grown in 
four T175 cm2 flasks, which had been incubated for 48 h at 37°C in a humidified CO2 
incubator (8% CO2, 92% air). These flasks were washed with 30 ml of DMEM+ and 
incubated with media (25 ml media/flask), which consisted of DMEM supplemented 
with 4500 mg D-glucose/L without FCS, peptidase inhibitors or penicillin/streptomycin. 
After the incubation period, conditioned media was collected and centrifuged at 3000 g 
for 15 min at 4°C. The supernatant was then transferred into fresh tubes and stored at -
80°C.  
Conditioned medium (900 ml) collected from a total of 36 T175 cm2 flasks was used for 
purification of proET-1 peptides from EA.hy 926 cells. The characterisation 
methodology used for the conditioned medium collected from A549 cells differed from 
the EA.hy 926 cells (Figure 4.1) and it is described in section 4.2.5.  
 
4.2.2 Characterisation of proET-1 peptides from the EA.hy 926 
conditioned medium using ion exchange chromatography  
4.2.2.1  Q-Sepharose Fast Flow columns as a strong anion exchanger 
Q-Sepharose gel was gently swirled and the gel slurry (6 ml) was transferred into 10 ml 
columns fitted with PTFE filters on a vacuum manifold (Alltech, Fisher Scientific). A 
small vacuum was applied to allow the gel to settle.  The gel was rinsed with (10 ml) 10 
mM acetic acid (CH3COOH) before application of the sample. Conditioned medium 
(900 ml in DMEM) collected from EA.hy 926 cells after 48 h incubation was acidified 
with 1.25% CH3COOH and centrifuged at 3,000 rpm at 4°C for 15 min. Pellets were 
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reconstituted in SAB and retained for immunoassay to confirm that there was no loss of 
proET-1 peptides. Supernatants were loaded in equal volumes (30 ml) on to 10 pre-
equilibrated Q-Sepharose fast flow columns (6 ml swelled gel per column). The columns 
were then washed with 15 ml volumes of 10 mM CH3COOH. Material recovered in the 
washes was pooled with the unadsorbed sample and then loaded on to a CM column. Q-
Sepharose clean-up of EA.hy 926 cell medium followed by recovery of proET-1 
peptides by CM ion exchange was performed in 3 batches (300 ml media per batch). 
Acidic peptides adsorbed on to the Q-Sepharose column were eluted with 15 ml 1 M 
NaCl containing 0.1 M G-HCl and subjected to immunoassay to confirm absence of 
proET-1 peptides. 
 
4.2.2.2  Cation exchange using carboxymethyl column  
Each unadsorbed pooled sample and washings from the Q-Sepharose columns (~45 ml 
per column) were loaded onto CM Fractogel weak cation exchanger column (2.8 ml) 
that had been equilibrated with 40 ml of 10 mM CH3COOH. After loading samples, the 
columns were then rinsed with 10 ml of 10 mM CH3COOH. This was combined with 
the unadsorbed sample from CM column and retained to verify proET-1 peptides had 
been adsorbed on the CM column. The CM columns were then eluted with increasing 
concentrations of NaCl and G-HCl (3 ml per elution step):  
(1) 0.125 M NaCl,  
(2) 0.25 M NaCl,  
(3) 0.25 M NaCl + 0.1 M G-HCl,  
(4) 0.5 M NaCl + 0.1 M G-HCl,  
(5) 1 M NaCl + 0.1 M G-HCl 
(6 – 11) 1 M NaCl + 0.5 M G-HCl 
 
All fractions were assayed for NT-proET-1, ELDP and CT-proET-1 according to the 
immunoassay methodology described in Chapter 2, section 2.2.2.3  Tris-Base (0.55 M) 
was used to neutralise samples before assay (pH 7.0 – 7.5). 
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4.2.3  Concentration and desalting of proET-1 peptides 
4.2.3.1  Solid-phase extraction  
Sep-Pak C2 ethyl cartridges (500 mg, Waters) were used according to the manufacturer’s 
instructions with sequential washing of the C2 silica matrix with 10 ml of 100% 
methanol for full penetration of particles (called priming), which was followed by 
washing with 10 – 15 ml of 80% acetonitrile, and then 0.1% TFA, prior to the addition 
of the sample that had been acidified with 0.1% TFA. Table 4.2 shows the C2 extraction 
procedure applied for proET-1 peptides.   
Table 4.2: Solid-phase extraction procedure with C2 cartridges. 
Sample preparation Acidify with 0.1% TFA, optimal pH 2.0 
Priming and washing 
10 ml, 100% methanol 
10 – 15 ml, 80% acetonitrile 
10 – 15 ml, 0.1% TFA 
Sample addition 
Washing 5 ml, 0.1% TFA 
Elution 2 x 2 ml, 80% CH3CN/0.1% TFA 
 
4.2.4  Reverse Phase HPLC   
HPLC was performed with a MERCK Hitachi L-6200 Intelligent Pump with 2 ml 
injection loop. Elution of endothelin-1 and proendothelin-1 fragments and other peptides 
was monitored at 280 nm using a Shimadzu SPD-6A UV detector. Chromatographic 
data were collected and processed by PRIME software. Fractions were collected using 
a Pharmacia LKB Helifrac fraction collector. 
Before running the samples, the column was first flushed with 100% CH3CN containing 
0.1% TFA followed by equilibration with 0.1% TFA. Gradient elution was performed 
with monitoring of eluted peptides by measuring UV absorbance at 280 nm. All samples 
were filtered using 0.2 µm microcentrifuge filter tubes before injection. Once the column 
was equilibrated and a stable baseline was confirmed, the samples were injected 
manually on to the HPLC column.  
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4.2.4.1  Semi-preparative RP-HPLC  
This was performed using a Jupiter® column (Phenomenex, Part Number: 00G-4169-
N0) packed with butyl-bonded silica C4 with 300 Å pore size and 15 µm particle size (1 
x 25 cm). The column was equilibrated with 0.1% TFA and subjected to gradient elution 
at a flow rate of 2 ml/min: 0 – 15% solvent B (80% CH3CN with 0.1% TFA) over 2 min, 
followed by 15 – 60% B over 45 min and further increased to 100% B over 5 min and 
held at 100% B for 8 min. Following gradient elution the column was re-equilibrated at 
0% B before running further samples or standards. 
 
4.2.4.2  Analytical RP-HPLC  
This was performed using ACE-5 C4-300 (Advanced Chromatography Technologies), 
5 µm particle size with 300 Å pore size (4.6 x 250 mm). Samples were eluted at a flow 
rate of 1 ml/min using gradient of 0 – 10% solvent B (80% CH3CN with 0.1% TFA) 
over 2 min, followed by 10 – 30% B over 50 min and further increased to 100% B by 
70 min and held at 100% B for another 5 min. After gradient elution the column was re-
equilibrated at 0% B before running further samples or standards. 
Purified NT-proET-1, ELDP and CT-proET-1 immunoreactivity for both HPLC steps 
were assessed in aliquots of fractions after they were completely dried under a stream of 
N2 at 30°C and reconstituted with 300 µl of SAB. 
 
4.2.5  Characterisation of proET-1 peptides from the  
  A549 conditioned medium 
The approach described above for isolating proET-1 peptides from medium collected 
from EA.hy 926 cells did not work for conditioned medium from A549 cells because of 
a high level of shed membrane particles that readily blocked the chromatography 
columns. To overcome this conditioned media was treated to remove these membrane 
particles. Previous (NH4)2SO4 precipitation experiments showed that at 90% saturation 
proET-1 fragments were precipitated, while at 20% saturation immunoreactivities of 
NT-proET-1, ELDP and CT-proET-1 could not be detected in the reconstituted 
precipitates, showing these peptides remained in the supernatant. Thus, (NH4)2SO4 
precipitation at 20% saturation was used as an intermediate step to remove impurities 
from the A549 conditioned medium. 
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4.2.5.1  Ammonium sulphate precipitation of A549 conditioned medium 
Conditioned medium (20 ml) collected after 48 h incubation with A549 cells was 
acidified with 0.2 M CH3COOH to pH 4.0 before the addition of (NH4)2SO4 to 20% 
saturation [2.12 g (NH4)2SO4 for 20 ml acidified conditioned medium = 20% saturation]. 
Acidified conditioned medium was centrifuged at 20,000 rpm for 40 min at 4°C using a 
Beckman ultracentrifuge (rotor type 70ITI). After the centrifugation step, 0.1% TFA was 
added to the supernatant (pH 4.0) prior to loading on to a primed SPE C2 cartridge. C2 
extraction was carried out as described in Table 4.2 using a vacuum manifold. The 
peptides were eluted with 2 x 2 ml of 80% CH3CN containing 0.1% TFA. After applying 
a stream of N2 to concentrate the sample, fractions were subjected to NT-proET-1, ELDP 
and CT-proET-1 immunoassays. Concentrated eluates (1.5 ml) were filtered through 0.2 
µm pore size 1.5 ml microcentrifuge tubes and the resultant filtrate was injected onto 
analytical RP-HPLC (ACE-5 C4-300 column: 5 µm,  4.6 x 250 mm) using the same 
gradient as described in section 4.2.4.2.  
 
4.2.6  HPLC analysis of synthetic proET-1 peptide standards 
Synthetic standards of NT-proET-1 (70 nmol/ml), ELDP (85 nmol/ml) and CT-proET-
1 (59 nmol/ml) were diluted (20 µl of each proET-1 peptide) into 1.5 ml of 0.2% formic 
acid (at a final concentration of 1.4, 1.7 and 1.2 nmol, respectively) and subjected to 
analytical RP-HPLC (C4 300 Å, 5 µm, 4.6 x 250 mm). The elution position of synthetic 
standards was only assessed on analytical RP-HPLC monitoring absorbance at 280 nm 
and by immunoassay. To avoid cross-contamination of purified peptides this was done 
after samples from conditioned media had been run. 
For comparison, NT-proET-1, ELDP and CT-proET-1 standards in quantities similar to 
those being purified from conditioned media samples were diluted (20 µl) in DMEM 
(10 ml) at final concentrations of 140, 170 and 120 pmol/ml, respectively. Acidified with 
0.1% TFA and extracted on SPE C2 cartridges. After partially drying to remove CH3CN, 
filtered eluate was loaded on to analytical RP-HPLC (C4, 5 µm 4.6 x 250 mm) and 
elution positions of proET-1 fragments were verified by immunoassay.  
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4.3  RESULTS 
4.3.1 Initial purification and characterisation of proET-1 
peptide fragments by carboxymethyl ion exchange 
chromatography 
The initial purification step from the EA.hy 926 conditioned medium was carried out 
using a strong anion exchanger, Q-Sepharose fast flow column (section 4.2.2.1). This 
was used to remove low MWt contaminants (e.g. phenol red) and acidic proteins from 
the conditioned medium. Acidic proteins bound to the anion exchanger were eluted with 
3 ml of 1 M NaCl containing 0.1 M G-HCl.  
Unadsorbed basic proteins including the washes were then loaded on to a weak cation 
exchanger CM Fractogel column. The CM column was eluted with increasing 
concentrations of NaCl (ionic strength) and G-HCl (competing cation) concentration. 
Counter ions (Na+) in NaCl containing G-HCl displaces the adsorbed peptides from the 
binding sites in order of their net charge. ProET-1 peptides eluted from the CM IEC 
were measured by using immunoassays for NT-proET-1, ELDP and CT-proET-1. 
However, efficient recovery of NT-proET-1 immunoreactivity from EA.hy 926 medium 
was not achieved using CM IEC.  
NT-proET-1 immunoreactivity was mainly present in the unadsorbed pooled sample that 
had passed through Q-Sepharose column, and then through the CM Fractogel column, 
indicating inefficient binding of this peptide to the CM column. The mean levels of NT-
proET-1 from the three batches of EA.hy 926 conditioned medium processed in this way 
were 12.6 ± 0.1 fmol/ml. As a result, the unadsorbed pooled sample from Q-Sepharose 
and CM Fractogel columns was used for the isolation and purification of NT-proET-1 
from the EA.hy 926 conditioned medium (section 4.3.2.2). 
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Both ELDP and CT-proET-1 were mainly eluted in CM fractions 3 – 5 and 6 – 8, which 
corresponded to an increase in both ionic strength (4 – 5) and competing cation 
concentration (5 – 6). Therefore, proET-1 peptides mainly eluted according to their 
isoelectric points (NT-proET-1 [pI 6.3], ELDP [pI 9.4] and CT-proET-1 [pI 10.5]) 
however, without resolution between ELDP and CT-proET-1 peptides. From EA.hy 926 
cells, ELDP levels measured from the pooled fractions 4 – 5 and 6 – 8 were 11.7 and 
13.8 pmol/ml, respectively. The recoveries of ELDP and CT-proET-1 from the CM 
fractions were 57% and 72%, respectively. 
 
 
Figure 4.2: Carboxymethyl IEC of EA.hy 926 conditioned medium showing elution 
of ELDP and CT-proET-1 immunoreactivity. Results from a representative batch of 
300 ml of conditioned medium loaded onto ten CM fractogel columns after Q-Sepharose 
pre-treatment. Each CM column was washed with 10 mM acetic acid (10 ml/column) to 
remove unbound material (Und), and then eluted with 3 ml of the following conditions. 
(1): 0.125 M NaCl, (2): 0.25 M NaCl,   (3): 0.25 M NaCl + 0.1 M G-HCl, (4): 0.5 M 
NaCl + 0.1 M G-HCl, (5):  1 M NaCl + 0.1 M G-HCl, (6 – 11): 1 M NaCl + 0.5 M G-
HCl. ELDP and CT-proET-1 were measured by immunoassays; the mean 
concentrations per fraction for each peptide are indicated.  
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4.3.2  Purification and characterisation of NT-proET-1, ELDP
  and CT-proET-1 using HPLC 
4.3.2.1  EA.hy 926 conditioned medium fractions 
Carboxymethyl IEC fractions containing the highest amounts of ELDP and CT-proET-
1 were pooled together (4 – 5 and 6 – 8). These pooled fractions were acidified with 
0.1% TFA (pH 2.0) and loaded onto primed C2 cartridges. Adsorbed peptides were 
eluted with 2 ml of 80% CH3CN containing 0.1% TFA. Eluates were then concentrated 
by a gentle stream of N2 gas to ~400 μl. In order to remove any particulate material 
before loading on to a semi-preparative RP-HPLC system (Jupiter C4 column, 15 µm, 
300 Å and 1 x 25 cm), the concentrated eluate was filtered through 0.2 µm 
microcentrifuge tubes. Using this semi-preparative HPLC system, the pooled 
concentrated and filtered eluates were run separately from each other (fractions 4 – 5 
and 6 – 8), with two runs per pooled fraction. The column was eluted with a gradient of 
CH3CN containing 0.1% TFA at a flow rate of 2 ml/min. Immunoassay of fractions for 
ELDP and CT-proET-1 showed adequate resolution of the two peptides (Table 4.3), 
allowing each peptide to be chromatographed separately in subsequent analytical HPLC 
steps. 
 
Table 4.3: Semi-preparative HPLC analysis of EA.hy 926 ELDP and CT-proET-1 
from CM IEC. Peak fractions eluted from CM IEC (4 – 5 and 6 – 8) were extracted 
using C2 columns. Eluted samples were concentrated, pooled as indicated and subjected 
to semi-preparative RP-HPLC column (Jupiter C4 300 Å, 15 µm, 1 x 25 cm). Collected 
fractions (2 ml/min) were immunoassayed for ELDP and CT-proET-1. 
Semi-preparative HPLC analysis 
HPLC 
runs 
CM fractions ELDP CT-proET-1 
1 
4 – 5 26 – 27 22 – 23 
6 – 8 25 – 28 22 – 23 
2 
4 – 5 25 – 27 20 – 21 
6 – 8 25 – 27 21 – 22 
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Fractions corresponding to peak ELDP and CT-proET-1 immunoreactivity (Table 4.3) 
were pooled and concentrated under N2 and filtered using 0.2 µm filters for further 
purification using the analytical HPLC procedure (C4 column: 5 µm, 4.6 x 250 mm). 
Collected fractions (1 ml/min) were assayed for ELDP and CT-proET-1. 
Analytical HPLC provided better resolution between ELDP and CT-proET-1 peptides. 
Peak fractions of CT-proET-1 were identified in fractions 27, 28 and 31, whereas ELDP 
was eluted in fractions 43 and 47 (Figure 4.3A – B).  
 
4.3.2.2 Recovery of NT-proET-1 from the EA.hy 926 conditioned medium  
NT-proET-1 peptide in conditioned medium from EA.hy 926 cells did not bind to the 
CM IEC system but was identified in the unadsorbed sample and 10 mM acetic acid 
wash. To recover NT-proET-1 for further characterisation and to concentrate this dilute 
sample [1350 ml sample (900 ml EA.hy 926 conditioned medium + 450 ml 10 mM 
acetic acid wash)], it was subjected to SPE with C2 cartridges. Eluates from the C2 
extraction were further concentrated by N2, filtered using 0.2 µm microcentrifuge tubes 
before loading on to the semi-preparative RP-HPLC system. The conditions of the semi-
preparative HPLC separation were as described for ELDP and CT-proET-1 peptides in 
section 4.3.2.1. Peak NT-proET-1 immunoreactivity from the semi-preparative HPLC 
separation was detected in fractions 27 – 29 (data not shown). These fractions were 
pooled and concentrated with a stream of N2, filtered and subjected to analytical HPLC. 
NT-proET-1 immunoreactivity from the analytical HPLC was eluted in fraction 41 
(Figure 4.3C). 
 
Synthetic proET-1 standards NT-proET-1, ELDP, and CT-proET-1 were subjected to 
analytical RP-HPLC (at 1.4, 1.7 and 1.2 nmol, respectively) and their elution positions 
were verified by monitoring A280 and by immunoassay. NT-proET-1, ELDP and CT-
proET-1 synthetic standards were eluted at fractions 46, 45 and 28, respectively. Elution 
positions are indicated by the marked arrows (Figure 4.3). 
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Comparison of HPLC profiles obtained from synthetic peptides with those of the native 
proET-1 peptides extracted and purified from EA.hy 926 conditioned medium showed 
that ELDP and CT-proET-1 synthetic peptides were eluted (fraction 28 for CT-proET-1 
and fraction 45 for ELDP) at very close proximities to the native proET-1 peptides 
(fractions 28, 29 and 31 for CT-proET-1 and fractions 43 and 47 for ELDP). However, 
the elution profile of ELDP and CT-proET-1 was heterogeneous, which suggest some 
degree of post-translational modification during purification. 
NT-proET-1 synthetic standard (fraction 46) did not co-elute at the same position as the 
native peptide (fraction 41) that was extracted from the EA.hy 926 conditioned medium. 
Earlier elution of the native NT-proET-1 peptide in comparison to the synthetic peptide 
suggested that it may be less hydrophobic.  
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Figure 4.3: Analytical HPLC characterisation of proET-1 peptides from EA.hy 926 
(A) CT-proET-1, (B) ELDP and (C) NT-proET-1.  Peak fractions of CT-proET-1, 
ELDP and NT-proET-1 from semi-preparative RP-HPLC column (C4 300 Å, 15 µm, 1 
x 25 cm) were pooled and subjected to separate analytical RP-HPLC analyses (C4 300 
Å, 5 µm, 4.6 x 250 mm). Arrows mark the elution positions of synthetic CT-proET-1, 
ELDP and NT-proET-1, which eluted in fractions 28, 45 and 46, respectively. 
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4.3.2.3 Characterisation of proET-1 peptides from the A549 conditioned 
medium  
Characterisation of proET-1 peptides from A549 conditioned medium was problematic. 
Impurities such as lipoproteins and other lipid material released into the conditioned 
medium blocked the Q-Sepharose and CM Fractogel IEC columns. This is likely due to 
cell membrane shedding of microvesicles by tumour cells in culture (Muralidharan-
Chari et al., 2010). Thus, to allow further characterisation of proET-1 peptides using 
HPLC, an alternative approach using (NH4)2SO4 precipitation was employed to remove 
contaminants released from A549 cells into the conditioned medium. 
Conditioned medium from A549 cells was subjected to (NH4)2SO4 precipitation at 20% 
saturation to remove particulate material (see section 4.2.5.1). The supernatant was 
extracted on SPE C2 cartridges, and adsorbed proET-1 peptides were eluted with 80% 
CH3CN containing 0.1% TFA. Immunoassays of NT-proET-1, ELDP and CT-proET-1 
showed efficient recoveries for all proET-1 fragments. The recovery of NT-proET-1 
from SPE was 84%, while ELDP and CT-proET-1 recoveries were ~100%. Eluates were 
concentrated, pooled together and filtered before subjecting to analytical RP-HPLC (C4 
column, 5 µm, 4.6 x 250 mm). Peak fractions of NT-proET-1, ELDP and CT-proET-1 
were eluted in 34 – 35, 37 – 40 and 21 – 24, respectively (Figure 4.4), corresponding to 
65%, 89%, and 47% recoveries in comparison to C2 extraction. NT-proET-1 and ELDP 
eluted as single peaks. The elution profile of CT-proET-1 however, showed some 
heterogeneity with a double peak. 
Synthetic peptide standards of NT-proET-1, ELDP and CT-proET-1 were diluted in 
DMEM and extracted in the same way as previously described for the A549 conditioned 
medium. Eluates were run on the analytical HPLC and their elution positions were 
verified by immunoassay. NT-proET-1 and ELDP eluted in the same fractions 43 – 44, 
while CT-proET-1 eluted in fractions 27 – 28. Hence, proET-1 peptides extracted from 
the conditioned medium of A549 cells did not closely correspond with the elution 
positions of the synthetic standards. However, the synthetic standards for ELDP and CT-
proET-1 both eluted six fractions later in gradient. NT-proET-1 (43 – 43) on the other 
hand, was eluted more distant from the native peptide (34 – 35). Elution positions of 
synthetic peptides were almost identical to the previous calibration of this column after 
analytical HPLC of peptides isolated from EA.hy 926 conditioned medium. One 
explanation for the earlier elution of peptides extracted from A549 conditioned medium 
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is that column had been overloaded with the extracted sample, which underwent limited 
pre-fractionation before analytical HPLC. The elution characteristics of the column may 
have been modified by contaminating materials from the conditioned medium so that 
the column efficiency was compromised. For NT-proET-1, differences between the 
native and synthetic standards likely contributed to the marked difference in elution 
times. 
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Figure 4.4: Analytical HPLC chromatogram showing characterisation of NT-proET-1, ELDP and CT-proET-1 from conditioned medium of 
A549 cells. A549 conditioned medium was acidified with 0.2 M CH3COOH to pH 4.0.  (NH4)2SO4 was added to 20% saturation and centrifuged 
at 20,000 rpm for 40 min at 4°C. Supernatant was extracted on a C2 cartridge, proET-1 peptides were eluted with 80% CH3CN containing 0.1% 
TFA (2 x 2 ml), and concentrated to ~400 µl before analytical RP-HPLC (C4 300 Å, 5 µm, 4.6 x 250 mm). ProET-1 fragments were detected using 
immunoassays for NT-proET-1, ELDP and CT-proET-1. Arrows marking fractions 27 – 28, indicate the elution positions of CT-proET-1 and 43 
– 44 indicate the elution positions of NT-proET-1 and ELDP synthetic peptides. 
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4.4  DISCUSSION 
A combination of chromatography-based methods was used for purification and 
characterisation of proET-1 fragments that are co-released with ET-1 from EA.hy 926 
and A549 cells. While IEC provided a suitable method of purification for proET-1 
peptides from EA.hy 926 conditioned medium, ammonium sulphate precipitation was 
necessary for characterisation of proET-1 peptides from A549 conditioned medium prior 
to RP-HPLC characterisation. Both conditioned media samples were then subjected to 
SPE. This was essential for buffer exchange and to concentrate NT-proET-1, ELDP, and 
CT-proET-1 peptides for further characterisation using RP-HPLC. 
For EA.hy 926 conditioned medium, Q-Sepharose “clean up” to remove acidic proteins 
or contaminants followed by CM cation exchange chromatography proved to be an 
efficient process for isolating the basic proET-1 fragments ELDP and CT-proET-1. In 
pilot experiments to test this two-step procedure with small volumes of medium (20 
ml/column), NT-proET-1 was also recovered in the CM fractions. Hence, for the large 
scale purification the aim was to isolate all three proET-1 fragments for HPLC 
characterisation. However, NT-proET-1 was present mainly in the unadsorbed pool 
from CM chromatography, which had been subjected to Q-Sepharose pre-treatment 
prior to loading on to CM Fractogel. Lack of binding and poor recovery of the NT-
proET-1 was likely due to the following reasons:  
i. NT-proET-1 has the lowest pI (6.3), so did not bind efficiently to the CM 
Fractogel. 
ii. The binding capacity of the column was exceeded in the large-scale purification, 
such that NT-proET-1 was readily displaced by other peptides or proteins with 
higher pIs.  
iii. Low levels of NT-proET-1 eluted in multiple CM fractions, but were not 
detected by the NT-proET-1 immunoassay because G-HCl interferes in this 
assay resulting in reduced sensitivity. Hence, unless there is adequate dilution of 
sample to compensate, low amounts of immunoreactivity in fractions are not 
detected.   
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Native NT-proET-1 purified from EA.hy 926 (Figure 4.3) and A549 conditioned media 
samples (Figure 4.4) were eluted after CT-proET-1. This indicated that NT-proET-1 is 
more strongly retained on the C4 column, and thus has characteristics of a more 
hydrophobic (non-polar) peptide than the CT-proET-1 requiring a higher concentration 
of CH3CN for its desorption. The elution position of native NT-proET-1 peptide purified 
from EA.hy 926 conditioned medium was earlier (at fraction 41) than the synthetic 
peptide (at fraction 46). Thus, the native peptide is less hydrophobic than the synthetic 
peptide. RP-HPLC separation of peptides depends largely on their hydrophobicity. 
Although this can be influenced by size and conformation/folding and the proportion of 
hydrophilic amino acids, the overriding determinant is the most hydrophobic sequence 
providing greatest affinity for the non-polar hydrophobic particle surface of the column. 
Ion-pairing of basic residues with TFA also increase hydrophobicity and peptide 
retention on HPLC. It seems likely that the C-terminal sequence of NT-proET-1 
(WRLRRS) in the presence of TFA contributes greatly to the overall retention of NT-
proET-1, however why there is so much difference between the elution characteristics 
of the native and synthetic peptides is unclear. The NT-proET-1 immunoassay is very 
specific for this sequence, and therefore unlikely to detect this peptide if this sequence 
is not intact. 
It is often difficult to synthesise peptides with (poly)proline sequences (Wawra & 
Fischer, 2006). NT-proET-1 has five proline residues in its amino acid sequence (Table 
4.1). The N-terminal sequence of NT-proET-1 has one and the C-terminal sequence has 
four proline residues in a short six amino acid sequence, including two adjacent residues. 
Proline is the only natural cyclic amino acid that is unusual in forming cis peptide bonds 
at a frequency (~5%) much higher than any other naturally occurring amino acid 
(<0.1%) (Lummis et al., 2005). Therefore, multiple proline residues in the C-terminal 
sequence of NT-proET-1 may undergo cis/trans isomerisation during chemical 
synthesis, leading to different structural folding that results in different HPLC elution 
positions. The synthetic peptide was a single peak, and had been shown to have the 
correct mass by LC-MS (see Chapter 2, section 2.1.3.1). Because antibody recognition 
is directed to the N- and C-terminal sequences, internal structural modification may not 
be detected by immunoassay. Hence, further structural characterisation of the synthetic 
peptide would be necessary to confirm whether this underlies the differing elution 
pattern to native peptide. Mass spectrometry provides great resolution and determines 
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structural features such as amino acid sequence, mass, post-translational modifications 
and it is also useful for the assignment of disulphide bonds. Therefore, mass 
spectrometric identification of the purified proET-1 peptide fractions could confirm the 
peptide identities. This may also define the reasons for heterogeneity, which have 
resulted from differences in amino acid sequence due to degradation products generated 
during purification or on storage. 
 
 
Analytical HPLC of ELDP and CT-proET-1 peptides isolated from the conditioned 
medium of EA.hy 926 cells did not generate a single peak of immunoreactivity. 
However, the degree of heterogeneity was low with only two closely eluting peaks for 
ELDP and three for CT-proET-1 on an acetonitrile gradient with higher resolving 
potential (gradient increase 0.4% B per min). In both cases the purified native peptides 
eluted close to the corresponding synthetic peptides. Differences could result from 
modifications either during the 48 h incubation period where the conditioned medium 
was in contact with cells, or could have occurred during the various purification steps. 
Likely modifications could include oxidation of sulphur-containing methionine residues 
during the course of sample extraction and freeze/thaw process. This is a frequent 
observation for peptides in acidic solution. The side chain of normal methionine is long, 
flexible, and non-polar (Richardson & Richardson, 1989; Hoshi & Heinemann, 2001) 
but when it is oxidised to methionine sulphoxide by the addition of an extra oxygen 
atom, it becomes stiffer and more polar (hydrophilic) than that of the methionine side 
chain (Hoshi & Heinemann, 2001). Thus, the oxidised form is eluted before the native 
peptide. Other possible amino acid modifications during peptide purification under 
acidic conditions include: hydrolysis of amide side chains of asparagine and glutamine 
to aspartic acid and glutamic acid; hydroxylation of tyrosine, tryptophan or proline and 
oxidation of histidine and tryptophan. The reason for two main peaks for ELDP and CT-
proET-1 is likely methionine oxidation as both peptides have a single methionine 
residue. Additional heterogeneity is likely due to a combination of other modifications 
under the acidic conditions used for the isolation and purification procedure. 
 
 
Three-dimensional structure of the human ET-1 (PDB: P05305) determined by X-ray 
crystallography (to 2.18 Å resolution) demonstrated two disulphide bridges at ppET-1 
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positions 53 – 67 and 55 – 63 (Janes et al., 1994). Similarly, ELDP sequence consists of 
six cysteine residues, in which the spacing between the first four cysteine residues is the 
same as in ET-1 sequence. Therefore, it is likely that these residues might form 
disulphide bridges at amino acid positions 109 – 123, 111 – 119, with a further 
disulphide bridge at 148 – 155. Disulphide bonds can contribute to protein folding. 
Correct disulphide bond formation parallels correct folding and formation of secondary 
structure, which reinforces the stability of a protein (Creighton, 1993; Zhang et al., 
2011). Thereby, ELDP can be highly susceptible to protein folding and more compact 
structure of the folded ELDP can result in prolonged interactions with the hydrocarbon 
groups of the C4 column.  
 
In general, both HPLC chromatograms showed well resolved peaks of purified proET-
1 fragments detected using sensitive immunoassays. Further investigation is required to 
confirm the sequence identities of the native peptides using mass spectrometry. Mass 
spectrometric identification of the specific proET-1 fragments identified by the NT-
proET-1 (ppET-1[18 – 50]), ELDP (ppET-1[93 – 166]) and CT-proET-1 (ppET-1[169 – 212]) 
immunoassays was investigated in Chapter 5. 
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CHAPTER 5 
Verification of proendothelin-1 sequence identities 
using mass spectrometry 
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5.1  INTRODUCTION  
5.1.1  Identification of proteins using mass spectrometry  
Peptide mass fingerprinting (PMF) was introduced in 1981 by Henzel and colleagues 
(1993) and involves digestion of a protein with a specific protease (most often trypsin) 
to determine the masses of peptides resulting from the proteolytic cleavage (Henzel et 
al., 2003). Trypsin cleaves at the C-terminal side of lysine and arginine residues with 
the exception being when the next amino acid is proline (Link & LaBaer, 2011). 
However, identification of proteins from PMF alone can be inconclusive. 
Tandem mass spectrometry (MS/MS) combines peptide separation with fragmentation 
and provides enhanced specificity for identification of protein mixtures over PMF alone. 
The “bottom-up” approach involves proteolytic digestion and MS/MS analysis. 
Molecular weights of proteolytic peptides are submitted to database search engines such 
as MASCOT or SEQUEST (Eng et al., 1994), which results in a powerful and rapid 
approach for protein identification.  On the other hand, “top-down” approach provides 
characterisation of intact proteins with no enzymatic digestion. The intact mass and 
fragmentation data (precursor mass) are matched to search algorithms using absolute 
mass, sequence tag or a subset of larger sequence (biomarker) (Kellie et al., 2010). This 
approach provides the potential for full localisation and characterisation of post-
translational modifications (PTMs). 
 
5.1.2 Fragmentation of peptides with collision-induced 
dissociation (CID) 
There are several techniques that can generate peptide fragments: Electron Transfer 
Dissociation (ETD), Electron Capture Dissociation (ECD), and Collision-Induced 
Dissociation (CID). CID is the main method of fragmenting peptides in 
ion trap/quadrupole mass spectrometers. 
Peptide ions are protonated with electrospray ionisation (ESI). These protonated peptide 
ions are then fragmented with CID using an inert gas such as helium.  This cleavages 
the weakest amide bond first. Peptide fragmentation mainly occurs on the peptide 
backbone, often with the transfer of one or two hydrogen(s) to form a stable ion. Under 
CID peptide fragmentation, a nomenclature proposed by Roepstorff and Fohlman, 1984 
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was used to define N-terminal and C-terminal fragment ions as a, b, c and x, y, z, 
respectively (Figure 5.1) (Roepstorff, 1984). Low energy CID of peptides mainly 
produces b- and y- type fragment ions (Maleknia & Johnson, 2011). 
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Figure 5.1: Roepstorff nomenclature: x, y, and z represent C-terminal fragments and 
a, b, and c represent N-terminal fragments. Under low-energy CID, b-ion is generated 
when the charge (proton, H+) is retained on the N-terminal and y-ion is generated when 
the charge is retained on the C-terminal end (Modified from Maleknia & Johnson, 
2011). 
 
Fragmentation of precursor/parent ions generates product ions. The mass difference 
between each product ion corresponds to the mass of the amino acid residue. This 
defines the amino acid sequence of a peptide. Peptides are often digested to smaller 
fragments for effective fragmentation. Main fragmentation principles using CID are 
explained briefly.  
(1) Sequencing starts from the C-terminal fragment. In tryptic peptides due to basic 
C-terminal arginine or lysine residue, more intense y-ions are generated (Tabb et 
al., 2004, 2006). 
(2) N-terminal fragment ions (b-ions) are calculated by adding the mass of a proton 
(H, 1.008 Da) to the residue masses while the C-terminal fragment ions (y-ions) 
are calculated by adding the mass of water and a proton (19.018 Da) to the 
residue masses. 
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(3) The last b-ion loses -17 Da (OH), while the last y-ion loses the mass of the last 
fragment ion and hydrogen (M+H). 
(4) Peptide ions containing aspartic acid, glutamic acid, serine and threonine can 
neutrally lose water (18 Da) while asparagine, arginine, glutamine and lysine 
side chains can lose ammonia (17 Da) (Wu et al., 2008; Medzihradszky, 2005). 
Other amino acids could also lose either water or ammonia.  
(5) Proline can produce dominant y-ions, resulting from cleavage on N-terminal side 
of proline and suppressed b-ions (Breci et al., 2003).  
 
Sequencing tryptic peptides using low energy CID has some limitations. Examples of 
these include: (1) modifications such as disulphide bonds are not typically fragmented 
by CID (Loo et al., 1990); (2) leucine and isoleucine have identical masses and cannot 
be differentiated (Papayannopoulos, 1995); (3) both b1- and y1- fragment ions are usually 
not observed in the spectra due to their low mass range, which is mainly a problem in 
ion traps but not in QTOF, Orbitrap or quadrupole mass spectrometers. (4) In addition, 
low MWt immonium ions that can confirm the identification/presence of amino acids 
such as oxidised methionine, histidine and proline at m/z 120, m/z 110 and m/z 70, 
respectively may not be observed in ion traps. (5) The C-terminal side of proline is often 
not cleaved and not observed (Maleknia & Johnson, 2011). This results from increased 
gas-phase basicity of the proline nitrogen and the ring structure of the proline side chain 
that inhibits the attack of the carbonyl on the N-terminal side of the proline (Maleknia 
& Johnson, 2011). 
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5.1.3 Identification of post-translational modifications using 
mass spectrometry 
Examples of frequently occurring PTMs in proteins are described here. Some of the 
modifications are introduced during sample preparation; as such oxidation of methionine 
residues is the most commonly observed example. 
 
5.1.3.1  Oxidation 
Methionine, tryptophan, histidine and cysteine residues are susceptible to oxidation. 
Oxygen and reactive oxygen species (ROS) such as superoxide (O2
-), hydrogen per 
oxide (H2O2), hydroxyl radical (
●HO), and hypochlorite (ClO-) can oxidise methionine. 
This yields methionine sulphoxide (MetSO). Further oxidation can lead to methionine 
sulphone (MeS), but to a much lesser extent (Nielsen et al., 1985). Following CID 
fragmentation, MetSO can be detected with a mass increment of 15.995 Da and MeS 
with a mass increment of 31.99 Da. Oxidised methionine can also be detected by the 
presence of additional b- and y-ions that are 64 Da lower in mass than the MetSO ion. 
This corresponds to a neutral loss of methane-sulphenic acid (CH3SOH) from the side 
chain of MetSO (Rebrin et al., 2010). In CID, this characteristic loss of CH3SOH 
indicates the presence of MetSO (Guan et al., 2003). 
Histidine and tryptophan oxidation is usually mediated by metal-catalysed 
(Fe(II)/Cu(II)) or ROS (H2O2) (Ji et al., 2009). Tryptophan oxidation can result in mass 
increases of 3.995, 15.995 and 31.99 Da, corresponding to the formation of kynurenine, 
hydroxytryptophan, and N-formyl-kynurenine/dihydroxytryptophan (doubly oxidised 
trptophan), respectively (Perdivara et al., 2010; Swiderek et al., 1998). Histidine has an 
imidazole ring and oxidation can lead to degradation products of asparagine, aspartic 
acid and 2-oxo-histidine (Uchida & Kawakishi, 1994). Histidine oxidation is usually 
catalysed with Cu(II) yielding 2-oxo-histidine as the most predominant product (Uchida 
& Kawakishi, 1994; Li et al., 1995) and it is detected with a mass increment of 31.99. 
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5.1.3.2  Deamidation 
Deamidation of asparagine and glutamine residues can generate aspartic acid and 
glutamic acid.  This results in a mass increase of 0.984 Da. Under acidic conditions, 
deamidation of asparagine via direct hydrolysis generates a mixture of isoaspartate and 
aspartic acid in a 1:3 ratio (Capasso & Salvadori, 1999). Similarly, direct hydrolysis of 
the glutamine side chain amide can generate glutamic acid. Under basic or neutral 
conditions, deamidation arises through the formation of a succinimide ring (cyclic 
imide) intermediate, which then hydrolyses forming isoaspartate and aspartic acid. At 
basic or neutral pH, glycine increases the rate of deamidation by providing high local 
backbone flexibility and lack of steric hindrance imposed by its side chain (Bischoff & 
Kolbe, 1994). The rate of the reaction can be increased when alanine, serine and aspartic 
acid are at the C-terminal side of asparagine residue. 
 
5.1.3.3  Pyro-glutamate formation 
Under acidic conditions, N-terminal glutamine residue can cyclise to form 
pyroglutamate, which could make it more resistant to proteolytic hydrolysis and 
degradation (Chelius et al., 2006). 
 
5.1.3.4  Disulphide bond formation 
Disulphide bonds can be formed by the oxidation of highly reactive sulphydryl groups 
(–SH) of cysteine residues. They provide stability to the native correctly folded protein.  
 
In this project MS/MS analysis was applied to peak fractions from analytical RP-HPLC 
purification of proET-1 peptide fragments isolated from EA.hy 926 conditioned 
medium.  
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5.1.4  Identification strategy for proET-1 peptide fragments 
The identification strategy for purified and characterised proET-1 peptide fragments is 
summarised in Figure 5.2. Briefly, identification of ELDP and CT-proET-1 was based 
on fragmentation of tryptic peptides with CID (bottom-up), while NT-proET-1 was 
analysed in its intact form without digestion (top-down). Samples purified using IEC 
and HPLC.  
HPLC fractions containing the highest immunoreactivity for NT-proET-1 were dried 
under vacuum with centrifugal force with SpeedVac and reconstituted in 0.1% TFA and 
analysed using LTQ Orbitrap XL connected online to a nanoflow UPLC with a C4 
column. HPLC fractions containing the highest immunoreactivity for ELDP and CT-
proET-1 were dried using SpeedVac, reconstituted in H2O, digested with trypsin, 
acidified and desalted using Graphitic Carbon C18 spintips. ELDP/CT-proET-1 were 
dried in the SpeedVac and reconstituted in 0.1% TFA and analysed using LTQ Orbitrap 
XL connected online to a nanoflow UPLC with a C18 column.  
Peptides were initially separated on a reverse-phase column and then directly 
electrosprayed into LTQ Orbitrap MS. Elution conditions for nanoflow HPLC involved 
a gradient of CH3CN with 0.1% formic acid (FA). Pilot experiments with synthetic 
peptides showed that ELDP and CT-proET-1 do not elute from either C4 or C18 
nanoflow columns with CH3CN/FA, hence the need for tryptic digestion for MS/MS 
characterisation. 
Raw data obtained from MS/MS was subjected to a database search using MASCOT 
and data analysis provides identification of peptide sequences.  
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Figure 5.2: Workflow of identification strategy for purified and characterised proET-
1 peptides from EA.hy 926 conditioned medium using LTQ Orbitrap mass 
spectrophotometer.   
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5.1.5  Hypothesis and aims 
Main aims of this chapter were to (1) investigate whether the secreted proET-1 peptide 
sequences corresponded with the inferred amino acid sequences derived from the EDN1 
gene sequence; (2) define the reasons for the heterogeneity of elution profiles observed 
on analytical HPLC (Chapter 4); and (3) confirm the presence of disulphide bonds in the 
endothelin-like domain (Cys109 – Cys123 and Cys111 – Cys119) in which the spacing 
between cysteine residues is exactly the same as in ET-1 (Cys53 – Cys67 and Cys55 – 
Cys63) (N.B. Cys numbering based on the full-length ppET-1 sequence). 
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5.2  METHODS 
Synthetic peptides were initially studied to optimise the conditions to ensure efficient 
fragmentation of proET-1 peptide fragments purified from EA.hy conditioned medium 
(serum-free). Identification of purified/native proET-1 peptide fragments was performed 
using LTQ Orbitrap XL MS (Thermo Fisher Scientiﬁc, Hemel Hempstead, UK) coupled 
online to a nanoﬂow ultrahigh pressure liquid chromatography (UPLC, nanoAcquity, 
Waters).  
 
5.2.1  Sample preparation for LTQ Orbitrap XL MS 
5.2.1.1  ProET-1 synthetic standards  
NT-proET-1, ELDP and CT-proET-1 were diluted in 0.1% TFA from stock solutions or 
from HPLC fractions obtained on analytical HPLC of synthetic peptides (NT-proET-1, 
fraction 41; ELDP, fraction 45; and CT-proET-1, fraction 28). A calibration curve 
(concentration range 0.98 – 125 fmol/µl) was prepared from stock solutions of synthetic 
proET-1 peptides. Stock concentrations of synthetic NT-proET-1, ELDP and CT-proET-
1 were 70, 85 and 59 nmol/ml, respectively. An equal volume of sample (20 µl) was 
then transferred into 0.2 ml natural slick-seal tubes (Bioquote) and 4 µl of each sample 
was injected for each analysis. 
 
 
5.2.1.2  HPLC fractions of purified native peptides 
HPLC fractions containing the highest proET-1 immunoreactivity were concentrated 
using centrifugal force (SpeedVac, CHRIST) and stored at -80°C until the day of 
analysis. Prior to analysis, NT-proET-1 fractions (native: 41 and synthetic: 46) were 
reconstituted in 0.1% TFA and diluted at 100 fmol/µl in 0.1% TFA. Of note, the final 
concentration of purified/native NT-proET-1 (fraction 41) after reconstitution with 50 
µl of 0.1% TFA was 89.4 fmol/µl.  
HPLC fractions containing the highest ELDP and CT-proET-1 immunoreactivity were 
digested using trypsin, without reduction or alkylation. 
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5.2.1.3  Trypsin digestion 
1. Lyophilized trypsin (20 µg) (Promega) was prepared at 0.5 µg/µl by 
reconstituting in 40 µl of trypsin resuspension buffer that is composed of 50 
mM acetic acid. Reconstituted enzyme was stored at -80°C. 
2. HPLC fractions of purified proET-1 peptides were reconstituted in H2O. 
Samples were then diluted in 20 mM ammonium bicarbonate buffer, pH 7.8. 
3. Modified sequence-grade trypsin (prepared at 0.5 µg/µl) was added at a final 
trypsin:protein ratio of 1:50 in lo-binding microcentrifuge tubes (Eppendorf, 
Cat# 022431081). The pH of the resulting mixture should be 7.5 – 8.5. 
4. Following a gentle vortex, incubated at 37°C overnight (18 h) on a shaker at 
900 rpm. 
5. Trypsin was inactivated by acidification with TFA to 0.1% of the final digest 
volume, followed by chilling the reaction on ice. 
 
5.2.1.4 Desalting and removal of contaminants from digestion mixtures 
(Reverse-Phase desalting using Graphitic Carbon C18 spintips) 
Trypsin digested samples were desalted and contaminants were removed by Graphitic 
Carbon C18 stationary phase spintips (Glygen Corp, USA). Graphitic Carbon can also 
recover hydrophilic portion of digested fragments. Prior to desalting, samples were 
acidified with 0.1% TFA and desalting was carried out according to the protocol as 
shown in Table 5.1. The flow was obtained by centrifugation for 2 min at 1600 g at the 
end of each step, discarding the flow-through until the elution step. 
Table 5.1: Desalting protocol with Graphitic Carbon C18 spintips. 
Priming 2 x 200 µl of 50% CH3CN/0.1% TFA           
Centrifugation 
2 x 200 µl 1% CH3CN/0.1% TFA  
Centrifugation 
Sample addition 
(200 µl) and 
washing 
200 µl 1% CH3CN/0.1% TFA  
Centrifugation 
100 µl 1% CH3CN/0.1% TFA  
Centrifugation 
Elution 4 x 50 µl 50% CH3CN/0.1% TFA  
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At the end of elution step, samples were centrifuged for 2 min at 13,000 rpm and 
transferred to a fresh lo-bind 2 ml microcentrifuge tube, dried under vacuum at room 
temperature using a rotational vacuum concentrator and stored at -80°C. Dried samples 
were reconstituted in 0.1% TFA prior to analysis with LTQ Orbitrap.  
 
5.2.2  LTQ Orbitrap MS/MS Analysis 
Flow from the nanoacquity UPLC system was directed to a LTQ Orbitrap XL MS 
equipped with a nano-ESI source (positive mode). NT-proET-1 separation was 
performed directly in nanoACQUITY UPLC BEH300 (Ethylene Bridged Hybrid) C4 
reverse-phase column with 1.7 µm particle size, 75 µm x 100 mm in dimensions and 
300 Å pore size (Waters, 186004639) without on-line trapping/desalting. Injection 
volume was set to 4 µl, which was followed by a gradient elution at 300 nl/min over 50 
min. Gradient elution was from 99% A (A = 0.1% FA in LC-MS grade H2O), 5% B (B 
= 0.1% FA in LC-MS grade CH3CN) to 50% CH3CN followed by a 25 min wash with 
H2O. 
Trypsin digested ELDP and CT-proET-1 fragments were loaded onto a trapping 
nanoAcquity UPLCTM column, Symmetry® C18, 5 µm, 180 µm x 20 mm (Waters). The 
nanoflow UPLC loading ﬂow rate was set at 2 µl/min for 8 min, which operated with a 
back pressure of about 3,000 psi and sample elution at a flow rate of 300 nl/min. Peptide 
separation was performed on a nanoAcquity UPLC BEH130 column packed with C18 
resin, 1.7 µm, 100 µm inner diameter x 100 mm (Waters, Part No 186003546) using a 
linear gradient of 1 – 35% in 10 min, followed by an increase to 85% B in 10 min and 
held at 85% B for another 10 min. The gradient was followed by a gradual decrease to 
1% B in 10 min, which was followed by a 25 min H2O wash. 
Full scan survey spectra (m/z 375 – 1800) were acquired by the Orbitrap with a 
resolution of 30,000 at m/z 400. A data dependent analysis was employed in which the 
ﬁve most abundant multiply charged ions present in the survey spectrum were 
automatically mass-selected, fragmented by CID (normalised collision energy 35%) and 
analysed in the LTQ (m/z 50 – 2000). 
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5.2.3  Peptide Identification via MASCOT Database Search 
ProET-1 peptide fragments were identified by an automated database MASCOT 
Daemon (Matrix Science Ltd, London, UK). MASCOT Daemon 2.2 server was used to 
process mass spectrometry raw data. MASCOT Daemon automates the use of MASCOT 
Distiller (v2.3.2.), to smooth and centroid the MS/MS data, and MASCOT search engine 
(v2.2.02), to search for the target protein sequence against all known proteins present in 
mammalian genomes using UniProt database (http://www.uniprot.org). 
The search was performed by using the following parameters: no enzymatic digestion 
for NT-proET-1, and trypsin as the digestion enzyme for ELDP and CT-proET-1. Up to 
two missed cleavages were allowed in all searches. Variable modifications included in 
the search criteria were oxidation of methionine (15.995 Da), Gln->pyro-Glu (N-term 
Q) and deamidation of asparagine and glutamine residues to aspartic acid and glutamic 
acid (0.984 Da). Data sets were searched with a mass accuracy of ± 10 ppm (parts-per-
million), peptide charge +2 +3, –MS/MS tolerance of ± 600 mmu (milli-mass units). 
Ions with single and unrecognized charge states were excluded. 
MASCOT data output includes the identification of peptides (amino acid sequence), 
parent ion m/z, retention time and confidence scores based on the probability (Perkins 
et al., 1999). MASCOT calculates ions score using -10*Log(P), where P is the 
probability that the observed match is a random event.  
Precursor ion tolerance in LTQ Orbitrap was 5 – 20 ppm. Instrument type was ESI FT 
ICR CID (Fourier Transform Ion Cyclotron Resonance). Product ion tolerance in LTQ 
Orbitrap was set at 0.5 – 0.8 Da for ion trap mode and 0.01 – 0.02 Da for Orbitrap mode. 
Monoisotopic masses of the proET-1 peptides were calculated using ProteinProspector 
(http://prospector.ucsf.edu/). The following parameters were selected: MS product → 
maximum charge 8 → instrument ESI FT ICR CID. EDN1 gene (endothelin-1, P05305) 
was identified for the proET-1 peptides. Raw chromatograms were subsequently 
processed and analysed using Xcalibur. 
  
Chapter 5                     Verification of proendothelin-1 sequence identities using mass spectrometry 
  
142 
 
Ion fragments of each trypsin digested ELDP and CT-proET-1 peptides were obtained 
from ProteinProspector. Fragment ions were identified in the MS/MS spectra from Qual 
Browser and labelled manually for the b- and y-ions, confirming MS/MS fragmentation 
from MASCOT. 
In order to ensure correct identification, all samples were run twice on two separate days 
and only peptides that were present in all analyses are shown here.  
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5.3  RESULTS 
The workflow for proET-1 identification strategy is illustrated in Figure 5.2 for the 
proET-1 peptides purified and characterised from EA.hy 926 conditioned medium. In 
addition to the native purified peptides, synthetic standard peptides were added to 
medium samples and subjected to the same extraction and HPLC procedures (Chapter 
4). A calibration curve (concentration range 0.98 – 125 fmol/µl) prepared with each 
proET-1 synthetic standard was used to optimise a methodology to enable identification 
of each purified proET-1 peptide using LTQ Orbitrap MS. 
 
Following MASCOT database search of the MS/MS data, NT-proET-1 amino acid 
sequence was not identified from the native/purified sample (fraction 41) but was 
detected from the NT-proET-1 synthetic standard (fraction 46). Therefore, the identity 
of the native NT-proET-1 could not be confirmed with MS/MS. 
 
Precursor ion masses of trypsin digested ELDP and CT-proET-1 fragments were 
obtained from MASCOT. Initially these m/z values were identified in the extracted ion 
chromatogram (XIC) acquired on a LTQ Orbitrap with their corresponding charges 
(data not shown) and these were manually verified in MS/MS spectra.  
 
 
5.3.1 Peptide sequences of ELDP and CT-proET-1 identified 
using MASCOT 
Peptide identities of ELDP and CT-proET-1 were determined from partial sequences 
obtained from trypsin digestion. Detailed list of ELDP and CT-proET-1 peptide 
sequences are shown in Table 5.2 and Table 5.3, respectively.  
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5.3.1.1  MASCOT identification of purified native ELDP  
Tryptic peptides identified from HPLC fractions 43 and 47 purified (native peptide), and 
45 (synthetic standard) are shown in Table 5.2A – C. These data include residue numbers 
of the tryptic proET-1 fragments, parent ion m/z (monoisotopic), ion score, peptide 
charge and identification. 
The first peptide fragment identified in both fractions was ELRAEDIMEK, where M 
represents an oxidised methionine residue. Methionine oxidation results in a mass 
increment of 15.995 Da. Fraction 47 also contained non-oxidised form of this fragment. 
The N-terminal fragment of the ELDP (ppET-1[93 – 101]) corresponding to ALENLLPTK 
(m/z at 499.7992+) was not detected in either 43 or 47 fractions but was an abundant 
fragment from the synthetic peptide (ion score 63). 
The second peptide fragment identified with two missed-cleavages was 
ELRAEDIMEKDWNNHK. Fraction 43 contained a precursor ion at m/z 681.9993+ and 
511.7444+, corresponding to oxidised methionine and both oxidation of methionine and 
deamidation of asparagine, respectively. Deamidation of asparagine results in a 
monoisotopic mass increment of 0.984 Da. Fraction 47 contained precursor ions at m/z 
676.6573+ (no modification), m/z 681.9903+ (methionine oxidation), and m/z 687.3213+ 
(both methionine and tryptophan oxidation). 
The third peptide fragment identified was AEDIMEK, which had an oxidised 
methionine in fraction 43 and both oxidised and unoxidised forms in fraction 47.  
The fourth peptide fragment identified with a missed-cleavage was 
AEDIMEKDWNNHK. Two precursor ions were detected at m/z 823.3672+ and m/z 
549.2473+. In addition, fractions 47 also contained the native peptide with no PTMs as 
well as a fragment with both oxidation of methionine and histidine. This fragment was 
also detected with an additional missed-cleavage of lysine at the C-terminal. 
The fifth peptide fragment was a precursor ion at m/z 540.2872+ corresponding to 
CIYQQLVR. This fragment is the closest fragment to the C-terminal of the ELDP 
sequence and was identified in both fractions. 
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Table 5.2: MASCOT identification of tryptic peptides from purified native ELDP fractions (A) 43, (B) 47 and synthetic ELDP standard (C) 45. 
Data show start-end residue masses corresponding to the ppET-1 peptide sequence (ELDP; ppET-1 residues 93 – 166), monoisotopic and 
experimental average masses, charge, score and peptide identification. Underlined M and W indicate oxidation of the corresponding methionine 
and tryptophan, respectively. Underlined N indicates deamidation of asparagine. Bold m/z values correspond to peptide ions that were selected 
for MS/MS to provide data for primary structure determination. 
(A) Purified native ELDP, fraction 43: 
ppET-1 Residues 
Start-End 
Observed mass, m/z 
(Da) 
Experimental Mass 
(MWt expt) 
Charge Score Peptide 
128 – 137 625.308 1,248.602 2 44 ELRAEDIMEK 
128 – 143 
681.990 2,042.948 3 26 ELRAEDIMEKDWNNHK 
511.744 2,042.948 4 12 ELRAEDIMEKDWNNHK 
131 – 137 426.195 850.375 2 26 AEDIMEK  
131 – 143 
823.368 1,644.721 2 61 
AEDIMEKDWNNHK 
549.247 1,644.721 3 36 
131 – 144 
887.414 1,772.814 2 43 AEDIMEKDWNNHKK 
591.942 1,772.805 3 26 AEDIMEKDWNNHKK 
597.277 1,788.810 3 35 AEDIMEKDWNNHKK 
155 – 162 540.287 1,078.560 2 49 CIYQQLVR  
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(B) Purified native ELDP, fraction 47: 
ppET-1 Residues 
Start-End 
Observed mass, m/z 
(Da) 
Experimental Mass 
(MWt expt) 
Charge Score Peptide 
128 – 137 
617.310 1,232.605 2 34 ELRAEDIMEK 
625.308 1,248.602 2 50 ELRAEDIMEK 
128 – 143 
676.657 2,026.950 3 47 ELRAEDIMEKDWNNHK 
681.990 2,042.948 3 21 ELRAEDIMEKDWNNHK 
687.321 2,058.942 3 21 ELRAEDIMEKDWNNHK 
131 – 137 
418.197 834.380 2 47 AEDIMEK  
426.194 850.374 2 26 AEDIMEK 
131 – 143 
815.369 1,628.723 2 34 
AEDIMEKDWNNHK 
543.915 1,628.724 3 28 
549.247 1,644.719 3 39 
AEDIMEKDWNNHK 
823.367 1,644.719 2 35 
554.579 1,660.716 2 23 AEDIMEKDWNNHK 
131 – 144 
879.417 1,756.820 2 56 
AEDIMEKDWNNHKK 
586.61 1,756.808 3 50 
887.415 1,756.815 2 46 
AEDIMEKDWNNHKK 
591.943 1,772.808 3 28 
591.945 1,772.814 3 33 AEDIMEKDWNNHKK 
597.606 1,789.795 3 23 AEDIMEKDWNNHKK 
155 – 162 540.287 1,078.559 2 49 CIYQQLVR  
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(C) Synthetic ELDP, fraction 45: 
ppET-1 Residues 
Start-End 
Observed mass, m/z 
(Da) 
Experimental Mass 
(MWt expt) 
Charge Score Peptide 
93 – 101 
499.798 997.582 2 57 ALENLLPTK 
499.798 997.581 2 18 ALENLLPTK 
93 – 105 721.404 1,440.793 2 64 ALENLLPTKATDR 
93 – 108 
920.997 1,839.979 2 24 ALENLLPTKATDRENR 
614.334 1,839.981 3 
128 – 137 
617.311 1,232.607 2 37 ELRAEDIMEK 
625.308 1,248.601 2 35 ELRAEDIMEK 
128 – 143 
1,014.483 2,026.951 2 46 ELRAEDIMEKDWNNHK 
676.658 2,026.952 3 38 
1,022.482 2,042.949 2 60 ELRAEDIMEKDWNNHK 
511.744 2,042.947 4 25 ELRAEDIMEKDWNNHK 
681.990 2,042.947 3 22 ELRAEDIMEKDWNNHK 
687.321 2,058.942 3 24 ELRAEDIMEKDWNNHK 
1,030.478  2,058.941 2 38 ELRAEDIMEKDWNNHK 
131 – 137 426.195 850.375 2 26 AEDIMEK 
131 – 143 
815.370 1,628.724 2 42 AEDIMEKDWNNHK 
543.915 1,628.724 3 38 
823.367 1,644.720 2 62 AEDIMEKDWNNHK 
549.247 1,644.720 3 37 
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Table 5.2 continued; (C) Synthetic ELDP, fraction 45: 
ppET-1 Residues 
Start-End 
Observed mass, m/z 
(Da) 
Experimental Mass 
(MWt expt) 
Charge Score Peptide 
131 – 143 
554.580 1,660.717 2 33 AEDIMEKDWNNHK 
549.575  1,645.703 2 27 AEDIMEKDWNNHK 
831.364  1,660.714 2 74 AEDIMEKDWNNHK 
131 – 144 
879.417 1,756.820 2 68 AEDIMEKDWNNHKK 
586.614 1,756.820 3 80 
887.415 1,756.815 2 46 AEDIMEKDWNNHKK 
591.943 1,772.806 2 25 
887.415  1,772.815 2 41 AEDIMEKDWNNHKK 
591.945 1,772.814 3 33 AEDIMEKDWNNHKK 
591.945 1,772.813 3 25 AEDIMEKDWNNHKK 
895.412 1,788.810 2 50 AEDIMEKDWNNHKK 
597.278  1,788.811 3 40 
879.910 1,757.805 2 35 AEDIMEKDWNNHKK 
597.606 1,789.795 3 23 AEDIMEKDWNNHKK 
151 – 162 483.618 1,447.833 3 27 LGKKCIYQQLVR 
154 – 162 
575.820 1,149.625 2 25 KCIYQQLVR 
576.314 1,150.614 2 17 KCIYQQLVR 
155 – 162 540.286 1,078.557 2 44 CIYQQLVR  
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5.3.1.2  MASCOT identification of purified native CT-proET-1  
MASCOT identification of CT-proET-1 was only confirmed from HPLC fraction 28. 
Identified tryptic peptides are shown in Table 5.3. No peptide fragments corresponding 
to EDN1 were detected in fraction 29. A precursor ion at m/z 395.2032+, corresponding 
to YVTHNR (ppET-1[204 – 209]) was detected in fraction 31 (P = 0.006). However, 
following an error tolerant search (Creasy & Cottrell, 2002), SSFHDPKLKGKPSRER 
(m/z 625.6743+) containing 4 missed-cleavages was also identified in both fractions 29 
and 31 on re-analysis.  
The first tryptic fragment identified in fraction 28 was SSEEHLRQTRSETMR (m/z 
461.7354+). The ion score assigned by MASCOT was low and therefore the 
identification was not statistically significant. This peptide was also identified in the 
fraction 28 for the synthetic peptide with a low ion score that was insufficient for peptide 
identification (Table 5.3B). However, detection of a smaller fragment, SSEEHLRQTR 
(m/z 414.8783+) with a higher ion score supported the identification of this sequence in 
the synthetic peptide. This sequence corresponds to the proposed N-terminal sequence 
of CT-proET-1. 
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Table 5.3: MASCOT identification of CT-proET-1 tryptic peptides from (A) purified native peptide (fraction 28) and (B) synthetic peptide 
(fraction 28_std). Data shows start-end residue masses corresponding to the ppET-1 peptide sequence (CT-proET-1; ppET-1 residues 169 – 212), 
monoisotopic and experimental average mass, charge, score and peptide identification. Underlined M indicates oxidation of the corresponding 
methionine. Bold m/z values correspond to peptide ions that were selected for MS/MS to provide data for primary structure determination. 
(A) Purified native CT-proET-1, fraction 28 
ppET-1 Residues 
Start-End 
Observed mass, m/z 
(Da) 
Experimental Mass 
(MWt expt) 
Charge Score Peptide 
169 – 183 461.735 1,842.911 4 2 SSEEHLRQTRSETMR 
179 – 187 534.261 1,066.508 2 23 SETMRNSVK 
184 – 196 496.273 1,485.796 3 20 NSVKSSFHDPKLK 
188 – 196 529.786 1,057.557 2 30 SSFHDPKLK 
188 – 201 
528.627 1,582.86 3 60 SSFHDPKLKGKPSR 
396.722 788.393 2 20 SSFHDPKLKGKPSR 
204 – 209 395.204 788.393 2 12 YVTHNR 
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(B) Synthetic CT-proET-1, fraction 28_std  
ppET-1 Residues 
Start-End 
Observed mass, m/z 
(Da) 
Experimental Mass 
(MWt expt) 
Charge Score Peptide 
169 – 178 
 
414.878 1,241.611 3 14 SSEEHLRQTR 
414.878 1,241.611 3 16 SSEEHLRQTR 
169 – 183 616.627 1,846.860 3 7 SSEEHLRQTRSETMR 
176 – 183 496.235 990.455 2 42 QTRSETMR 
179 – 187 526.755 1,051.495 2 16 SETMRNSVK 
184 – 196 743.904 1,485.794 2 25 NSVKSSFHDPKLK 
188 – 194 409.196 816.378 2 23 SSFHDPK 
204 – 209 395.204 788.393 2 12 YVTHNR 
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5.3.2 Verification of ELDP and CT-proET-1 peptide identities 
from the MS/MS spectra 
Both C-terminal (y-ions) and N-terminal (b-ions) fragment ions were obtained from 
MASCOT and y-ions were manually labelled in the MS/MS spectra along with their 
corresponding amino acid residues. This provided amino acid composition, confirming 
the identification of the corresponding peptide sequences with their assigned PTM(s).  
 
5.3.2.1  Evaluation of the MS/MS spectra for purified native ELDP  
  (fraction 43): 
Figure 5.3 illustrates three low-energy CID MS/MS spectra for precursor ions at m/z (A) 
625.3082+, (B) 887.4142+, and (C) 540.2872+, corresponding to ELRAEDIMEK, 
AEDIMEKDWNNHKK and CIYQQLVR, respectively. 
The first tryptic peptide corresponded to ELRAEDIMEK (ppET-1 residues 128 – 137) 
consisted of an oxidised methionine. This was illustrated with a y3 ion at m/z 359.193 
(KEM) (Figure 5.3A). It was 63.998 Da lower than the unmodified methionine residue. 
This was corresponding to a neutral loss of methane-sulphenic acid (CH3SOH) from the 
side chain of methionine sulphoxide. In the spectrum, y2-H2O (m/z 258.144), b6-H2O 
(m/z 696.331), and b7-H2O (m/z 809.415) ions had a neutral loss of H2O (-18 Da) while 
y9-NH3 (m/z 1,039.542) had a neutral loss of NH3 (-17 Da).  To note, there were also a 
few unassigned peaks at m/z 529.024, 584.365, 593.522, and these are likely to belong 
to contaminating peptides. 
The MS/MS spectrum of AEDIMEKDWNNHKK (Figure 5.3B) had a dominance of y-
ions with almost full identification of the amino acid residues in the peptide sequence. 
This spectrum also contained unknown abundant peaks whose identity could not be 
confirmed by manual inspection of the MS/MS spectrum. 
Figure 5.3C shows the MS/MS spectrum of CIYQQLVR, which represents sequence 
closest to the C-terminal of ELDP peptide that could be identified after tryptic digestion. 
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ELDP (ppET-1[128 – 137]): ELRAEDIMEK
C-Term     K E M I D E A R L E      N-Term
ELDP (ppET-1[131 – 143]): AEDIMEKDWNNHKK
C-Term    K K H N N W D K E M I D E A N-Term
(A)
(B)
m/z= 887.4142+
m/z= 625.3082+
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Figure 5.3: MS/MS spectra of purified/native ELDP (fraction 43) precursor ions at 
m/z (A) 625.308
2+
, (B) 887.414
2+ 
and (C) 540.287
2+
. MS/MS spectra were manually 
annotated for C-terminal fragment ions (y-) and N-terminal fragment ions (b-) 
confirming the sequence identities of the precursor ions obtained from MASCOT. The 
mass differences between the y-ion series indicate amino acid residues of the 
corresponding fragment ions, which are shown above the spectrum. Annotations of –
NH
3
 or H
2
O at b- and y-ions represent a loss of ammonia or water at the corresponding 
fragment ions with a loss of 17 and 18 Da, respectively. 
 
  
ELDP (ppET-1[155 – 162]): CIYQQLVR
C-Term     R V L Q Q Y I C     N-Term
m/z= 540.2872+
(C)
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5.3.2.2 Evaluation of the MS/MS spectra for purified native CT-proET-1 
(fraction 28): 
Figure 5.4 illustrates four MS/MS spectra (A – D) showing precursor ions at m/z (A) 
461.7354+, (B) 534.2612+, (C) 528.6273+ and (D) 395.2042+. The MS/MS spectrum 
shown in Figure 5.4A corresponds to the N-terminal sequence of CT-proET-1, 
SSEEHLRQTRSETMR with 2 missed-cleavages. The spectrum contained highly 
abundant background ions, resulting in a low signal-to-noise ratio. Of note, the quality 
of the spectrum was poor and the ion score obtained from MASCOT was not significant. 
However, despite the poor quality spectrum, isomeric leucine was identified (m/z 
113.084) correctly. The identification of the peptide accounted mostly doubly charged 
y-ions. These were y12-MH2
2+ (EHLRQTRSETMR), y10-MH2
2+
, y9-MH2
2+
, and y8-
MH2
2+. From the N-terminal fragment ions, only b2 ion corresponding to serine (m/z 
175.071) was detected. However, this ion could also be y1 ion corresponding to arginine 
(m/z 175.119). 
This fragment was also found in CT-proET-1 synthetic standard with a precursor ion at 
m/z 616.6272+ containing a deamidated glutamine residue (see Table 5.3B). The signal 
intensity was low resulting in a low ion score. Moreover, there were two shorter peptides 
SSEEHLRQTR (m/z 414.8783+) with deamidation of glutamine and QTRSETMR (m/z 
496.2352+) with the N-terminal glutamine converted to pyro-glutamic acid. These 
fragments had better ion scores than the longer peptide. However, neither of these were 
detected in the sample of purified native peptide. 
Figure 5.4B shows the MS/MS spectrum of a precursor ion at m/z 534.2612+, 
corresponding to SETMRNSVK with an oxidised methionine residue. There was a 
neutral loss of 64 Da (HSOCH3) from MetS. Although the peak at m/z 502.406 was 
unassigned, it may represent the neutral loss of 64 Da (32 m/z difference x 2 charges). 
Figure 5.4C shows the MS/MS spectrum of a precursor ion at m/z 528.6273+, which 
corresponded to SSFHDPKLKGKPSR. 
 Figure 5.4D shows the MS/MS spectrum of a precursor ion at m/z 395.2042+. Although 
none of the b-ions were detected in this spectrum dominated C-terminal ions generated 
a high quality spectrum with full identification of the peptide sequence corresponding to 
YVTHNR. The most abundant peak generated for y4 ion at m/z 527.269 corresponded 
to RNHT.  
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CT-proET-1(ppET-1[169 – 183]):SSEEHLRQTRSETMR
C-Term     R M T E S R T Q R L H E E S S N-Term
(A)
(B)
CT-proET-1(ppET-1[179 – 187]): SETMRNSVK
C-Term     K V  S  N R  M T  E  S     N-Term
m/z= 461.7354+
m/z= 534.2612+  
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Figure 5.4: MS/MS spectra of purified/native CT-proET-1 (fraction 28) precursor ions 
at m/z (A) 461.735
4+
, (B) 534.261
2+
, (C) 528.627
3+
 and (D) 395.204
2+
. MS/MS spectra 
were manually annotated for C-terminal fragment ions (y-) and N-terminal fragment 
ions (b-) confirming the sequence identities of the precursor ions obtained from 
MASCOT. The mass differences between the y-ion series indicate amino acid residues 
of the corresponding fragment ions, which are shown above the spectrum. Annotations 
of –NH
3
 or H
2
O at b- and y-ions represent a loss of ammonia or water at the 
corresponding fragment ions with a loss of 17 and 18 Da, respectively.  
CT-proET-1 (ppET-1[204 – 209]): YVTHNR
C-Term     R  N  H  T  V  Y     N-Term
(D)
m/z= 395.2042+
CT-proET-1(ppET-1[188 – 201]): SSFHDPKLKGKPSR
C-Term     R  S P  K G  K L  K  P  D  H  F  S  S N-Term
(C)
m/z= 528.6273+
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5.4  DISCUSSION 
The aim of this chapter was to verify the identities of the purified native proET-1 
peptides that were initially characterised using a combination of IEC, HPLC and 
immunoassay (Chapter 4). Here, a mass spectrometric approach was pursued with an 
initial series of experiments using synthetic peptide standards for optimisation of the 
methodology. Native proET-1 peptides purified from EA.hy 926 conditioned medium 
were analysed according to the methodology as shown in Figure 5.2. 
 
The identity of the undigested native purified NT-proET-1 peptide (fraction 41) was not 
confirmed using mass spectrometry. Nevertheless, the same methodology identified this 
EDN1 derived peptide from fraction 46, which represented the synthetic standard in 
medium and in the calibration curve prepared with NT-proET-1 synthetic standard. All 
samples were run with the same analysis parameters, suggesting that the problem was 
related to the purified sample itself rather than being associated with the methodology. 
The main limitation for identification of NT-proET-1 was insufficient peptide, so that 
the levels were below the detection limit of the method. This is likely the result of: (1) 
low levels of NT-proET-1 in the EA.hy 926 conditioned medium; (2) poor recovery 
following IEC; (3) degradation during sample concentration. Both HPLC fractions were 
dried overnight under vacuum with centrifugal force with SpeedVac (at room 
temperature), and stored at -80°C until the day of proteomic analysis.  Degradation 
further reduces peptide levels and this is likely to contribute to poor recovery and 
identification of NT-proET-1 peptide. The fact that fraction 46 was dried in the same 
way, similar rate of peptide loss was expected from the native/purified sample. 
However, the final concentration of the native NT-proET-1 following reconstitution in 
0.1% TFA was 132-fold less than the synthetic standard; 89 and 11,774 fmol/µl, 
respectively. This may result in differences in the rate of recovery. Thus, the resulting 
peptide concentration may not be sufficient or may be lower than the detection limit 
(<62.5 fmol/µl). In contrast, fraction 46 could be degraded to a lesser extent, in which 
the final levels were still sufficient for its identification.  
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Analysis of full-length ELDP and CT-proET-1 with an analytical UPLC BEH130 C18 
column (1.7 µm, 100 µm x 100 mm) produced poor ionisation and fragmentation. Due 
to longer amino acid sequences and hydrophobicity, elution from the analytical column 
was not sufficient for analysis. In principle, this directly affects the number of peptides 
being subjected to ESI, which then directs ions into the LTQ before being sent to the 
Orbitrap for mass analysis (Schwartz et al., 2002).  
The first step for ELDP and CT-proET-1 identification involved trypsin digestion. This 
was followed by desalting prior to MS analysis. Buffers containing salts compromise 
ESI-MS performance leading to ion suppression. Following solvent exchange and 
concentration, samples were analysed using LTQ Orbitrap coupled online to a nanoﬂow 
UPLC equipped with a C18 column. Peptide sequences of ELDP and CT-proET-1 were 
manually verified from the MS/MS spectra (Figures 5.3 and 5.4). The relative abundance 
of fragment ions was normalised according to the most abundant fragment ion in the 
same MS/MS spectrum. Co-elution of contaminating or unknown fragment ions can 
result in ion suppression, and this reduces the intensity of fragment ions. This presents 
difficulties for detection of low abundance peptides particularly those closer to the 
signal-to-noise ratio. The presence of an intense contaminating fragment ion was an 
associated limitation for identification of less abundant proET-1 fragment ions (Figures 
5.3A and 5.4B).  
The N-terminal fragment of synthetic ELDP corresponded to ALENLLPTK (ppET-1[93 
– 101]). This fragment was only identified in the synthetic standard (fraction 45) (Table 
5.2C) but not in the native peptide samples (fractions 43 and 47). Comparison of the 
XICs between the synthetic and the native peptide samples failed to identify a precursor 
ion at m/z 499.7982+, which corresponded to ALENLLPTK (data not shown). Moreover, 
the intensity of the purified/native samples was very low for this precursor ion 
suggesting that the peptide is either not sufficiently abundant for detection or not present. 
However, because the purification procedure for ELDP (and CT-proET-1) focussed on 
recovery of peptides with high pI, it is likely that contaminating peptides would be rich 
in lysine and arginine. Hence, such contaminants would have competed as substrates for 
trypsin or potentially acted as trypsin inhibitors. This could affect digestion efficiency, 
resulting in longer peptides and these may not have been recovered from the trapping 
column.  
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ELDP contains an evolutionary conserved endothelin-like domain (ppET-1[109 – 123]). 
Importantly, the positioning of the first four cysteine residues was exactly the same as 
in ET-1 (see Tables 1.1 and 1.6). Based on this similarity, disulphide bonds have been 
proposed to be formed between ppET-1 residues 109 – 123 and 111 – 119 
[C109QC111ASQKDKKC119WNFC123QAGK] without supporting experimental 
evidence (Uniport). Correct disulphide linkages are likely important for correct folding 
and structural stability (Zhang et al., 2011). Therefore, a biological function associated 
with this peptide is likely to be preserved with correct folding. Thus, it was particularly 
important to show whether purified/native ELDP samples were forming these two intra-
linked disulphide bonds as expected. In addition, ELDP consists of two more cysteine 
residues in its C-terminal end that were also likely to form disulphide bridges between 
Cys148 – Cys155. In order to confirm the presence of disulphide bonds, ELDP analysis 
was carried out under non-denaturing conditions keeping cysteine residues intact. 
However, MASCOT database was unable to identify a tryptic peptide belonging to this 
region, either from the purified/native or the synthetic ELDP sample. In order to ensure 
that a peptide belonging to this region was absent from the MS/MS spectra, precursor 
ion masses (calculated from ProteinProspector) of both the full-length fragment 
containing non-cleaved DKK residues (CQCASQKDKKCWNFCQAGK) and the 
fragment with cleaved DKK residues (CQCASQK−−−CWNFCQAGK) were searched 
from the XICs. Searching further precursor ion masses with missed-cleavages (e.g. 
ENRCQCASQKDKKCWNFCQAGK, ENRCQCASQK−−−CWNFCQAGK, and 
ENRCQCASQK−−KCWNFCQAGK) and considering possible amino acid 
modifications such as deamidation of an asparagine (N) and glutamine (Q) residues, 
both individually and in combination failed to detect potential peptides. However, none 
of the calculated masses were detected for the purified native sample of ELDP or the 
synthetic peptide standard. In part, this might be explained by (i) inaccessibility of 
trypsin into the core of ELDP for cleavage; (ii) insufficient recovery of the resulting 
peptide from the separation column; or (iii) the presence of unexpected modifications. 
Moreover, it is well known that cysteine residues yield limited fragmentation and 
disulphide bonds are generally resistant to cleavage by low collision energies using CID 
fragmentation (Loo et al., 1990).  Furthermore, MASCOT and Sequest rely on 
fragmentation efficiency of peptides and this limits identification of peptides with 
disulphide bridges under non-denaturing conditions. Possibly, these factors are likely to 
contribute to the inability to identify this region of the ELDP peptide sequence. On the 
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other hand, synthetic ELDP was shown to naturally form three disulphide bonds on 
refolding at pH 8 (MWt 8,636.32 compared to 8,642.37 for unfolded peptide in which 
the mass difference of 6.05 Da represents loss of six hydrogens).  
In support of the identification of ELDP sequence, the processing is likely to occur at 
the Lys-Arg and Arg-Arg at ppET-1 positions 91/92 and 167/168, respectively. 
Although ELDP sequence has four other processing sites, these were unlikely to yield a 
cleaved peptide. Cleavage at these other dibasic processing sites (Lys-Lys and Arg-Lys) 
occurs less frequently. In addition, the specificity of the PCs to cleave at these dibasic 
processing sites can be influenced by the conformation and the characteristics of the 
amino acid residue adjacent to the dibasic processing site (e.g. cleavage is less likely to 
occur if the next residue is proline). Secondary and tertiary structures influence 
accessibility of the PCs for cleavave. For example, cleavage is less likely to occur if the 
dibasic processing site is within a disulphide bond, making the site inaccessible by the 
proteolytic enzyme. This is likely to be the case for ppET-1 residues 127/128 (Lys-Lys) 
and 153/154 (Lys-Lys).  
All peptide fragments with a methionine residue were oxidised to methionine sulphoxide 
(MetSO), resulting in a mass increment of 16 Da. Methionine oxidation can display a 
neutral loss of 64 Da, corresponding to methane-sulphenic acid (CH3SOH). The MS/MS 
spectrum of a precursor ion at m/z 625.3082+ (ELRAEDIMEK) (Figure 5.3A) and other 
ions at m/z 625.3082+, 681.9903+, 823.3682+, 549.2473+ and 887.4142+ (data not shown) 
all displayed this characteristic loss. Although oxidation of methionine is among the 
most common PTM, it could also be a potential by-product resulting from the 
purification/digestion and/or storage conditions. Oxidation to MetSO, 2-oxo-histidine, 
and hydroxytryptophan usually occur as a result of sample handling following protein 
separation (Perdivara et al., 2010). MASCOT results have shown more PTMs to be 
associated with fraction 43, in comparison to fraction 47. This was in agreement with 
previous HPLC elution profiles in which fraction 43 was eluted earlier that fraction 47 
(Chapter 4, Figure 4.3). Oxidation can alter folding and structural stability of a protein 
(Torchinsky, 1981). In addition, deamidation of asparagine or glutamine may change 
the conformation by transforming a neutral amide side chain to a negatively 
charged carboxylic acid (-NH2→-CO). Oxidised peptide becomes more polar 
(hydrophilic) than the unoxidised peptide and as a result elutes earlier. Similarly, 
deamidated peptide elutes earlier than the unmodified peptide.  
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CT-proET-1 peptide sequence was confirmed by detection of both the N-terminal and 
C-terminal fragment ions corresponding to SSEEHLRQTRSETMR (ppET-1[169 – 183]) 
and YVTHNR (ppET-1[204 – 209]), respectively (see Figure 5.4). The identification of 
native CT-proET-1 was only confirmed from fraction 28 without identification of an 
EDN1 peptide from fractions 29 and 31. On the day of analysis, final concentration of 
CT-proET-1 fractions 28, 29 and 31 (51.9, 60.3, and 43.3 fmol/µl, respectively) were 
~2-fold less than the optimal sample concentration (100 fmol/µl), and this as a result can 
limit the identification of less abundant fragments ions.  
The MS/MS spectrum for SSEEHLRQTRSETMR had poor resolution for both the 
synthetic and native CT-proET-1 samples (Figure 5.4A). This could result from: (1) 
inefficient ionisation of the adjacent serine and acidic glutamine residues. In particular, 
non-volatile materials (e.g. endogenous metabolites) and molecules with a higher mass 
(Annesley, 2003) contribute to ion suppression. More polar samples are also more 
sensitive to ion suppression (Bonfiglio et al., 1999). (2) Poor recovery following 
desalting. (3) Inefficient elution from the separation column. The theoretical pI of this 
peptide was calculated as 6.5. The analytical column is packed with silica particles, 
which are stable under acidic conditions. Yet, the acidic peptide may not be eluted 
effectively under acidic conditions. (4) Low ion scores from MASCOT could simply 
suggest low abundance. Moreover, considering low ion scores and poor quality spectra, 
the difference between the experimental (1,842.911) and the calculated mass 
(1,842.923) was -0.118 Da, and the determined sequence was within a -6.43 ppm 
precision.  
In summary, accessibility of peptides to trypsin for proteolytic cleavage, solubility and 
ionisation efficiency (nebulisation) of the tryptic digest combine to influence peptide 
fragmentation and detection using mass spectrometry. Differences in these factors may 
produce different signal intensities and affect the quality of an MS/MS spectrum. The 
results showed close agreement with experimental and calculated MWts showing correct 
identification of proET-1 peptide fragments. 
In conclusion, these data confirm that the peptides ELDP and CT-proET-1 identified by 
sandwich immunoassay and purified from conditioned medium of EA.hy 926 cells are 
authentic proET-1 fragments. For CT-proET-1 (ppET-1[169 – 212]) the MS data fully 
confirm for the first time the identity of this peptide. For the novel proET-1 derived 
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peptide ELDP (ppET-1[169 – 212]), the MS data in combination with immunoassay results, 
and elution profile on HPLC relative to synthetic peptide standard all provide evidence 
of the correct identification of this peptide. But key structural features such as the 
disulphide bonds of the endothelin-like domain sequence could not be confirmed. For 
NT-proET-1 isolation of further peptide is required to confirm the sequence of this 
peptide and to determine the reasons underlying the differences in HPLC elution 
characteristics of the purified native peptide and the synthetic standard. 
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CHAPTER 6 
Evaluation of ELDP and CT-proET-1 as biomarkers of 
cardiovascular and renal disease 
 
Chapter 6   ELDP and CT-proET-1 as biomarkers of cardiovascular and renal disease   
165 
 
6.1  INTRODUCTION  
6.1.1  Metabolism and clearance of ET-1 
ET-1 has a short circulating half-life (30 – 60 s) (Gasic et al., 1992; Corder & Vane, 
1994). Rapid clearance and low circulating levels of ET-1 results from a combination of 
factors: (i) most ET-1 is released abluminally (Wagner et al., 1992) and then acts in a 
paracrine or autocrine manner on endothelial and smooth muscle cells; (ii) binding to 
ETB receptors that are primarily located in the pulmonary vascular endothelium accounts 
for the majority (53%) of clearance (Wagner et al., 1992; Dupuis et al., 1996b), but also 
contributing to clearance from the kidney; and (iii) degradation by NEP-24.11 (Abassi 
et al., 1992; Vijayaraghavan et al., 1990; D'Orléans-Juste et al., 2003). Therefore, 
measuring plasma concentrations may not correctly reflect ET-1 biosynthesis as this 
mainly reflects the spillover of total synthesis (Dupuis et al., 1996). There is a well-
coordinated regulation between biosynthesis and clearance. 
 
6.1.2 Physiological role of ET-1 in cardiovascular and renal 
function 
Physiological actions of ET-1 are mediated by activation of ET receptors, ETA and ETB. 
ETA receptors predominate on the underlying VSMC throughout the cardiovascular 
system and mediate vasoconstriction. ETB receptors are less abundant (15%) also 
mediate vasoconstriction (Davenport & Maguire, 1994; Haynes et al., 1995). In contrast, 
in the renal system, ETB receptors predominate and mediate vasodilatation, natriuresis 
and diuresis (Davenport & Maguire, 2006).  
Endothelial cell-specific deletion of ETB results in impaired clearance of exogenous ET-
1 however, without increasing blood pressure (BP) (Bagnall et al., 2006).  In contrast, 
inner medullary collecting duct (IMCD) specific deletion of ETB results in salt-sensitive 
hypertension without altering the clearance of ET-1 (Bagnall et al., 2006; Ge et al., 
2006). Therefore, these results suggested that while endothelial ETB receptors mainly 
contribute to clearance, IMCD ETB receptors mediate natriuretic action of ET-1. Some 
studies that defined the role of ET-1 for the maintenance of vascular tone and BP are 
briefly explained in the next section. 
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6.1.2.1  Effects of ET-1 in the regulation of basal vascular tone  
In healthy man, brachial artery infusion of ET-1 produces concentration-dependent 
vasoconstrictor and pressor responses. After infusion, an initial transient vasodilatation 
[indicated by increased forearm blood flow (FBF)] was followed by a slowly developing 
but sustained vasoconstriction that lasted for 2 h (Clarke et al., 1989; Kiowski et al., 
1991). In general, while selective ETA (BQ-123) or ETA/B receptor (TAK-044) 
antagonism resulted in vasodilatation (minimal) and reduced BP (Haynes, 1995; Haynes 
et al., 1996; Schmetter et al., 1998; Hand et al., 1999; Verhaar et al., 1998), selective 
ETB receptor antagonism caused vasoconstriction (Spratt et al., 2001). This suggested 
that endogenous ET-1 contributes to basal vascular tone by mediating vasoconstriction 
through ETA receptor activation and that selective ETA receptor antagonists could have 
superior therapeutic benefits.  
 
6.1.2.2  Effects of ET-1 in renal physiology and haemodynamics 
ET-1 is synthesised by most renal cell types. In pig, the synthesis of ET-1 was shown to 
be higher in the IMCD than any other organ (Kitamura et al., 1989). Renal vasculature 
is also more sensitive to ET-1 than other vascular beds (Pernow et al., 1989).  
Exogenous ET-1 at low concentrations reduced renal plasma flow (RPF) and Na+ 
excretion without having an effect on BP. At higher concentrations, ET-1 reduced 
glomerular filtration rate (GFR) and increased renal vascular resistance (Weitzberg et 
al., 1991) (Table 6.1). Physiological actions of ET-1 (at low and high doses) differed 
depending on the experimental model, receptor localisation, and relative subtype 
abundance. Selective ETA antagonism (BQ-123) in chronic kidney disease (CKD)  
patients increased renal blood flow (RBF), reduced BP and effective filtration fraction 
(FF) suggesting ETA mediated preferential efferent arteriolar constriction without 
changing GFR (Goddard et al., 2004). Selective ETB receptor antagonism (BQ-788) 
caused renal vasoconstriction both in chronic renal failure and in healthy controls 
(Goddard et al., 2004). The physiological role of ET-1 and its receptors in renal system 
were defined by specific knockout (KO) studies and some of these results are 
summarised in Table 6.2.   
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Table 6.1: Haemodynamic effects of exogenous ET-1 in healthy man. BP = blood 
pressure, GFR = glomerular filtration rate, FBF = forearm blood flow, FF = filtration 
fraction, RBF = renal blood flow, RPF = renal plasma flow, HR = heart rate, CO = 
cardiac output, MAP = mean arterial blood pressure. 
Doses of 
exogenous ET-1 
administered in 
the forearm of 
healthy man 
Effects of ET-1 Reference(s) 
<1 pmol/kg/min 
● Decreased Na+ excretion by 36%, 
without having an effect on systemic 
or renal haemodynamics. 
Rabelink et al., 1994 
 
2.5 pmol/kg/min 
● Balanced GFR, thus relatively 
constant FF.  
● Increased RBF and induced 
natriuresis and diuresis by inhibiting 
apical Na+ and water reabsorption. 
Kaasjager et al., 1995 
 
1.5 and 3 
pmol/kg/min 
● Decreased HR and CO, increased 
systemic vascular resistance and 
impaired left and right ventricular 
diastolic filling.  
Kiely et al., 1997 
 
 
≤4 pmol/kg/min ● Reduced FBF and increased MAP. Haynes & Webb, 1998 
4 pmol/kg/min 
● Reduced RPF and GFR and 
increase renal vascular resistance. 
● Increased glomerular capillary 
pressure and MAP. 
● Reduced FF. 
● Reduced urinary Na+ and water 
excretion (urine volume). 
Weitzberg et al., 1991 
Vuurmans et al., 2004 
Sørensen et al., 1994  
Rabelink et al., 1994 
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Table 6.2: Physiological role of ET-1 in the regulation of blood pressure and renal function: A perspective from collecting duct (CD) 
specific knockouts (KO) of ET-1, ETA and ETB receptors. 
Model of study Effects of ET-1 and ETA/ETB receptors Reference(s) 
CD ET-1 KO 
mice 
● Salt-sensitive hypertension in which high salt diet further increased BP.  
● Amiloride, which is a direct inhibitor of epithelial Na+ channel (ENaC), partly restored 
BP. This indicated that Na+ epithelial channel is involved in regulation of Na+ excretion. 
● Impaired ability to excrete Na+ and acute water load. Increased arginine vasopressin 
(AVP)-induced cAMP accumulation. 
Ahn et al., 2004 
Kurihara et al., 1994 
Kisanuki et al., 2010 
Ge et al., 2005a 
CD ETA KO 
mice 
● Normal BP and urinary Na+ excretion even after a high salt diet. 
● Reduced water reabsorption associated with lower AVP-stimulated IMCD cAMP 
accumulation. Increased diuresis after water load. 
Ge et al., 2005b 
Tomita et al., 1993 
CD ETB KO rats ● Salt-sensitive hypertension that is partly restored with amiloride. ETB was suggested to 
regulate Na+ excretion at the epithelial Na+ channel in CD cells.  
● Increase in BP was smaller (50%) in comparison to CD ET-1 KO and combined ETA/B 
KO. 
Gariepy et al., 2000 
Webb et al., 1998 
Ge et al., 2006; 2008 
Schneider et al., 2008 
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6.1.3 ELDP and CT-proET-1 as biomarkers of vascular and 
renal disease  
6.1.3.1  Chronic heart failure 
Plasma levels of ET-1 are elevated in patients with heart failure (HF) (Stewart et al., 
1992; Rodeheffer  et al., 1992; McMurray et al., 1992) and in experimental models (e.g. 
dogs) (Motte et al., 2003) through increased ET-1 synthesis by cardiomyocytes, vascular 
endothelial cells and cardiac fibroblasts (Porter & Turner, 2009). Plasma levels of ET-1 
directly correlate with pulmonary artery pressure (Moraes et al., 2000). ET-1 expression 
is increased in lung tissue and in the circulation of patients with pulmonary artery 
hypertension (PAH) (Giaid et al., 1993; Bauer et al., 2002). In contrast, hypertensive 
patients had lower ET-1 levels with the exception of black Africans (Ergul et al., 1996). 
 
6.1.3.2  Chronic kidney disease 
Renal ET-1 production is upregulated in CKD (Orisio et al., 1993). Increased plasma 
(Goddard et al., 2007) and urinary (Dhaun et al., 2009) ET-1 levels correlate with 
declining renal function measured as estimated GFR (eGFR). Moreover, urinary ET-1 
excretion is independent of plasma ET-1 concentrations (Serneri et al., 1995). It is 
mainly derived from renal tubular secretion and reflects renal ET-1 production (Benigni 
et al., 1991). Thus, urinary ET-1 excretion was suggested as a potential biomarker for 
renal disease (Ohta et al., 1991).  
CKD is strongly associated with increased cardiovascular disease risk (Go et al., 2004). 
According to the National Kidney Foundation (USA), classification of CKD is based on 
albumin-creatinine ratio in spot urine and eGFR from serum creatinine measurements 
(National Kidney Foundation, 2002).  
Proteinuria is a risk factor associated with progression of renal disease (Lea et al., 2005) 
and reported as a marker of renal failure in CKD (Dhaun et al., 2011).  Increased ET-1 
production in CKD contributes to excessive protein filtration (increased protein 
excretion) through its haemodynamic effects leading to increased glomerular capillary 
pressure via ETA mediated renoconstriction of efferent arterioles (Barton, 2008) and 
glomerular permeability (Saleh et al., 2010).  
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6.1.4  Hypothesis and aims 
Despite strong evidence that ET-1 is involved in cardiovascular and renal disease 
pathology, plasma measurements of ET-1 have a number of limitations (described in 
section 6.1.1) and have yielded inconsistent findings (Schiffrin et al., 1997; Goddard & 
Webb, 2000). Early identification of these diseases still remains a challenge. Hence, 
stable fragments of proET-1 synthesis may have greater utility over current markers for 
earlier diagnosis, assessing disease progression and treatment outcomes, and may 
provide a non-invasive measure of cardiovascular function that directly reflects BP or 
cardiac changes. Therefore, the aim of this chapter was to (i) identify stable proET-1 
peptide fragment(s) as alternative markers of ET-1 synthesis and (ii) test their potential 
as markers of cardiovascular and renal diseases. Accordingly, to test this hypothesis, 
initially clearance rates in rats, and the stability of proET-1 peptides were evaluated. 
Their usefulness as biomarkers of cardiovascular and renal disease was then assessed 
using samples collected in four studies:  
Study 1: The effects of TNF-α infusion on proET-1 levels in healthy man. 
Study 2: ProET-1 levels in mild/pre-hypertension and in chronic HF. 
Study 3: ProET-1 levels in CKD. 
Study 4: The effects of sitaxentan on plasma concentrations of proET-1 
peptides. Assess correlation of proET-1 peptide levels with functional 
parameters that were previously reported in Dhaun et al., 2011, 2013. 
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6.2  METHODS 
6.2.1  Stability and metabolism of proET-1 peptides 
Clearance and metabolism of proET-1 peptides were evaluated using synthetic NT-
proET-1 (ppET-1[18 – 50]), ELDP (ppET-1[93 – 166]) and CT-proET-1 (ppET-1[169 – 212]). 
 
6.2.1.1  Clearance rates of proET-1 peptides in vivo in rat circulation  
Four male Wistar rats (Charles River UK Limited) with a mean ± s.e.m weight of 345 ± 
6 g were anaesthetised with sodium thiopentone intraperitoneally (i.p.) (120 mg/kg). 
Polyethylene catheters (PE-50) were inserted into the left carotid artery for blood 
collection. A 25G needle was attached to the PE-50 catheter containing saline. 
A mixed peptide solution containing 1 nmol/ml of each proET-1 peptide (NT-proET-1, 
ELDP and CT-proET-1) was prepared in 0.9% NaCl/0.1% BSA and filtered (0.2 µm) 
before use. An initial blood sample (1 ml) was collected at -5 min at rest, before injecting 
the proET-1 peptide solution. A bolus dose containing 1 nmol/kg of each proET-1 
peptide was administered intravenously (i.v.) into the femoral vein.  
After injection, arterial blood samples (500 µl) were collected through the carotid artery 
at 0.5, 1, 2, 5, 10, 20 and 40 min into chilled 1.5 ml microcentrifuge tubes containing 50 
Units/ml of heparin as an anticoagulant. Samples were kept on ice until the end of 40 
min. Plasma was then collected after centrifugation of samples at 12,000 rpm for 2 min 
at 4°C and transferred into fresh 1.5 ml microcentrifuge tubes avoiding red blood cell 
contamination. Small aliquots of samples were stored at -80ºC for subsequent analyses. 
NT-proET-1, ELDP and CT-proET-1 were assayed using magnetic bead-based 
multiplex assays using Luminex methodology (see Chapter 2, section 2.2.3).  
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6.2.1.2 Stability of proET-1 peptides in human whole blood and 
plasma  
Blood was withdrawn from a forearm vein of a healthy volunteer and collected into a 
syringe containing heparin (50 Units/ml). In order to carry out plasma incubations of 
synthetic peptides, one third of whole blood was immediately separated into chilled 2.0 
ml microcentrifuge tubes and centrifuged at 12,000 rpm for 2 min at 4°C to collect 
plasma. Heparin anticoagulated plasma was separated into fresh 2.0 ml microcentrifuge 
tubes and kept on ice.  
Peptide mix (1 nmol/ml) stock solution was diluted in freshly prepared saline (0.9% 
NaCl/0.1% BSA, 0.2 µm filtered before use). This interim dilution was added into the 
remaining whole blood and to the plasma giving a final concentration of 500 fmol/ml of 
each proET-1 peptide. The tubes were mixed gently by inverting several times. Aliquots 
of whole blood (750 µl) and plasma (250 µl) were separated into 1.5 ml microcentrifuge 
tubes and incubated at room temperature (22 – 24°C) and on ice (4°C) for 5, 10, 20, 40, 
and 60 min. At the end of each time point, whole blood was centrifuged and the separated 
plasma samples were stored on ice until the end of incubation.  Samples had no visible 
evidence of haemolysis. Samples from the plasma incubations were frozen immediately 
after each incubation time. All samples were stored at -80°C. Concentrations of proET-
1 peptides were determined using double-site sandwich based immunoassay (Chapter 2, 
section 2.2.2.4). 
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6.2.2  Biomarker investigation study details 
6.2.2.1  The effects of TNF-α infusion on ELDP and CT-proET-1 levels  
Collection of samples used for this investigation was described in Patel et al., 2002. ET-
1 release in response to TNF-α infusion was studied in 6 healthy subjects (mean age 56 
years; male:female 5:1). Briefly, FBF and plasma flow responses to acetylcholine (ACh) 
and sodium nitroprusside (SNP) were monitored before and during TNF-α infusion over 
6 h. TNF-α was administered to the brachial artery aiming to achieve a local 
concentration of 200 pg/ml (in venous blood, observed concentration was 40 pg/ml). 
Arterial and venous blood samples were collected at baseline and during TNF-α infusion 
for up to 300 min.  
 
6.2.2.2  Heart failure 
Blood samples from patients with chronic stable HF study were collected at the London 
Chest Hospital, Barts Health NHS Trust with the approval of the local research ethics 
committees and the written informed consent of each subject (East London and the City 
Research Ethics Committee – reference number 07/Q0604/24). The levels of proET-1 
peptides in patients with chronic HF (HF, n = 24) were compared with untreated subjects 
with pre-hypertension/mild hypertension (pre-H, n = 24) collected in the Centre for 
Clinical Pharmacology, William Harvey Research Institute, Charterhouse Square (East 
London and the City Research Ethics Committee – reference number 07/Q0605/44). 
Subject demographic data are shown in Table 6.3. After patients had been at rest for at 
least 15 min, blood samples were collected into pre-chilled EDTA tubes, placed on ice 
and centrifuged within 10 min using a cooled centrifuge (4000 rpm for 10 min at 4ºC). 
Supernatant plasma was stored at -80ºC until immunoassay. 
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Table 6.3: Demographic and clinical characteristics of patients in heart failure study. 
Values are given as mean ± s.e.m. NA indicates measurements for which data was not 
available. 
Heart Failure   Pre-hypertension 
n      24    24 
Age (years)     70 ± 2.0   55.4 ± 1.5 
Male gender     20 (80%)    24 (100%) 
Weight (kg)     85.7 ± 4.3   80.4 ± 3.0 
Body Mass Index (kg/m2)   29.6 ± 1.2   26.7 ± 0.5 
Systolic Blood Pressure (mmHg) 126.3 ± 3.6   144.8 ± 2.1 
Diastolic Blood Pressure (mmHg)  71.0 ± 2.0   87.1 ± 1.3 
Heart rate (bpm)   64.0 ± 1.4   69.3 ± 2.0 
NYHA chronic HF Class II/III  20 (80%)/ 4 (20%)  NA 
LVEF (%)    31.2 ± 2.0   NA 
NT-proBNP (pg/ml)   1970 ± 288   NA 
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6.2.2.3  Chronic Kidney Disease   
Plasma and urine samples were obtained through collaboration with Prof. David J. Webb 
at the University of Edinburgh. CKD patients classified as stage 1 to 5 based on the 
Kidney Disease Outcome Quality Initiative (K/DOQI) classification criteria (National 
Kidney Foundation, 2002) had renal disease without co-existing morbidities. Venous 
plasma and urine samples were collected after a 12 h fast and stored frozen at -80ºC until 
ELDP and CT-proET-1 analysis. Details of these patients and sample collection have 
been described previously (Lilitkarntakul et al., 2011). 
 
6.2.2.4  Proteinuric CKD receiving renoprotective treatment  
Plasma and urine samples were from a clinical trial conducted by Dhaun et al., 2011, 
2013. This  was a randomized, double-blind, three-way crossover study in 27 patients 
with proteinuric CKD, which investigated the effects of sitaxentan (Thelin, Encysive 
Pharmaceuticals), nifedipine and placebo on proteinuria, BP, arterial stiffness and urine 
ET-1/creatinine (renal ET-1 production). Cardiovascular indices were monitored at 
baseline, week 3, and week 6 of each treatment period and samples were collected for 
biochemical analyses. Oral administration of sitaxentan (100 mg/day) (Dhaun et al., 
2007a) and nifedipine (30 mg/day) were as once daily doses. Both were recommended 
therapeutic doses for human. 
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6.2.3 Evaluation of CT-proET-1 antibodies for biomarker 
investigations 
Sheep were immunised with N-terminal (ppET-1[169 – 179]) and C-terminal (ppET-1[204 – 
212]) CT-proET-1 peptides to produce highly specific and sensitive antibodies for capture 
and detection with low cross-reactivity. The aim of this approach was to reduce non-
specific binding, as this is crucial for accurate detection of lower peptide concentrations 
and for increasing assay sensitivity. The assay performance of the new antibodies was 
compared with the existing CT-proET-1 antibodies to determine the best antibody 
combination to use for the analysis of plasma samples in Chapter 6. 
 
Affinity purification of antisera (see section 2.2.4.6.3) obtained from sheep immunised 
with C-terminal CT-proET-1 (Lys203-CT-proET-1[204 – 212]) peptide produced the highest 
binding IgG in fractions I, H – J and E – F (from the 3rd bleed sample, obtained 2 weeks 
after the 4th immunisation with peptide antigen). These IgG fractions were biotinylated 
(section 2.2.4.1.3) and compared to the existing rabbit anti ppET-1[204 – 212] biotinylated 
IgG. For this comparison, black clear bottom Costar 96 well plates were coated with the 
CT-proET-1 capture antibody [sheep anti ppET-1[169 – 186] IgG] at 1 µg/ml, and incubated 
with SAB (0 fmol/ml) to determine background signal/non-specific binding or CT-
proET-1 standard at 5 and 50 fmol/ml. Detection of bound peptide was achieved with 
biotinylated rabbit anti ppET-1[204 – 212] IgG diluted at 1:100 or with biotinylated sheep 
anti ppET-1[204 – 212] IgG fractions I, H – J and E – F, each tested at three dilutions 
corresponding to ~30, 15 or 7.5 ng/well (Table 6.4). The assay methodology was carried 
out as described in section 2.2.2.3. 
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Table 6.4: Comparison of existing biotinylated antibody (rabbit anti ppET-1[204 – 212]) 
with affinity purified biotinylated sheep anti CT-proET-1 IgG fractions I, H – J and 
E – F. Sheep anti CT-proET-1(ppET-1[169 – 186]) IgG capture antibody (1 µg/ml) was 
incubated with assay buffer or CT-proET-1 standard at 5 and 50 fmol/ml followed by 
the biotinylated detection antibodies  I, H – J and E – F (~30, 15 and 7.5 ng/well). 
 
Detection with affinity purified biotinylated IgG [sheep anti ppET-1[204 – 212]] fractions I 
(at 1:4,000) and H – J (at 1:3,200) (i.e. both IgG diluted to ~7.5 ng/well) produced very 
similar results with lower non-specific binding and greater signal-to-noise ratio (S:N) 
when compared to biotinylated rabbit anti ppET-1[204 – 212] IgG (Table 6.4).  
 
 
 
0 5 50 
Mean Mean S:N Mean S:N 
Rabbit anti IgG at 
1:100 
3,185.7 8,941.5 2.8 60,107.9 18.9 
I at 1:1,000 2,722.9 19,649.5 7.2 135,146.6 49.6 
I at 1:2,000 429.7 16,779.7 39.1 128,154.9 298.2 
I at 1:4,000 120.7 14,624.2 121.2 119,148.0 987.1 
H – J at 1:800 1,983.3 18,843.8 9.5 129,847.8 65.5 
H – J at 1:1,600 400.7 15,701.9 39.2 122,594.6 306.0 
H – J at 1:3,200 99.2 13,497.9 136.1 112,750.0 1,136.6 
E – F at 1:1,400 436.8 8,709.8 20.0 75,940.0 173.9 
E – F at 1:2,800 73.4 4,136.6 56.4 44,352.3 604.3 
E – F at 1:5,600 30.6 1,264.4 41.3 22,333.3 729.8 
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Affinity purification of IgG from antisera collected from sheep immunised with N-
terminal CT-proET-1 (CT-proET-1[169 – 179]) resulted in elution of highest binding 
antibodies in fractions H – I and E – F. These fractions were used as capture antibodies 
at 2 µg/ml, with the same standard concentrations and biotinylated antibody dilutions 
being used as described above. The signal from the new coating antibodies was 
compared to the existing capture antibody (Table 6.5).  
 
Table 6.5: Comparison of biotinylated rabbit anti ppET-1[204 – 212] IgG with affinity 
purified sheep anti ppET-1[204 – 212] IgG fractions I, H – J and E – F with the capture 
antibody sheep anti ppET-1[169 – 179] IgG fractions E – F. 
 
Sheep anti ppET-1[169 – 179] (H – I) IgG used as the capture antibody did not produce any 
binding (data not shown), while sheep anti ppET-1[169 – 179] (E – F) IgG produced higher 
background signal than the existing capture antibody [sheep anti ppET-1[169 – 186] IgG] 
 
0 5 50 
Mean Mean S:N Mean S:N 
Rabbit anti IgG at 
1:100 102,256.0 105,825.6 1.0 145,945.6 1.4 
I at 1:1,000 132,328.4 150,649.0 1.1 208,684.3 1.6 
I at 1:2,000 88,191.8 104,299.6 1.2 181,241.3 2.1 
I at 1:4,000 57,866.1 73,651.6 1.3 157,748.3 2.7 
H – J at 1:800 149,430.8 160,939.2 1.1 213,543.7 1.4 
H – J at 1:1,600 89,202.9 105,512.3 1.2 178,999.4 2.0 
H – J at 1:3,200 53,283.4 71,084.1 1.3 153,866.5 2.9 
E – F at 1:1,400 92,123.2 99,935.3 1.1 154,673.4 1.7 
E – F at 1:2,800 64,129.0 73,251.4 1.1 128,163.6 2.0 
E – F at 1:5,600 46,022.2 52,662.8 1.1 91,335.0 2.0 
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(Table 6.5). As a result, the main improvement for the CT-proET-1 immunoassay was 
achieved with the new C-terminal CT-proET-1 anti-sheep biotinylated IgG I at 1:4,000 
dilution or H – J at 1:3,200 with the existing N-terminal CT-proET-1 sheep anti ppET-
1[169 – 186] IgG. Biotinylated anti ppET-1[204 – 212] sheep IgG fraction I was chosen as the 
detection antibody for further characterisation and application in biomarker studies 
because the total antibody purified in this fraction was ~5 times more than in the pooled 
side fractions H – J.  
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6.2.3.1 Analysis of matrix effects of plasma and serum on ELDP and CT-
proET-1 standard curves  
To determine matrix effect of human plasma in ELDP and CT-proET-1 assays the 
standard curves (concentration range 3.125 – 200 fmol/ml) were prepared in assay 
buffer, horse serum and heparin anticoagulated plasma using the assay methodology 
described in section 2.2.2.4. These studies were performed in high-binding white plates 
(Costar), which increase by more than 100-fold the chemiluminescence signal generated 
during assay end-point measurement. Here, after blocking as usual, standard curves were 
prepared by adding 25 µl nSAB to all wells, followed by 25 µl of each matrix (nSAB, 
horse serum, or plasma) and 50 µl of standards. 
Figure 6.1 shows close similarity between all three matrixes at the higher concentration 
range. However, both ELDP and CT-proET-1 standards prepared in heparin 
anticoagulated plasma had higher counts at the lower range of the standard curve (0 – 
12.5 fmol/ml) (Figure 6.1). This finding was also consistent for standard curves prepared 
in EDTA anticoagulated human plasma (data not shown). The signal observed with the 
low concentrations of proET-1 standards is likely primarily due to endogenous peptide 
present in the test plasma. This was a consistent observation across all plasma samples 
evaluated. Therefore, standard curves prepared in human plasma (either heparin or 
EDTA anticoagulated) were unsuitable for determining ELDP and CT-proET-1 
concentrations in patient samples. In comparison, the background signal from horse 
serum was very similar to that obtained when standards were diluted in assay buffer. 
This is expected as horse proET-1 has only low homology over the sequences used to 
generate specific antibodies for ELDP and CT-proET-1 (http://www.ensembl.org 
Equus_caballus EDN1 gene ENSECAG00000011618), so even if present would not 
cross react in these assays. Standard curves prepared in horse serum were more similar 
to standards diluted in nSAB showing it as a more suitable matrix for preparation of 
standard curves than human plasma. However, horse serum did not appear to provide 
any advantages over standard curves prepared in nSAB. Therefore, for biomarker assays 
ELDP and CT-proET-1 peptide concentrations were determined from standard curves 
diluted in nSAB.  
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Figure 6.1: Standard curves of (A) ELDP and (B) CT-proET-1 prepared in nSAB, 
horse serum and heparin anticoagulated plasma.  
 
Figure 6.2 demonstrates the reproducibility of ELDP and CT-proET-1 immunoassays 
with standard curves (concentration range 0.09 – 200 fmol/ml for ELDP and 0.27 – 200 
fmol/ml for CT-proET-1) prepared in nSAB for the analysis of plasma samples obtained 
from patients analysed in Chapter 6.  
 
 
 
Figure 6.2: Reproducibility of ELDP and CT-proET-1 standard curves produced 
during biomarker investigations. ELDP (n = 6) and CT-proET-1 (n = 7) standard 
curves generated during analysis of plasma samples.  
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6.2.4 Immunoassays for plasma and urinary ELDP and CT-
proET-1 measurements 
Specific double-recognition site sandwich ELISAs were optimised for plasma 
measurements of ELDP and CT-proET-1. All samples in the biomarker investigation 
were analysed using the immunoassay assay methodologies described in Chapter 2, 
section 2.2.2.4. The lower limit of detection for ELDP (n = 12) in plasma was 0.3 
fmol/ml and 0.09 fmol/ml in urine. The detection limit for CT-proET-1 (n = 18) in 
plasma was 0.6 fmol/ml and 0.34 fmol/ml in urine. These were calculated using the 
formula “mean of background + (3 x standard deviation of background)” and the values 
used were from the standard curves used for the analysis of samples described in this 
chapter. All assays were performed blinded to the sample code. 
 
6.2.5  Statistical analysis 
Plasma levels were expressed as mean ± s.e.m (fmol/ml). Changes in ELDP and CT-
proET-1 levels between baseline and different time points or groups were compared 
using one-way ANOVA with Bonferroni post-hoc test. Plasma levels of ELDP and CT-
proET-1 after TNF-α infusion and in pre-hypertension and chronic HF were compared 
using Student’s t-test (unpaired, two-tailed) and by two-way ANOVA with Bonferroni 
post-hoc test. Effects of treatments (sitaxentan, nifedipine, and placebo) on plasma 
levels of ELDP and CT-proET-1 were shown as percentage change (%) from baseline. 
The difference in plasma levels at week 3 and week 6 of each treatment was compared 
to baseline levels and significance was determined by ANOVA with repeated measures. 
Relationships between proET-1 peptides and other cardiovascular and renal parameters 
(e.g. eGFR or 24 h Na+ excretion) were investigated using linear regression analysis 
(GraphPad Prism 5). In the scatter plots P values and r2 (linearity of the data) are 
reported. 
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6.3  RESULTS 
6.3.1  Clearance and metabolism of proET-1 peptides 
6.3.1.1 Clearance rates of proET-1 peptides in rat circulation 
A mixed proET-1 peptide solution was administered as a bolus dose of 1 nmol/kg. 
Arterial plasma levels determined before injection (-5 min) and at 0.5, 1, 2, 5, 10, 20 and 
40 min following injection showed markedly different elimination rates for the proET-
1 peptides (P <0.001; one-way ANOVA) (Figure 6.3). At 30 sec after the injection, the 
levels of NT-proET-1, ELDP and CT-proET-1 were 287 ± 23, 3648 ± 234, and 11736 ± 
639 fmol/ml, respectively. Assuming 100 g body weight (BW) of a rat has a circulating 
blood volume of 7.2 ± 0.3 ml (Argent et al., 1994), then according to mean weight of 
Wistar rats (345 ± 6 g), the total circulating blood volume was 24.8 ± 1.8 ml. The 
maximum observed concentration of proET-1 peptides was likely to be 23 – 35 pmol/ml 
assuming a haematocrit of 40 – 60%. According to these assumptions with a haematocrit 
of 50%, the percentage of NT-proET-1, ELDP and CT-proET-1 remaining 0.5 min after 
the injection was ~1%, ~13%, and ~42% of the administered peptide, respectively.  
The time coarse of measurements showed NT-proET-1 had the most rapid clearance (<5 
min) in which only 1.8 ± 0.8% of initial values (at 0.5 min) remained 5 min after 
injection in the plasma (estimated half-life <1 min). ELDP and CT-proET-1 had slower 
clearance rates, in which 2.5 ± 0.2% and 13.3 ± 1.0% of initial values remained 20 min 
after injection, respectively. Clearance rates for ELDP and CT-proET-1 both showed 
two phases with estimated half-lifes of 0.52 and 0.74 min for phase 1, and 5.73 and 7.25 
min for phase 2 (Figure 6.3). 
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Figure 6.3: Clearance rates of NT-proET-1 (  ), ELDP (  ) and CT-proET-1 (  ) in vivo. 
A bolus dose of 1 nmol/kg of each proET-1 peptide was injected through the femoral 
vein of male Wistar rats (n = 4). Arterial plasma concentrations of NT-proET-1, ELDP 
and CT-proET-1 were determined using Luminex based assay methodology. Data were 
expressed as fmol/ml and values represent mean ± s.e.m from a single experiment.   
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6.3.1.2  Stability of proET-1 peptides in whole blood and plasma 
To evaluate the effect of blood samples not being centrifuged immediately after 
collection, or plasma not being frozen rapidly, the stability of proET-1 peptides were 
investigated with room temperature incubation (22°C) of blood samples. Addition of 
NT-proET-1, ELDP and CT-proET-1 peptides at 500 fmol/ml (from 1 nmol/ml of 
peptide stock) showed relative stability of ELDP and CT-proET-1 over 60 min 
incubation at 22°C. In whole blood, 92.7 ± 3.1% and 94.6 ± 3.6% of initial ELDP and 
CT-proET-1 concentrations remained after 60 min incubation, respectively (Figure 
6.4A). In plasma, 99.4 ± 0.7% and 104.3 ± 1.4% of initial ELDP and CT-proET-1 
concentrations remained after 60 min incubation with plasma, respectively (Figure 
6.4B).  
In contrast, degradation of NT-proET-1 occurred rapidly at 22°C. In whole blood, 24.2 
± 4.1% of initial NT-proET-1 concentration remained after 60 min incubation in whole 
blood and 25.4 ± 1.4% of initial NT-proET-1 concentration remained after 60 min 
incubation in plasma (Figure 6.4A and 6.4B). NT-proET-1 levels were significantly 
lower than ELDP and CT-proET-1 over 60 min incubation (P <0.001 at all time-points; 
two-way ANOVA). 
There were no significant differences between whole blood and plasma whether NT-
proET-1 was incubated on ice or at 22°C. In whole blood 56.1% of initial NT-proET-1 
concentration remained after 60 min incubation while in plasma 81.3% of initial NT-
proET-1 concentration remained after 60 min incubation on ice (data not shown).   
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Figure 6.4: Ex vivo stability of NT-proET-1 (  ), ELDP (  ) and CT-proET- 1 (  ) 
synthetic peptides (at 500 fmol/ml) following room temperature incubation in: (A) 
Whole blood and (B) Plasma. At the end of each time point, whole blood was 
centrifuged and plasma was kept on ice. NT-proET-1, ELDP, and CT-proET-1 were 
measured using double-recognition site sandwich immunoassay. Values are expressed 
as a percentage remaining relative to initial sample measured after 5 min incubation of 
proET-1 peptides (mean ± s.e.m)  (n = 2).  
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6.3.1.3  Stability of ELDP and CT-proET-1 synthetic standards in urine  
ELDP and CT-proET-1 synthetic standards were diluted at 200 fmol/ml and 1 in 3 serial 
dilutions were prepared (concentration range 0.27 – 200 fmol/ml) in urine that was 
centrifuged at 8,000 rpm for 5 min at 4°C. Aliquots of each sample containing equal 
volumes were separated into 1.5 ml microcentrifuge tubes and incubated on ice and at 
25°C for 1 h. For comparison, synthetic standards of ELDP and CT-proET-1 were 
diluted in nSAB and serial dilutions were prepared in the same concentration range and 
these were incubated at room temperature for 1 h. At the end of 1 h incubation, all 
samples were stored at -80°C. Concentrations of ELDP and CT-proET-1 were 
determined using the optimised urine immunoassay (section 2.2.2.4). There were no 
temperature dependent changes in the stability of either ELDP or CT-proET-1 (Figure 
6.5). 
 
 
Figure 6.5: The stability of (A) ELDP and (B) CT-proET-1 synthetic standards in 
urine.  Dilution curves prepared with each synthetic standard were incubated at 4°C 
and at 25°C for 1 h and the peptide levels were measured using double-recognition site 
sandwich immunoassay.     
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6.3.2 Plasma levels of ELDP and CT-proET-1 in response to 
TNF-α administration 
Arterial and venous plasma levels of ELDP and CT-proET-1 were measured at baseline 
and after i.v. TNF-α infusion over 250 min in healthy control subjects. Arterial levels of 
ELDP at baseline and post-TNF-α were 5.7 ± 0.4 fmol/ml and 7.5 ± 0.6 fmol/ml, 
respectively (unpaired, two-tailed t-test, P = 0.02). Venous levels of ELDP at baseline 
and post-TNF-α were 6.6 ± 0.4 fmol/ml and 8.0 ± 0.9 fmol/ml, respectively. The change 
between venous ELDP levels at baseline and post TNF-α was not significant (Figure 
6.6A). However, overall ELDP levels after TNF-α infusion for arterial and venous 
samples together were significantly greater than combined baseline arterial and venous 
values (2-way ANOVA, P = 0.009). There was no significant difference between arterial 
and venous levels at baseline or after TNF-α infusion.  
  
Arterial levels of CT-proET-1 at baseline and post-TNF-α were 6.5 ± 1.5 fmol/ml and 
9.6 ± 2.0 fmol/ml, respectively. Venous levels of CT-proET-1 at baseline and post-TNF-
α were 6.2 ± 1.6 fmol/ml and 7.4 ± 2.1 fmol/ml, respectively. In comparison to venous 
levels of CT-proET-1, arterial levels showed a greater increase after TNF-α infusion 
(Figure 6.6B). However, neither arterial nor venous levels were significantly changed 
after TNF-α infusion. 
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Figure 6.6: Arterial and venous plasma concentrations of (A) ELDP and (B) CT-
proET-1 after TNF-α infusion. Results shown are plasma levels of ELDP and CT-
proET-1 (fmol/ml) at baseline and post-TNF-α. The data were expressed as mean ± 
s.e.m. A comparison between arterial and venous levels at baseline and post-TNF-α was 
performed using a Student’s t-test (unpaired, two-tailed). * represents a significant 
increase in ELDP levels from arterial plasma following TNF-α infusion (P = 0.02). 
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6.3.3 Evaluation of ELDP and CT-proET-1 as biomarkers of 
cardiovascular disease 
6.3.3.1 Comparison of ELDP and CT-proET-1 levels in pre-hypertension/mild 
hypertension and chronic heart failure 
Baseline levels of ELDP and CT-proET-1 were measured in untreated subjects with pre-
H (n = 24) and in patients with chronic HF (n = 24). Plasma levels of ELDP were 
significantly different between pre-H and chronic HF (P <0.001; unpaired t-test) (Figure 
6.7A). Plasma levels (mean ± s.e.m) of ELDP were 6.5 ± 0.2 and 7.8 ± 0.3 fmol/ml for 
pre-H and chronic HF, respectively (95% CI of 6.1 – 6.8 and 7.3 – 8.3, respectively). 
 
Similarly, CT-proET-1 showed a significant difference between the two patient groups 
(P <0.001; unpaired t-test), with CT-proET-1 being significantly greater than ELDP in 
each group (P <0.05; one-way ANOVA) (Figure 6.7A). Plasma levels of CT-proET-1 
in pre-H and in chronic HF were 9.9 ± 0.5 and 16.3 ± 0.8 fmol/ml, respectively (95% CI 
of 8.9 – 11.0 and 14.7 – 18.0, respectively). 
 
There was a positive correlation between plasma levels of ELDP and CT-proET-1 (P 
<0.001, r2 = 0.44) in which patients with chronic HF had higher proET-1 peptide levels 
and patients with pre-H had lower proET-1 peptide levels (Figure 6.7B). 
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Figure 6.7: (A) Plasma ELDP and CT-proET-1 (fmol/ml) levels in pre-hypertension 
and chronic heart failure. (B) Scatter plot comparing plasma levels of ELDP with 
plasma levels of CT-proET-1. (A) Results are expressed as mean ± s.e.m. 
Concentrations of ELDP and CT-proET-1 in each group were compared by Student`s t-
test, *** = P <0.001. (B) Linear regression analysis comparing plasma ELDP with CT-
proET-1 showed a positive correlation.  
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6.3.4 Evaluation of ELDP and CT-proET-1 as biomarkers of 
chronic kidney disease 
6.3.4.1  Plasma measurements in CKD 
Plasma levels of ELDP (mean ± s.e.m) were 6.3 ± 0.4 for control subjects (n = 16) and 
6.2 ± 0.3 (n = 31), 7.0 ± 0.4 (n = 30), 7.7 ± 0.3 (n = 29), 9.8 ± 0.8 (n = 10) and 12.4 ± 
2.0 (n = 5) fmol/ml for CKD stages 1 to 5, respectively (P <0.05 for the overall trend; 
comparison of means by ANOVA). In comparison to healthy controls, similar levels of 
ELDP were observed in CKD stages 0 – 3, but there was a significant increase in CKD 
stages 4 – 5 (P <0.001 ANOVA) (Figure 6.8A). 
Plasma levels of CT-proET-1 were 8.9 ± 1.3 for control subjects (n = 14) and 9.4 ± 1.0 
(n = 29), 11.4 ± 1.2 (n = 30), 16.4 ± 1.3 (n = 28), 19.7 ± 2.1 (n = 11), and 29.6 ± 3.5 (n 
= 5) fmol/ml for CKD stages 1 to 5, respectively (P <0.001 for the linear trend; 
comparison of means by ANOVA). In comparison to healthy controls, CT-proET-1 
levels were significantly higher from CKD stages 3 – 5 (Figure 6.8B). 
Scatter plots of eGFR (ml/min/1.73m2) against plasma concentrations of ELDP and CT-
proET-1 (Figure 6.8C and 6.8D) had a negative linear correlation (P <0.001 and r2 = 
0.26 for ELDP and P <0.001 and r2 = 0.29 for CT-proET-1). Thus, with increasing 
eGFR, proET-1 peptide concentrations tended to be lower. There was a positive 
correlation between plasma levels of ELDP and CT-proET-1 (P <0.001, and r2 = 0.40) 
(data not shown).  
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Figure 6.8: Plasma levels of ELDP and CT-proET-1 in chronic kidney disease (A – 
B) and their correlation with eGFR (C – D). Bar graphs in the upper panel show mean 
± s.e.m for plasma concentrations (fmol/ml) of (A) ELDP and (B) CT-proET-1. ** = P 
<0.01, and *** = P <0.001 comparison of means to control (CKD stage 0) by ANOVA. 
Scatter plots in the lower panel show plasma levels of (C) ELDP (P <0.001, r2 = 0.26) 
and (D) CT-proET-1 (P <0.001, r2 = 0.29) against eGFR (ml/min/1.73m2). The 
relationship between proET-1 peptide levels and eGFR was assessed by linear 
regression analysis.  
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6.3.4.2  Urinary ELDP and CT-proET-1 in CKD 
Urinary ELDP levels did not increase with increasing CKD stages (Table 6.6). Mean 
ELDP levels were 1.1 ± 1.2 pmol/L, but there was a marked difference (>70-fold) 
between the minimum and maximum values of 0.09 and 6.7 pmol/L. There was no 
relationship between urinary ELDP and eGFR (data not shown). Urinary ELDP levels 
also did not correlate with plasma ELDP levels (data not shown).  
 
Table 6.6: ELDP concentrations in urine from patients with chronic kidney disease. 
Mean ELDP levels are expressed as pmol/L. SD = standard deviation and n = the 
number of samples analysed.  
CKD stage Mean ELDP 
(pmol/L) 
SD n 
0 0.7 0.8 23 
1 1.3 1.6 29 
2 1.0 1.3 22 
3 1.0 1.3 22 
4 1.7 1.1 16 
5 1.2 0.8 7 
 
CT-proET-1 had very low levels in CKD urine samples, which were mostly lower than 
the detection limit of the assay (0.34 fmol/ml).  
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6.3.4.3 Effects of sitaxentan on ELDP and CT-proET-1 in patients with 
CKD 
The effects of an ETA receptor antagonist sitaxentan (100 mg/day), a long-acting 
formulation of calcium-channel blocker nifedipine (30 mg/day), and placebo were 
compared at baseline and after 3 and 6 weeks of treatment.  
Baseline levels of ELDP and CT-proET-1 were similar in all treatment groups with mean 
plasma levels being 11.7 ± 0.6 and 20.0 ± 1.1 fmol/ml, respectively (data not shown). 
Placebo treatment did not cause any significant changes in plasma levels of ELDP or 
CT-proET-1 between baseline, week 3 and week 6 (mean decrease in ELDP: -4% and 
CT-proET-1: -0.2%). Sitaxentan treatment resulted in significant increases in ELDP at 
both 3 and 6 weeks when compared to baseline (Figure 6.9A). Mean increase of plasma 
ELDP following sitaxentan treatment was 16.2 ± 3.3% (95% CI, 6.6% – 21.0%) (P 
<0.001). Similarly, CT-proET-1 levels significantly increased after 3 and 6 weeks of 
sitaxentan treatment (Figure 6.9B). Mean increase of plasma CT-proET-1 was 13.6 ± 
2.3% (95% CI, 8.9% – 18.7%) (P <0.001 by repeated measures ANOVA; comparison 
to baseline for both peptides).  
After treatment with nifedipine, there were no significant differences in ELDP or CT-
proET-1 levels compared to baseline at week 3 and week 6 (mean increase ELDP: 5.4% 
and CT-proET-1: 3.4%) (Figure 6.9A and 6.9B). 
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Figure 6.9: Effects of placebo, sitaxentan, and nifedipine on plasma levels of (A) 
ELDP and (B) CT-proET-1. Values (mean ± s.e.m) represent percent change of plasma 
ELDP and CT-proET-1 from baseline. Mean baseline levels of ELDP and CT-proET-1 
were 11.7 ± 0.6 and 20.0 ± 1.1 fmol/ml, respectively. *** represents P <0.001 by 
ANOVA with repeated measures for the comparisons made between baseline and after 
3 and 6 weeks of each treatment. 
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There was no difference between urinary ELDP levels at baseline and after 6 weeks of 
receiving placebo, sitaxentan and nifedipine (Table 6.7). Again, CT-proET-1 levels were 
mostly undetectable in urine (data not shown). 
 
Table 6.7: Effects of placebo, sitaxentan, and nifedipine on urinary ELDP 
concentrations. ELDP levels were expressed as mean ± SD (pmol/L) and measured at 
baseline and after 6 weeks of each treatment.  
Treatment Baseline 
(pmol/L) 
Week 6 
Placebo 0.8 ± 0.7 0.9 ± 0.8 
Sitaxentan 0.9 ± 0.7 0.8 ± 0.6 
Nifedipine 0.8 ± 0.6 0.8 ± 1.1 
 
 
 
6.3.5 Correlation of ELDP and CT-proET-1 levels with changes 
in clinical parameters 
ELDP and CT-proET-1 levels from CKD and proteinuric CKD after sitaxentan 
treatment were compared with cardiovascular and renal parameters, which were 
previously measured in Dhaun et al., 2011, 2013. These parameters were: BP [systolic 
blood pressure (SBP), diastolic blood pressure (DBP), MAP and pulse pressure (PP)]; 
FMD to assess endothelial function; pulse wave velocity (PWV) and central 
augmentation index-C as a measure of arterial stiffness; urine Na+, albumin:creatinine 
ratio (ACR), blood creatinine, urine creatinine, urine ET-1, and fractional excretion of 
ET-1. Parameters that showed significant correlations with plasma levels of ELDP and 
CT-proET-1 are discussed here. 
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6.3.5.1  Patients with proteinuric CKD receiving renoprotective  
  treatment 
There was no correlation between plasma ELDP or CT-proET-1 levels with 24 h Na+ 
excretion at baseline or after 3 weeks of sitaxentan treatment. However, after 6 weeks, 
plasma levels of ELDP and CT-proET-1 correlated negatively with 24 h Na+ excretion 
(ELDP: P = 0.01, r2 = 0.21 and CT-proET-1: P = 0.01, r2 = 0.22) (Figure 6.10). 
 
 
Figure 6.10: Relationship between plasma levels of (A) ELDP and (B) CT-proET-1 
with 24 h Na+ excretion (mmol/24 h) after 6 weeks of sitaxentan treatment. ELDP and 
CT-proET-1 had negative linear correlation with 24 h Na+ excretion (as assessed by 
linear regression analysis). 24 h Na+ excretion was expressed as mmol/24 h. 
 
In the sitaxentan treatment group, changes in plasma ELDP and CT-proET-1 did not 
correlate with changes in urinary protein excretion (UPE), protein:creatinine ratio 
(PCR), 24 h Na+ excretion, MAP, SBP, DBP and PWV.  
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In the nifedipine treatment group, there was no correlation between plasma ELDP or 
CT-proET-1 levels and 24 h Na+ excretion. However, changes in plasma levels of ELDP 
and CT-proET-1 after 6 weeks of treatment correlated with changes in 24 h Na+ 
excretion (ELDP: P = 0.04, r2 = 0.17; CT-proET-1: P = 0.005, r2 = 0.28)  (Figure 6.11). 
 
 
Figure 6.11: Scatter plots showing changes (%) in plasma levels of (A) ELDP and (B) 
CT-proET-1 with changes (%) in 24 h Na+ excretion (mmol/24 h) following nifedipine 
treatment over 6 weeks.    
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6.4  DISCUSSION 
In this chapter the potential of proET-1 peptides as biomarkers was investigated in rat 
and human studies. Firstly, their clearance rates were investigated in anaesthetised rats. 
Then in human studies ELDP and CT-proET-1 were measured after TNF-α infusion in 
healthy volunteers, in patients with chronic HF, and in patients with CKD.  
Slower clearance from the circulation and greater stability in whole blood/plasma 
favoured ELDP and CT-proET-1 as potential biomarkers of ET-1 synthesis. In 
comparison, NT-proET-1 had rapid clearance and degradation, and therefore has limited 
potential as a biomarker. Clearance of peptides from the circulation can be mediated by 
receptor-binding, proteolytic degradation, diffusion into interstitial fluid, and renal 
clearance. The exact mechanism that underlies relative short half-life of NT-proET-1 is 
unclear. The peptides were administered i.v. and arterial blood samples were collected. 
The very rapid disappearance of NT-proET-1 (Figure 6.3) was indicative of pulmonary 
clearance. This is similar to that observed with ET-1 (Sirviö et al., 1990; de Nucci et al., 
1988; Dupuis et al., 1996b), which is mainly due to receptor binding (Fukuroda et al., 
1994a; Dupuis et al., 1996a; Burkhardt et al., 2000). In comparison, angiotensin I is 
largely metabolised to angiotensin II by angiotensin converting enzyme (ACE) 
(Soubrier et al., 1993) as it passes through the pulmonary vasculature. The concentration 
of NT-proET-1, ELDP and CT-proET-1 measured after 30 s of injection were 287 ± 23, 
3648 ± 234, and 11736 ± 639 fmol/ml, respectively. If interstitial fluid is also included 
in the volume of distribution of peptides [volume of distribution = volume of 
extracellular fluid (15 – 20% of total BW)], then peptide concentrations would be 
expected in the 5 – 6.6 pmol/ml. Hence, the levels of proET-1 peptides reflect both 
dilution in plasma and diffusion into interstitial fluid, as well as metabolism. Whether 
clearance of NT-proET-1 is due to receptor binding or proteolytic degradation needs 
further investigation. Nevertheless, temperature dependent decreases in NT-proET-1 
(section 6.3.1.2 , Figure 6.4) were indicative of increased sensitivity to 
degradation by proteolytic enzymes. 
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In the first human study, the effects of TNF-α on proET-1 release were investigated by 
measuring the plasma levels of more stable fragments, ELDP and CT-proET-1. TNF-α 
is a pro-inflammatory cytokine and stimulates both mRNA expression and ET-1 peptide 
synthesis in endothelial and vascular smooth muscle cells (Corder et al., 1995; Woods 
et al., 1999). TNF-α can induce vascular inflammation and the levels are increased in 
patients with endothelial dysfunction and ischaemic heart disease (Ridker et al., 2000). 
Administering TNF-α to healthy individuals’ increased ET-1 release, measured in both 
arterial and venous blood (Patel et al., 2002). In response to TNF-α, the increase in ET-
1 release was greater in venous plasma in comparison to arterial levels. As a follow up 
to these investigations, plasma levels of ELDP and CT-proET-1 were measured in the 
same set of plasma samples. When compared to baseline, there was a slight increase in 
ELDP and CT-proET-1 levels after TNF-α. This elevation however was only significant 
in arterial ELDP (Figure 6.6A). To note, venous levels of ELDP at baseline were slightly 
higher than arterial levels (6.6 ± 0.4 vs. 5.7 ± 0.4 fmol/ml). A regional difference in 
vascular sensitivity to ET-1 was previously reported (Lüscher et al., 1990; Kelly & 
Whitworth, 1999) and higher ET-1 levels in venous plasma (at baseline) was also 
reported by Patel et al., 2002. However, after TNF-α infusion, the increase in ELDP in 
venous blood was minor. Post-TNF-α CT-proET-1 levels showed a greater increase in 
arterial plasma (1.5-fold) when compared to venous plasma. The reason for the 
differences observed between arterial and venous plasma levels of ET-1 and proET-1 
peptides is unclear. However, as the samples had been stored at -80º C for more than 12 
years prior to assay for ELDP and CT-proET-1, the long-term stability of these peptides 
may be an important factor affecting the observed plasma levels.  
The limitations of this study included small sample size. Due to invasiveness of the 
brachial artery catheterisation, the study was limited to 6 volunteers. Bigger sample size 
and limited freeze/thaw process of stored plasma samples could have increased the 
confidence of results. Nevertheless, increases in proET-1 peptide levels support the 
relationship with inflammatory and vasoconstrictor processes induced by TNF-α 
(Klemm et al., 1995).  
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In a second study of human samples, diagnostic utility of ELDP and CT-proET-1 was 
evaluated in patients with pre-H and chronic HF. Plasma levels of CT-proET-1 were 
comparatively higher than ELDP levels and in patients with chronic HF there was a more 
pronounced elevation with CT-proET-1 (1.6-fold increase) in comparison to ELDP (1.2-
fold increase). Nevertheless, lower and upper 95% CI of means showed differentiation 
between pre-H and chronic HF with both proET-1 peptides (ELDP: 6.1 – 6.8 and 7.3 – 
8.3; CT-proET-1: 8.9 – 11.0 and 14.7 – 18.0, respectively). The results of this study 
suggested that CT-proET-1 may be a better biomarker to distinguish patients with HF. 
The higher CT-proET-1 levels relative to ELDP are consistent with the relative 
difference in clearance rates of these peptides. Importantly, pre-H patients were not 
receiving any treatment and represented a rare population in which plasma 
measurements would reflect changes in proET-1 without drug interactions. 
Currently, diagnosis of HF is difficult during emergency conditions where a rapid, non-
invasive, easily accessible biomarker is critical for identification. NT-proBNP is the 
most powerful predictor of HF (Cowie et al., 1997; Maisel et al., 2002) and the diagnosis 
of acute coronary syndromes are accompanied by cardiac troponins and creatinine 
kinase MB. The first CT-proET-1 immunoassay (B.R.A.H.M.S GmbH, 
Hennigsdorf/Berlin, Germany) was described by Papassotiriou et al., 2006 is a 
chemiluminescence sandwich assay and uses polyclonal antibodies for the detection of 
ppET-1 residues 168 – 212. A comparison between CT-proET-1 (ppET-1[168 – 212]) and 
NT-proBNP demonstrated that CT-proET-1 increases the prognostic value for assessing 
patients with chronic HF   (Dieplinger et al., 2009; Jankowska et al., 2011). In addition, 
a variety of HF studies investigated the prognostic potential of CT-proET-1 along with 
other biomarkers such as plasma mid-regional pro-adrenomedullin (MR-proADM) 
(Adlbrecht et al., 2009), and the GISSI-HF trial measuring mid-regional pro-atrial 
natriuretic peptide (MR-proANP), MR-proADM, C-terminal pro-vasopressin (CT-
proAVP or copeptin) (Masson et al., 2010) and showed promising results with CT-
proET-1. Clinical trials investigating the prognostic potential of CT-proET-1 along with 
other cardiovascular biomarkers were summarised in Chapter 1, Table 1.8. Of note, the 
CT-proET-1 (ppET-1[168 – 212]) assay described in these studies differed from the CT-
proET-1 (ppET-1[169 – 212]) assay used in this thesis, as the antigen included an arginine 
at ppET-1 residue 168 (ppET-1 167-RR SSEEHLRQTRS) that is likely to be removed 
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during the processing. However, an assay for ppET-1[168 – 212] may be able to detect 
unprocessed fragments of ppET-1 as well as the fully processed peptide ppET-1[169 – 212]. 
In a previous study of CKD patients with minimal comorbidity, plasma ET-1 levels were 
increased linearly with declining renal function (declining GFR), while fractional 
excretion of ET-1 was increased exponentially (Goddard et al., 2007; Dhaun et al., 
2009). Therefore, plasma levels of ELDP and CT-proET-1 were investigated in CKD. 
In comparison to healthy controls, ELDP levels were significantly increased from CKD 
stage 4, while CT-proET-1 levels were increased from CKD stage 3 (Figure 6.8A and 
6.8B). Both proET-1 peptides lacked the sensitivity to differentiate between earlier CKD 
stages, which are crucial for prognosis and for preventing disease progression. The 
inverse relationship between plasma levels of ET-1 and eGFR (Goddard et al., 2007) 
was confirmed for plasma levels of ELDP and CT-proET-1 (reduced eGFR with 
increasing proET-1 peptides) (Figure 6.8C and 6.8D). In CKD, this was consistent with 
decreased renal filtration and thus removal of peptides from the circulation resulting in 
higher plasma levels. Furthermore, in comparison to plasma levels of ET-1 (Dhaun et 
al., 2009) linear regression curves of ELDP and CT-proET-1 had higher r2 values (ET-
1: r2 = 0.22 vs. ELDP: r2 = 0.26 and CT-proET-1: r2 = 0.29) indicating slightly better 
curve fittings and a closer relationship to renal filtration rates. Alternatively, increasing 
r2 values may reflect the ability to detect increased synthesis of ppET-1 with increasing 
severity of CKD. This finding is also consistent with CT-proET-1 having the longest 
circulating half-life. 
Earlier studies have indicated that urinary and plasma ET-1 concentrations are 
independent of each other (Serneri et al., 1995; Goddard et al., 2007) and the 
concentration of urinary ET-1 was well correlated with ET-1 production (Benigni et al., 
1991). Urinary ET-1 levels are elevated in CKD (Dhaun et al., 2006). These suggested 
that urinary ET-1 (instead of plasma ET-1) could be a better biomarker of renal disease. 
Here, this hypothesis was evaluated for proET-1 peptides. However, urinary ELDP 
levels were low (mean 1.1 ± 1.2 pmol/L) and did not change with the severity of disease 
either in CKD or in proteinuric CKD patients receiving renoprotective treatments and 
placebo. In addition, urinary CT-proET-1 levels were mostly undetectable. This 
suggested that the peptides (particularly CT-proET-1) might be differently metabolised 
in the kidney and that antibodies may not be recognising excreted fragments of ELDP 
and CT-proET-1 in urine. To support this hypothesis and to rule out the possibility of 
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stability issues in urine, synthetic standards of ELDP and CT-proET-1 prepared at 0.27 
– 200 fmol/ml were incubated for 1 h at room temperature and on ice. There was no 
temperature dependent change in the stability of peptides between the two incubation 
temperatures (25°C and 4°C) and they were relatively comparable to the standard curve 
prepared in nSAB (Figure 6.5). This suggested that the most likely reason is renal tubule 
proteolytic degradation. Abassi et al., 1993b showed that NEP-24.11, located at the 
brush border of renal proximal tubule degraded filtered ET-1. Therefore, it is likely that 
CT-proET-1 is excreted as proteolytic fragments rather than the full length peptide. 
Excretion of smaller fragments is also documented for plasma proteins such as albumin 
and transferrin (Burne et al., 1999). It may also be possible that, due to their larger MWt, 
only small amounts of ELDP and CT-proET-1 were excreted in urine. Identification of 
stable CT-proET-1 fragments excreted in urine is needed in order to fully evaluate and 
interpret the utility of measuring urinary ppET-1 fragments in patients with CKD.  
 
In a second study of patients with CKD, the effects of nifedipine, sitaxentan and placebo 
on the plasma and urinary levels of ELDP and CT-proET-1 were evaluated. The main 
aim of these investigations was to establish whether plasma levels of proET-1 peptides 
were modified with sitaxentan or nifedipine treatments, and if any changes in proET-1 
peptide levels were related to cardiovascular parameters (e.g. proteinuria, BP, and 
arterial stiffness, which modify systemic and renal haemodynamics). The clinical trial 
initially described in Dhaun et al., 2013 compared these changes with plasma and urine 
ET-1 concentrations. In this study, sitaxentan did not affect plasma levels of ET-1 
whereas urine ET-1/creatinine, which reflects renal ET-1 production, was reduced. 
Interestingly, in contrast to these findings, plasma levels of ELDP and CT-proET-1 were 
significantly elevated at 3 and 6 weeks after receiving sitaxentan (Figure 6.9). In general, 
ET-1 levels are not affected with selective ETA antagonist treatments (such as SB 
247083) (Douglas et al., 1998). Whereas, blocking ETB receptors either through an ETB 
selective antagonist (Fukuroda et al., 1994a) or endothelial cell-specific ETB KO 
(Bagnall et al., 2006; Kelland et al., 2010) was associated with increased circulating ET-
1 levels probably as a result of reduced clearance. In contrast, Opgenorth et al., 2000 
observed increased plasma ET-1 levels with selective ETA and ETB receptor antagonism 
in healthy humans in which the increase with ETB receptor antagonism was greater than 
that of ETA. More importantly, combined ETA and ETB receptor blockade increased ET-
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1 levels more than ETB alone. Based on this finding, Opgenorth et al., 2000 suggested 
this was due to blocking a negative feedback effect mediated via ETA receptors. 
Therefore, the mechanism underlying increased plasma levels of ELDP and CT-proET-
1 could be due to ETA blockade of a negative feedback mechanism leading to increased 
synthesis. Decreased fractional filtration after sitaxentan could also alter renal clearance, 
which would lead to a change in half-life of proET-1 peptides.  
 
Correlations between plasma levels of ELDP and CT-proET-1 with 24 h Na+ excretion 
and proteinuria markers confirmed previous findings of Dhaun et al., 2011, 2013 that 
acute selective ETA receptor blockade modifies cardiovascular parameters (reduces 
proteinuria, BP and arterial stiffness) in proteinuric CKD and may confer protection 
against disease progression. There was no change between sitaxentan and nifedipine in 
reducing BP parameters. Yet, a reduction seen in proteinuria with sitaxentan was greater 
than that of nifedipine (Dhaun et al., 2013). Plasma levels of ELDP and CT-proET-1 
had a negative correlation with 24 h Na+ excretion after 6 weeks of sitaxentan treatment. 
Thus, increasing concentrations of ELDP and CT-proET-1 were associated with 
reductions in 24 h Na+ excretion. The role of ETA receptors in regulation of Na
+ 
homeostasis is not well defined. Therefore, anti-natriuretic effect of sitaxentan is 
unclear. Most evidence from gene targeting studies suggested that ET-1 mediated 
natriuresis (increased Na+ excretion) is mainly regulated by the activation of ETB 
receptors (Ahn et al., 2004). Active reabsorption of Na+ and Cl- are mainly inhibited in 
the proximal tubule and thick ascending limb where ETB receptors have the highest 
density without ETA localisation (Kohan et al., 2011).  Thus, the contribution of ETA 
receptors to Na+ homeostasis is expected to be minor. Results from CD specific KO 
experiments indicated that (Table 6.2):  
(1) Specific CD ETA KO mice did not affect Na+ excretion or systemic BP (Ge et 
al., 2005). 
(2) Urine volume and Na+ excretion were similar between inducible nephron-
specific ETA KO mice (iETA) and control mice, on a normal or high Na
+ intake 
(Stuart et al., 2012).  
(3) ETA blockers had no effect on ET-1 inhibition of ENaC activity in isolated rat 
cortical CD (Bugaj et al., 2012).  
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(4) In contrast, CD ETA/B KO mice were shown to be more hypertensive and retain 
more Na+ than mice with CD ETB KO alone (Ge et al., 2008).  
 
Taking all these evidences together, there is a possibility that ETA receptors might 
contribute to regulation of Na+ homeostasis. This is possibly as a secondary effect 
through alterations on the renal haemodynamics. Sitaxentan was shown to reduce RBF, 
GFR, effective FF in CKD patients (Dhaun et al., 2011) and in a previous study these 
alterations in haemodynamics were shown to reduce urinary Na+ and water excretion 
(Claria et al., 1991). In support of the role of ETA receptors on Na
+ homeostasis, Stuart 
et al., 2013 has shown that ETA antagonist-induced fluid retention was mediated by CD 
ETA receptors.  In this study, ambrisentan and atrasentan (both at 100 mg/kg/day over 2 
weeks) were used as ETA receptor antagonists and their effect on fluid retention was 
investigated in control mice and in cell-specific ETA KO mouse lines [cardiomyocyte-
specific ETA KO, VSMC ETA KO (ETA KO of all SMCs), CD ETA KO, and nephron 
ETA KO]. 
In the nifedipine treatment group plasma levels of ELDP and CT-proET-1 did not 
correlate with any of the parameters tested. However, there was a relationship between 
changes in ELDP and CT-proET-1 levels and changes in 24 h Na+ excretion (Figure 
6.11).  
 
In summary, clearance and metabolism of proET-1 peptides demonstrated the 
superiority of CT-proET-1 as a biomarker of ET-1 synthesis. This was based on the 
longer half-life and greater differences observed in chronic HF and CKD stages, which 
is likely to be reflected by its longer stability in comparison to ELDP. However, the 
prognostic value of both peptides was limited for identification of CKD stages 1 – 2. 
Nevertheless, correlations with 24 h Na+ excretion and proteinuria markers indicated a 
relation with disease progression, suggesting measurements of ELDP and CT-proET-1 
may be useful for the assessment of kidney pathology and responses to treatment.  In 
addition, increased plasma levels of ELDP and CT-proET-1 after sitaxentan treatment 
(plasma ET-1 levels were unchanged) suggested that ETA antagonists might block a 
negative feedback effect of ET-1 on EDN1 gene expression (Stow et al., 2011). This 
requires further investigation, but observations of limited efficacy of ERAs in clinical 
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trials of HF suggest that ETA receptor blockade creates a vicious circle where the more 
effective the blockade the greater the upregulation of EDN1 gene expression. Measuring 
proET-1 peptides not only provide advantages over limitations associated with plasma 
measurements of ET-1, but also may be useful to assess responses associated with ETA 
receptor antagonism. Fluid retention (oedema) was an important side effect of ET 
receptor antagonism and increased morbidity in the clinical trials (Dhaun et al., 2007b; 
Ritz & Wenzel, 2010) (see Table 1.4, page 29). Although it requires further 
investigation, proET-1 peptides may serve useful in monitoring side effects associated 
with ETA receptor antagonism.  
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7  DISCUSSION AND GENERAL CONCLUSIONS  
7.1 Remaining questions from functional studies investigating 
the role of ET-1 and its receptors 
Over the past 25 years strong evidence has accumulated showing that ET-1, the most 
potent vasoconstrictor peptide known, plays a key role in the regulation of vascular tone 
and renal function. Genetic models of endothelial-specific deletion of EDN1 have 
demonstrated a physiological role of the ET system in regulation of BP (Kisanuki et al., 
2010). Similarly, cell specific deletions of EDN1, or ETA and ETB receptors have 
revealed important roles for ET-1 in the regulation of renal function and blood pressure 
(Kedzierski et al., 2003; Bagnall et al., 2006; Kelland et al., 2010). However, research 
to date has focused exclusively on the pathophysiological roles of the 21 amino acid 
peptide ET-1, rather than other peptide products of the 212 amino acid precursor – ppET-
1. Yet, the contribution EDN1 might play in human hypertension or regulation of BP is 
still not well understood.    
Cardiac overexpression of the human EDN1 gene in mice resulted in cardiac 
inflammation and hypertrophy (Yang et al., 2004). However, although it was anticipated 
that these changes were due to increased ET-1 synthesis, ERAs were unable to block the 
resulting lethal HF (Yang et al., 2004). Moreover, ERAs had either little or no benefit 
in human clinical trials of hypertension and left ventricular HF (Weber et al., 2009; 
Battistini et al., 2006; Mann et al., 2010; Galiè et al., 2011). Instead, treatment with 
ERAs was associated frequently with side effects including fluid retention. Following 
these investigations the unresolved question has been whether additional proET-1 
peptides, co-released with ET-1, contribute to the biological actions of EDN1 and lead 
to effects that are resistant to inhibition with ERAs.  
Plasma levels of ET-1 are an unreliable measure of vascular synthesis. Earlier diagnosis 
of patients at a higher risk of developing hypertension or HF is still clinically 
challenging. Indeed, there is an unmet need for a biomarker to enable earlier diagnosis 
of patients that are at a greater risk to develop cardiovascular or renal disease. Although 
ppET-1[168  –  212] (referred to as CT-proET-1) was proposed as an alternative biomarker 
of ET-1 synthesis on the basis of the assay described by Papassotiriou et al., 2006, 
detailed characterisation of ppET-1 processing was not carried out. The possibility of 
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processing to alternative peptides, which may be better biomarkers of ET-1 synthesis, 
therefore cannot be excluded.  
 
7.2 Characterisation and identification of proET-1 peptide 
sequences   
The initial work of our laboratory identified ppET-1 derived peptides from the EA.hy 
926 and A549 conditioned media samples based on antibody recognition using specific 
immunoassays and HPLC. These human cell lines are fast-growing and well 
characterised in terms of the ET-1 system (Waxman et al., 1994; Corder et al., 1993a; 
Corder et al., 1995; Deprez-Roy et al., 2000). Therefore, conditioned media collected 
after 48 h incubation allowed large-scale purification of proET-1 derived peptides. As a 
result of further purification and characterisation using IEC and HPLC, the identified 
secreted proET-1 peptides has shown processing results in three main fragments: NT-
proET-1 (ppET-1[18 – 50]), ELDP (ppET-1[93 – 166]), and CT-proET-1 (ppET-1[169 – 212]). 
Detection of these proET-1 peptides was achieved with double-recognition sandwich 
immunoassays. 
 
7.2.1  NT-proET-1 
Identification of the native NT-proET-1 sequence using mass spectrometry was not 
completed. This was primarily due to isolation of insufficient peptide. Definitive 
identification of NT-proET-1 was important for two main reasons. Firstly, NT-proET-1 
synthetic peptide (fraction 46) eluted later than the purified native peptide (fraction 41) 
(Figure 4.3C). So mass spectrometry could have confirmed whether the sequence of 
synthetic peptide (ppET-1[18 – 50]) corresponded to that of the native peptide. Secondly, 
the amino acid sequence of this peptide is based on a prediction (Bloch et al., 1989); 
with the first amino acid in its sequence following that of the proposed signal peptide 
sequence (ppET-1 residues 1 – 17). Thus, identification of the N-terminal sequence of 
NT-proET-1 could confirm both the amino acid sequence of signal peptide and the 
processing site for NT-proET-1.   
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Rapid clearance of synthetic NT-proET-1 from the circulation of rats (Figure 6.3), and 
the susceptibility of the synthetic peptide to proteolytic degradation (Figure 6.4) showed 
limited potential of this peptide as a biomarker. Attempts to measure native peptide in 
plasma samples were also unsuccessful, suggesting that native peptide was also rapidly 
degraded or cleared from the circulation. Although the amino acid sequence of NT-
proET-1 (ppET-1[18 – 50]) is highly conserved (e.g. 67% homology between human and 
sheep), there is not yet any evidence for a biological activity. 
 
7.2.2  ELDP and CT-proET-1 
Amino acid sequences of purified ELDP and CT-proET-1 peptides were determined 
from partial sequences on the basis of trypsin digestion. The N-terminal sequence of 
ELDP (ppET-1[93 – 101]) was not identified from the purified native samples (fractions 43 
and 47) (Table 5.2A and 5.2B). In contrast, under the same methodological conditions, 
the N-terminal sequence was identified from the purified synthetic sample (fraction 45) 
(Table 5.2C). Confirmation of disulphide bonds in the endothelin-like domain sequence 
(ppET-1[109 – 123]) from either native or synthetic ELDP samples was not achieved. 
Identification of these sequences could be limited by a number of factors including: (i) 
loss of lower abundance peptides during the extraction or C18 clean-up; (ii) poor 
chromatographic separation of the trypsin digested peptides; (iii) low amounts of 
purified native peptide sample; or (iv) non-specific proteolytic cleavage of proteins. 
Digestion with additional proteases with different cleavage capabilities could increase 
the amino acid sequence coverage and the confidence of results. Trypsin is the most 
commonly used digestion enzyme. However, in the case for ELDP, the use of this 
enzyme had two disadvantages. Firstly, abundance of lysine and arginine residues in a 
sequence produces high numbers of short peptides that are difficult to identify using 
mass spectrometry. The sequence of endothelin-like domain is rich in lysine and had 4 
potential cleavage sites. Peptide identification using database search engines is designed 
for linear peptides only. Therefore identification of additional peptides requires manual 
inspection of the raw data. Although all potential peptides were searched manually in 
the MS/MS spectra, greater number of potential peptides is likely to complicate 
identification. Secondly, the basic pH required for optimal trypsin digestion can cause 
disulphide bond rearrangement (Sanger, 1953; Ryle & Sanger, 1955). For both cases, 
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endopeptidase Glu-C could be advantageous for two reasons: (1) it cleaves peptide 
bonds C-terminal to glutamic acid residue (or at aspartic acid residue depending on the 
buffer) producing endothelin-like domain as a single fragment; and (2) has the option of 
carrying digestion under more acidic conditions (pH 4 or 8) (Lippincott & Apostol, 
1999). 
The sequence of endothelin-like domain is highly conserved (Table 1.6) and the spacing 
between first four cysteine residues is exactly the same as in ET-1 (see Table 1.1, page 
3). Although this was suggestive of a biological activity, previous attempts have failed 
to show this for ppET-1[110–130] (Cade et al., 1990). However, the C-terminal sequence 
of ELDP has two more cysteine residues (Cys148 and Cys155), which are also highly 
conserved. Therefore, the C-terminal sequence of ELDP could be necessary for receptor 
binding, and hence for biological activity.  
The proteolytic processing of peptides commonly occurs at double basic amino acid 
residues (most frequently at Lys-Arg and Arg-Arg). Identification of the C-terminal 
sequence of ELDP: CIYQQLVRGR (ppET-1[155 – 162]); and the N-terminal sequence of 
CT-proET-1: SSEEHLRQTRSETMR (ppET-1[169 – 183]), confirmed Arg-Arg at ppET-1 
residues 167 – 168 as the cleavage site for CT-proET-1 (155-
CIYQQLVRGRKIRRSSEEHLRQTRSETMR-183). The results shown in Figure 5.4 
also confirmed the sequence identity of CT-proET-1 (ppET-1[169 – 212]). The amino acid 
sequence of this peptide is highly divergent across species. As such, the human N-
terminal sequence of CT-proET-1 (SSEEHLRQTR) corresponding to ppET-1 residues 
169 – 178 is completely absent from other species. In addition to these observations, 
slow clearance of CT-proET-1 suggested that it is biologically inert. 
Although mass spectrometry of the purified proET-1 peptides yielded only limited data, 
the peptide sequences that were identified based on antibody recognition using double-
recognition site sandwich immunoassays, as well as HPLC elution characteristics of 
synthetic and native peptides strongly support the identities of ELDP and CT-proET-1 
as ppET-1[93 – 166] and ppET-1[169 – 212], respectively. However, the arrangement of 
disulphide bridges in ELDP were not confirmed by these studies.   
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7.3 ELDP and CT-proET-1 peptides as potential biomarkers 
of cardiovascular and renal disease 
The usefulness of ELDP and CT-proET-1 as biomarkers of cardiovascular and renal 
disease was assessed in plasma samples obtained from patients with pre-H, chronic HF 
and CKD. Consistent with previous studies showing upregulation of ET-1 in disease 
states, the levels of ELDP and CT-proET-1 were increased in chronic HF and CKD. 
Although plasma levels of CT-proET-1 were previously assessed in patients with HF 
(see Table 1.8), the results shown in Chapter 6 were the first to evaluate plasma levels 
of ELDP and CT-proET-1 in CKD. Comparison of plasma ELDP and CT-proET-1 
levels in patients with pre-H and chronic HF showed higher CT-proET-1 levels (65% 
vs. 21% increase from pre-H) (Figure 6.7). Similarly in CKD, the levels of CT-proET-1 
were higher than plasma levels of ELDP (Figure 6.8). This is likely a consequence of 
slower clearance of CT-proET-1 from the circulation. In addition, earlier increase in CT-
proET-1 levels (CKD stages 3 – 5) highlighted its superiority over ELDP (CKD stages 
4 – 5). However, the diagnostic ability of both peptides was limited for early CKD 
stages. 
On the other hand, creatinine-based measurements form the basis of renal function 
assessment and are commonly used in the clinic. Creatinine has a non-linear relationship 
with GFR and the levels start to increase as GFR ≤60/ml/min/1.73 m2 (National Kidney 
Foundation, 2002). Plasma levels of ELDP and CT-proET-1 had an inverse linear 
relationship with GFR (Figure 6.8C and 6.8D), which was consistent with the inverse 
linear relationship previously observed for plasma ET-1 (Goddard et al., 2007; Dhaun 
et al., 2009 and Lilitkarntakul et al., 2011) but more importantly, their levels increased 
earlier in the CKD classification. This is advantageous over the inaccuracy of creatinine 
measurements in the lower range and highlights the potential of proET-1 peptides as 
useful biomarkers of CKD. Furthermore, proET-1 assays have advantages over the 
limitations associated with ET-1 measurements. These are (1) immunoassays performed 
directly without the need of an extraction/purification step; (2) due to greater stability or 
lower degree of degradation their measurements are more accurate and reliable; and (3) 
avoid the cross-reactivity that is associated between ET isoforms. 
The negative linear relationship between plasma levels of proET-1 peptides and GFR 
(decrease in GFR while ELDP and CT-proET-1 increase) suggested reduced renal 
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filtration and therefore reduced renal clearance. In patients with chronic HF or CKD, 
there is already an existing upregulation of ET-1 synthesis due to the underlying 
pathology. Thus, increases in ELDP and CT-proET-1 could be due to increased EDN1 
expression and proET-1 synthesis. Increases in ELDP and CT-proET-1 levels as GFR 
declines provided further evidence that ET axis contributes to the progression of CKD.  
 
Pathological actions of ET-1 are mainly mediated by activation of ETA receptors. 
However, whether blocking ETA receptors is the best choice of treatment with ERAs 
still remains controversial. In patients with CKD, blocking ETA receptors has additional 
effects on renal haemodynamics and has been proposed to be superior to either dual or 
ETB receptor blockade (Goddard et al., 2004). Blocking ETA receptors in the treatment 
of CKD improved cardiovascular parameters (Dhaun et al., 2011) as such sitaxentan 
increased GFR, and reduced proteinuria and BP (Dhaun et al., 2013). However, plasma 
levels of ET-1 were unchanged after 6 weeks of treatment. As ET-1 measurements may 
not accurately reflect EDN1 peptide synthesis, plasma levels of ELDP and CT-proET-1 
were investigated in these plasma samples. The observed increases in ELDP and CT-
proET-1 levels provided a new insight into the effects of ETA receptor antagonism, 
which might be a consequence of increased synthesis. Plasma levels of ET-1 are mainly 
regulated by the ETB-mediated clearance. Blockade of ETB receptors increases plasma 
ET-1 levels mainly as a result of blocking pulmonary clearance (Fukuroda et al., 1994a; 
Dupuis et al., 1996a; Burkhardt et al., 2000), but this also in part reduces renal clearance 
of ET-1 (Gasic et al., 1992). As a result, ETB receptor blockade contributes to increased 
ET-1 levels (Goddard et al., 2007). In sitaxentan and nifedipine treatment groups, there 
was no correlation between changes in proET-1 levels and the reduction in GFR. Thus, 
from this data, increases in proET-1 peptides are less likely due to reduced renal 
clearance and the most likely explanation could therefore be increased EDN1 expression 
leading to proET-1 synthesis. Increases in ELDP and CT-proET-1 after ETA receptor 
blockade shows the first clinical evidence that increases previously observed in plasma 
ET-1 (Opgenorth et al., 2000; Verhaar et al., 2000) could be due to upregulation of its 
synthesis.  
After 6 weeks of sitaxentan treatment, increases in plasma levels of ELDP and CT-
proET-1 were correlated with reductions in 24 h urine Na+ excretion (Figure 6.10). 
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Although an increase in ETB-mediated natriuresis (increased Na+ excretion) was 
expected after ETA antagonist treatment, the reverse occurred. This finding suggests a 
potential link with adverse side effects (such as increased Na+ and possibly water 
retention) associated with ETA receptor antagonists in previous clinical trials (see Table 
1.4, page 29) and might explain the inefficiency of ERAs in clinical trials of HF. These 
side effects resulted in premature termination of clinical trials due to increased morbidity 
and mortality, and hence there is a requirement for a sensitive biomarker that would 
enable identification of patients that are more likely to develop oedema, which again 
lacks a good biomarker. Thus, measuring stable peptide fragments of proET-1 synthesis 
could be useful in this setting to provide more reliable measurements of active or 
upregulated ET-1 synthesis. In conjunction, a biomarker that reflects associated side 
effects of ERAs would enable better control on development/progression of side effects 
by adjusting the dose of antagonists to achieve maximal efficacy with minimal side 
effects. 
 
If increases in ELDP and CT-proET-1 levels were due to upregulation of ET-1 synthesis, 
then sitaxentan treatment blockade of the physiological negative feedback mechanism 
regulating EDN1 expression is likely to contribute to disease progression through 
alternative pathways. Renin-angiotensin-aldosterone system (RAAS) plays an important 
role in regulation of vascular homeostasis, fluid electrolyte balance and vascular growth 
(Fyhrquist & Saijonmaa, 2008). ET-1 reduced renin secretion from cultured mouse renal 
juxtaglomerular cells (Ackermann et al., 1995; Ritthaler et al., 1995), as well as directly 
increasing aldosterone secretion through the adrenal cortex (Nussdorfer et al., 1997). As 
interactions between ET-1 and aldosterone (Rossi et al., 2001) and Ang II (Emori et al., 
1991; Park & Schiffrin, 2001) are evident, increased Na+ and fluid retention could be 
induced by increased aldosterone secretion. The mechanism of aldosterone stimulation 
is mainly regulated by Ang II and there is no clinical evidence to show a link between 
ET-1 and aldosterone release. However, increased proET-1 peptide levels and Na+ and 
fluid retention following sitaxentan treatment may suggest that the underlying 
mechanism for Na+ and fluid retention, in part, could be regulated (i) directly by ELDP; 
or (ii) ELDP-mediated release of aldosterone secretion. The reason of suggesting ELDP 
as a potential contributor to this mechanism lies beneath its biological action to 
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potentiate vasoconstrictor activity of ET-1 (Yuzugulen et al., 2012). Therefore, it may 
also potentiate the action of another mediator that results in aldosterone secretion. (iii) 
ET-1 through ETB receptors. Although ETB-mediated natriuresis is largely evident, in 
rats, ET-1-induced aldosterone secretion was mediated by ETB receptors while ETA 
receptors had no direct effect (Belloni et al., 1996). 
 
7.4 Limitations and future experiments for biomarker 
investigations 
The sample size of TNF-α and chronic HF studies were limited to a small sample size 
in which samples were stored over a long time. Therefore, further validation of proET-
1 peptide levels in studies consisting of a larger sample size could provide further 
insights into their value as biomarkers. However, although CT-proET-1 had high 
stability in short-term incubations, the factors affecting its stability in long-term storage 
are not known. Sample collection may be improved by collecting blood samples into 
chilled microcentrifuge tubes containing protease inhibitors with analysis of peptide 
levels from freshly collected samples without the interference of peptide degradation or 
freeze/thaw process. Tests should be done to evaluate the impact of freeze/thaw cycles 
on CT-proET-1 stability, in case activation of clotting factors contributes to instability 
as this is a recognised consideration for repeated analysis of samples particularly after 
long-term storage. 
Biomarker investigations with ELDP and CT-proET-1 opened a new window in the ET 
field. The results of this study raised further questions, which require additional 
experiments: 
(1) Do selective ETA receptor antagonists block the physiological negative feedback of 
ET-1, resulting in increased EDN1 synthesis? One approach to test this hypothesis is 
measuring ppET-1 mRNA levels after sitaxentan treatment. Analysing ppET-1 mRNA 
levels from the plasma samples used in this study would be inaccurate due to 
degradation. However, investigating the mRNA levels in cultured cells and proET-1 
peptides in freshly collected culture medium (e.g. ECs or VSMC) after treatment with 
sitaxentan at a clinically relevant concentration could provide useful insights into this 
mechanism.  
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(2) Further work is needed to confirm that increases in plasma levels of ELDP and CT-
proET-1 in other studies of ETA receptor antagonism and to understand whether this is 
a class specific effect. As such, chronic administration of atrasentan (ABT-627, ETA 
selective antagonist) to healthy subjects increased ET-1 levels at a dose-dependent 
manner (Verhaar et al., 2000). Thus, analysing plasma levels of proET-1 peptides in 
similar studies could be advantageous.  
(3) Do ETA receptor antagonists (e.g. sitaxentan) reverse underlying cardiovascular risk 
factors in CKD, but at the same time contribute to the associated side effects (Na+ and 
water retention) observed in clinical trials? Therefore, the potential mechanism by which 
ELDP regulates aldosterone secretion needs to be investigated. One approach could be 
evaluation of arterial plasma levels of aldosterone in rats before and after i.v. infusion of 
synthetic ELDP (through femoral vein). Moreover, what would be more interesting is to 
measure ELDP, CT-proET-1 and aldosterone levels in patients with an existing oedema 
following treatment with ERAs. This could provide further clues on the underlying 
mechanism linking ETA receptor antagonist treatment and Na
+ retention.   
(4) Although weight gain or free water clearance was not measured in CKD study, it 
would be very important to confirm this link between water retention and increases in 
proET-1 peptide levels in patients treated with ETA receptor antagonists.   
(5) CKD patients involved in the study had minimal co-morbidities and a further 
investigation which includes other cohorts of patients would be useful. In particular, 
patients that are less responsive to treatment or at a higher risk of developing adverse 
effects that are linked to ETA receptor antagonism can be determined.  
(6) Although the ET system is an important contributor to the underlying pathology of 
PAH, ERAs are less likely to be used as the only line of treatment. In persistent PAH, 
advanced therapy includes ERAs in combination with phosphodiesterase type 5 (PDE5) 
inhibitors and prostaglandin analogues. There is a need for less expensive and more 
effective therapies. It would be interesting to investigate whether proET-1 peptide levels 
are increased in patients with PAH, and whether proET-1 peptide levels increase in 
patients treated with bosentan (ETA/B selective) or ambrisentan (ETA selective). This 
could provide an opportunity to evaluate whether increases in proET-1 levels correlate 
with Na+ or water retention, and determine whether this can distinguish patients that are 
more likely to develop oedema as a result of ETA receptor blockade. 
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(7) Crosstalk between ET receptors: where blockade of a single receptor subtype may 
influence or account for the deleterious effects of the other receptor subtype has been 
reported in a number of studies (Mickley et al., 1997; Ozaki et al., 1997; Adner et al., 
2001; Davenport & Kuc, 2004). Thus, comparing the effects of selective ETA and ETB 
and dual ETA/B receptor antagonism on increases in plasma levels of ELDP and CT-
proET-1 would be useful. Macitentan (ETA/B receptor antagonist with high tissue 
affinity) increased plasma ET-1 levels at ten times lower doses that were required to 
increase ET-1 levels to a similar extent with bosentan (moderate volume of distribution) 
(Weber et al., 1996). This shows an important consideration for the tissue 
distribution/selectivity of ERAs being investigated. Macitentan (Opsumit®) received its 
first approval for the treatment of PAH in USA (Patel & McKeage, 2014; Dingemanse 
et al., 2014) and further investigations of the effects of this antagonist on proET-1 
peptide levels might be of value. 
 
7.5  Summary of conclusions and future work 
In summary, results presented in this thesis identified a novel ppET-1 derived peptide, 
which was referred to as ELDP and confirmed the processing of CT-proET-1. These 
proET-1 peptides are stable in the circulation and therefore their measurement is superior 
to ET-1. Increases in proET-1 peptide levels in plasma samples obtained from patients 
with chronic HF and CKD highlighted their potential as useful biomarkers. However, at 
this stage, they cannot be considered as diagnostic tools for routine use. Increases in 
proET-1 peptide levels after ETA receptor blockade provided the first clinical evidence 
for which increases previously observed in plasma ET-1 could be as a consequence of 
increased EDN1 synthesis. The correlation between increased proET-1 peptide levels 
and Na+ (and hence fluid) retention after ETA receptor blockade suggests a link with the 
adverse side effects associated with ERAs. 
Low levels of ELDP and CT-proET-1 detected in urine samples from CKD patients 
suggested that their metabolism in urine could lead to shorter peptide fragments, which 
the antibodies being used did not recognise. Hence, identification of excreted peptide 
fragments in urine would be particularly useful. These immunoassays can be more 
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favourable than plasma immunoassays as interference of plasma proteins can be 
excluded.  
 
Further investigations are required to understand the role of ELDP. In addition, 
identification of its receptor would enable investigations to determine whether a clinical 
benefit can be achieved by blocking its biological activity. For instance, GPCR-37 or 
ETB receptor-like protein-1 (Uniprot: O15354) (Marazziti et al., 1997) could be a 
potential receptor to investigate. It would be very interesting to obtain X-ray 
crystallography data for ELDP to determine potential surface residues that are important 
in receptor binding. This requires a highly purified and a larger amount of ELDP. 
However, such investigations might enable identification of structural similarities 
between ELDP and ET-1 and provide insights for the development of antagonists.  
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Delta Mass − http://www.abrf.org/index.cfm/dm.home 
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FindMod – http://www.expasy.ch/tools/findmod/findmod_masses.html 
MASCOT − http://www.matrixscience.com 
ProteinProspector − http://prospector.ucsf.edu/prospector/mshome.htm 
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